| 1 |
Jiang S, Cai M, Zhang Z, Qian C, Wang J, Li Z, Guo Q, Zhou H, Xin H, Cai W, Wang H, Guo S, Huang Y, Xie Q. The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance. Hum Vaccin Immunother 2023;19:2161254. [PMID: 36683193 DOI: 10.1080/21645515.2022.2161254] [Reference Citation Analysis]
|
| 2 |
Zhang L, Yang L, Gao Y, Bi X, Lin Y, Deng W, Jiang T, Lu Y, Hao H, Wan G, Yi W, Xie Y, Li M. Nomogram for evaluating obvious liver inflammation in treatment-naïve HBeAg positive chronic hepatitis B virus infection patients with normal ALT. Virulence 2023;14:2158710. [PMID: 36600180 DOI: 10.1080/21505594.2022.2158710] [Reference Citation Analysis]
|
| 3 |
Liu R, Yang L, Jiang T, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hao H, Hu L, Gao Y, Xu M, Chen X, Yi W, Li M, Xie Y. Hepatitis B core-related antigen serum levels may be a predictor of acute flare of chronic hepatitis B among pregnant women in the immune-tolerant phase of chronic HBV infection after short-course antiviral therapy. Virulence 2023;14:2186335. [PMID: 36864005 DOI: 10.1080/21505594.2023.2186335] [Reference Citation Analysis]
|
| 4 |
Liu YQ, Zhang C, Li JW, Cao LH, Zhang ZQ, Zhao WF, Shang QH, Zhang DZ, Ma AL, Xie Q, Gui HL, Zhang G, Liu YX, Shang J, Xie SB, Li J, Zhang XQ, Zou ZQ, Chen YP, Zhang Z, Zhang MX, Cheng J, Zhang FC, Huang LH, Li JB, Meng QH, Yu HB, Mi YQ, Peng YZ, Wang ZJ, Chen LM, Meng FP, Ren WH, Bai L, Zeng YL, Fan R, Lou XZ, Liang WF, Liu H, Zhuang H, Zhao H, Wang GQ. An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir. J Clin Transl Hepatol 2023;11:304-13. [PMID: 36643032 DOI: 10.14218/JCTH.2022.00091] [Reference Citation Analysis]
|
| 5 |
Chen J, Lou S, Chen H, Zhou B, Sun J, Hou J, Jiang DK. CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients. J Clin Transl Hepatol 2023;11:295-303. [PMID: 36643051 DOI: 10.14218/JCTH.2022.00057] [Reference Citation Analysis]
|
| 6 |
He Z, Zhou J, Tian Y, Wu S, Sun Y, Ou X, Jia J, Wang B, Wu X, You H. Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis. Scand J Gastroenterol 2023;58:403-11. [PMID: 36227688 DOI: 10.1080/00365521.2022.2132532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Jeng WJ, Lok ASF. What will it take to cure hepatitis B? Hepatol Commun 2023;7:e0084. [PMID: 36972391 DOI: 10.1097/HC9.0000000000000084] [Reference Citation Analysis]
|
| 8 |
Aggarwal A, Odorizzi PM, Brodbeck J, van Buuren N, Moon C, Chang S, Adona M, Suthram S, Suri V, Trowe T, Turner S, Marcellin P, Buti M, Gaggar A, Fletcher SP, Diehl L, Feierbach B, Balsitis S. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells. JHEP Rep 2023;5:100664. [PMID: 36908748 DOI: 10.1016/j.jhepr.2022.100664] [Reference Citation Analysis]
|
| 9 |
Barlas T, Yalcin MM, Ozger HS, Altinova AE, Akturk M, Toruner FB, Karakoc A, Yetkin I. Overlooked complication of Cushing's syndrome: Reactivation of hepatitis B. Clin Endocrinol (Oxf) 2023;98:481-6. [PMID: 36443641 DOI: 10.1111/cen.14855] [Reference Citation Analysis]
|
| 10 |
Cao X, Hu Q, Xu W, Li Q, Zhang J, Chen L, Huang Y, Qi X. Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon-alfa. J Viral Hepat 2023;30:310-8. [PMID: 36529685 DOI: 10.1111/jvh.13787] [Reference Citation Analysis]
|
| 11 |
Wang AE, Terrault NA, Fong TL, Zhou K. Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system. Hepatol Commun 2023;7:e0081. [PMID: 36972389 DOI: 10.1097/HC9.0000000000000081] [Reference Citation Analysis]
|
| 12 |
Wang J, Huang R, Liu J, Lai R, Liu Y, Zhu C, Qiu Y, He Z, Yin S, Chen Y, Yan X, Ding W, Zheng Q, Li J, Wu C. A novel non-invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD. J Viral Hepat 2023;30:287-96. [PMID: 36696366 DOI: 10.1111/jvh.13808] [Reference Citation Analysis]
|
| 13 |
Ito D, Ito H, Ando T, Sakai Y, Ideta T, Ishii KJ, Ishikawa T, Shimizu M. Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice. Hepatol Commun 2023;7:e0104. [PMID: 36972390 DOI: 10.1097/HC9.0000000000000104] [Reference Citation Analysis]
|
| 14 |
Brancaccio G, Coco B, Nardi A, Quaranta MG, Tosti ME, Ferrigno L, Cacciola I, Messina V, Chessa L, Morisco F, Milella M, Barbaro F, Ciancio A, Russo FP, Coppola N, Blanc P, Claar E, Verucchi G, Puoti M, Zignego AL, Chemello L, Madonia S, Fagiuoli S, Marzano A, Ferrari C, Lampertico P, Di Marco V, Craxì A, Santantonio TA, Raimondo G, Brunetto MR, Gaeta GB, Kondili LA; PITER collaborating investigators. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination. Int J Infect Dis 2023;129:266-73. [PMID: 36791877 DOI: 10.1016/j.ijid.2023.02.006] [Reference Citation Analysis]
|
| 15 |
Zhang Q, Liu X, Pang X, Wang H, Du J, Ren H, Hu P. Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis B surface antigen levels. Cytokine 2023;164:156140. [PMID: 36738524 DOI: 10.1016/j.cyto.2023.156140] [Reference Citation Analysis]
|
| 16 |
Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Statin use is associated with better post-operative prognosis among patients with hepatitis B virus-related hepatocellular carcinoma. Eur J Clin Invest 2023;53:e13936. [PMID: 36504405 DOI: 10.1111/eci.13936] [Reference Citation Analysis]
|
| 17 |
Jiang H, Ye X, Chen C, Zhou G, Han G. Efficacy and Long-term Safety of Telbivudine Usage During Second or Third Trimester in Hepatitis B Surface Antigen Positive Mothers With High Viral Load: A 10-year Prospective Study. J Clin Gastroenterol 2023;57:423-8. [PMID: 36227027 DOI: 10.1097/MCG.0000000000001779] [Reference Citation Analysis]
|
| 18 |
Adraneda C, Tan YC, Yeo EJ, Kew GS, Khakpoor A, Lim SG. A critique and systematic review of the clinical utility of hepatitis B core-related antigen. J Hepatol 2023;78:731-41. [PMID: 36586590 DOI: 10.1016/j.jhep.2022.12.017] [Reference Citation Analysis]
|
| 19 |
Hui RW, Mak LY, Seto WK, Yuen MF, Fung J. Chronic hepatitis B - A scoping review on the guidelines for stopping nucleos(t)ide analogue therapy. Expert Rev Gastroenterol Hepatol 2023. [PMID: 36972516 DOI: 10.1080/17474124.2023.2196405] [Reference Citation Analysis]
|
| 20 |
Okonko IO, Chindah JO. Serological Evidence of Hbc Igm Virus Among Febrile Patients in Rumueme, Port Harcourt, Rivers State, Nigeria.. [DOI: 10.21203/rs.3.rs-2730410/v1] [Reference Citation Analysis]
|
| 21 |
Miodownik FG, Cardoso AC, Cancella Nabuco L, Franz C, Perez R, Alves Villela-nogueira C. Factors Associated with Disagreement of Fibrosis Stages between 2D-Shear Wave Elastography and Transient Elastography in Chronic Hepatitis B. Viruses 2023;15:846. [DOI: 10.3390/v15040846] [Reference Citation Analysis]
|
| 22 |
Jachs M, Sauberer R, Stiegler A, Dechêne A, Tazreiter R, Hartl L, Bauer D, Balcar L, Strassl R, Mandorfer M, Trauner M, Munda P, Ferenci P, Reiberger T. Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center. United European Gastroenterol J 2023. [PMID: 36965148 DOI: 10.1002/ueg2.12376] [Reference Citation Analysis]
|
| 23 |
Mak LY, Hui RW, Cheung KS, Fung J, Seto WK, Yuen MF. Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers. Expert Opin Drug Discov 2023;:1-16. [PMID: 36943183 DOI: 10.1080/17460441.2023.2192920] [Reference Citation Analysis]
|
| 24 |
Ghany MG, Saraswat VA. Patients With Compensated Hepatitis B Virus-Related Cirrhosis and Low-Level Viremia: Treat or Not to Treat? Am J Gastroenterol 2023. [PMID: 36940387 DOI: 10.14309/ajg.0000000000002224] [Reference Citation Analysis]
|
| 25 |
Moussa D, Wallace J, Manski-Nankervis JA, Doyle JS, Nguyen L, Boyle D, Stoové MA, Asselin J, Valaydon Z, Ahad M, Glasgow S, New K, Hocking JS, Sanci L, Thompson A, Hellard M, Howell J. Assessment of a primary care e-support package of automated case finding, simplified treatment algorithm and decision support to increase hepatitis B treatment uptake in primary care clinics in Australia (SIMPLY-B Study): protocol for a pilot evaluation. BMJ Open 2023;13:e070663. [PMID: 36927591 DOI: 10.1136/bmjopen-2022-070663] [Reference Citation Analysis]
|
| 26 |
Yendewa GA, James PB, Mohareb AM, Barrie U, Massaquoi SP, Yendewa SA, Ghazzawi M, Bockarie T, Cumming PE, Diallo IS, Johnson A, Vohnm B, Babawo LS, Deen GF, Kabba M, Sahr F, Lakoh S, Salata RA. Childhood Hepatitis B Immunization Coverage and Barriers in Sierra Leone, Liberia, and Guinea: Analysis of National Surveys (2018-2020).. [DOI: 10.1101/2023.03.16.23287374] [Reference Citation Analysis]
|
| 27 |
Svicher V, Salpini R, D’anna S, Piermatteo L, Iannetta M, Malagnino V, Sarmati L. New insights into hepatitis B virus lymphotropism: Implications for HBV-related lymphomagenesis. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1143258] [Reference Citation Analysis]
|
| 28 |
Hui KY, Fung J, Cheung KS, Mak LY, Seto WK, Yuen MF. Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B. Gut Liver 2023;17:280-7. [PMID: 36317514 DOI: 10.5009/gnl220122] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 29 |
Tang Q, Ye J, Zhang Y, Zhang P, Xia G, Zhu J, Wei S, Li X, Zhang Z. Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferonα and decision process based on response-guided therapy strategy.. [DOI: 10.21203/rs.3.rs-2609916/v1] [Reference Citation Analysis]
|
| 30 |
Kao WY, Tan EC, Lee HL, Huang YH, Huo TI, Chang CC, Chiou JF, Hou MC, Wu JC, Su CW. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. Aliment Pharmacol Ther 2023. [PMID: 36914943 DOI: 10.1111/apt.17438] [Reference Citation Analysis]
|
| 31 |
Chang ML, Liaw YF. Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure. Drugs 2023. [PMID: 36906663 DOI: 10.1007/s40265-023-01843-2] [Reference Citation Analysis]
|
| 32 |
Zheng H, Zhu Z, Wang N, Qin J, Guo Y, Xu Z, Li X, Qi C, Yuan X, Wu W, Wang J, Liu L, Nashan B. Entecavir Combined With Short-term Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Recurrence in Liver Transplant Recipients. Transplant Proc 2023:S0041-1345(23)00034-9. [PMID: 36907782 DOI: 10.1016/j.transproceed.2023.02.006] [Reference Citation Analysis]
|
| 33 |
Laschtowitz A, Lambrecht J, Puengel T, Tacke F, Mohr R. Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression. IJMS 2023;24:5295. [DOI: 10.3390/ijms24065295] [Reference Citation Analysis]
|
| 34 |
Gao Y, Li S, Huang Y. An inflammation-related gene landscape predicts prognosis and response to immunotherapy in virus-associated hepatocellular carcinoma. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1118152] [Reference Citation Analysis]
|
| 35 |
Ornos ED, Murillo KJ, Ong JP. Liver diseases: Perspective from the Philippines. Ann Hepatol 2023;:101085. [PMID: 36889673 DOI: 10.1016/j.aohep.2023.101085] [Reference Citation Analysis]
|
| 36 |
Fang HW, Hu TH, Wang JH, Hung CH, Lu SN, Chen CH. Post-treatment HBsAg decline predicts high rate of HBsAg loss after stopping entecavir or tenofovir in HBeAg-negative patients without retreatment. Dig Liver Dis 2023:S1590-8658(23)00220-7. [PMID: 36870864 DOI: 10.1016/j.dld.2023.02.006] [Reference Citation Analysis]
|
| 37 |
Ablikim D, Zeng X, Xu C, Zhao M, Yang X, Feng X, Liu J. The Multiple Facets and Disorders of B Cell Functions in Hepatitis B Virus Infection. J Clin Med 2023;12. [PMID: 36902786 DOI: 10.3390/jcm12052000] [Reference Citation Analysis]
|
| 38 |
Mourik K, Boers SA, van Rijn AL, Thijssen JCP, Wessels E, Claas ECJ. Clinical performance of two new, fully integrated molecular platforms used for HIV-1, HBV and HCV viral load analysis, the NeuMoDx 288 and the Alinity m. J Clin Virol 2023;160:105376. [PMID: 36640531 DOI: 10.1016/j.jcv.2022.105376] [Reference Citation Analysis]
|
| 39 |
Nathani R, Leibowitz R, Giri D, Villarroel C, Salman S, Sehmbhi M, Yoon BH, Dinani A, Weisberg I. The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection. J Viral Hepat 2023;30:195-200. [PMID: 36458863 DOI: 10.1111/jvh.13779] [Reference Citation Analysis]
|
| 40 |
Jeng WJ, Wong GL. The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? Hepatol Commun 2023;7:e0060. [PMID: 36790353 DOI: 10.1097/HC9.0000000000000060] [Reference Citation Analysis]
|
| 41 |
Huang C, Yang C, Su P, Chen Y, Huang S, Yen H. Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy. Biomedicines 2023;11:752. [DOI: 10.3390/biomedicines11030752] [Reference Citation Analysis]
|
| 42 |
Wagner J, Yuen L, Littlejohn M, Sozzi V, Jackson K, Martin R, Aeschbacher T, Suri V, Tan SK, Feierbach B, Gaggar A, Marcellin P, Buti Ferret M, Janssen HLA, Gane E, Meagher N, Price DJ, Wong D, Thompson AT, Revill PA. Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis B. Aliment Pharmacol Ther 2023;57:509-23. [PMID: 36427857 DOI: 10.1111/apt.17299] [Reference Citation Analysis]
|
| 43 |
Xu W, Hu Q, Chen C, Li W, Li Q, Chen L. FibroScan Predicts Liver Fibrosis Progression in Chronic HBV Infection Patients with No Clear Indication for Antiviral Therapy: A Retrospective Cohort Study. IDR 2023;Volume 16:1777-1785. [DOI: 10.2147/idr.s402990] [Reference Citation Analysis]
|
| 44 |
Wu JF, Tai CS, Chang KC, Chen HL, Ni YH, Hsu HY, Chang MH. Baseline Hepatitis B Virus Surface Antigen Titers in Childhood Predict the Risk of Advanced Liver Fibrosis in Adulthood. Clin Gastroenterol Hepatol 2023;21:663-669.e1. [PMID: 35240329 DOI: 10.1016/j.cgh.2022.02.046] [Reference Citation Analysis]
|
| 45 |
Agarwal K, Xu J, Gane EJ, Nguyen TT, Ding Y, Knox SJ, Alves K, Evanchik M, Zomorodi K, Ma J, Yan R, Huang Q, Colonno R, Stamm LM, Hassanein TI, Kim DJ, Lim YS, Yuen MF. Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study. J Viral Hepat 2023;30:209-22. [PMID: 36302125 DOI: 10.1111/jvh.13764] [Reference Citation Analysis]
|
| 46 |
Li S, Jin J, Jiang Y, Shi J, Jiang X, Lin N, Ma Z. Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate. Int J Antimicrob Agents 2023;61:106726. [PMID: 36646229 DOI: 10.1016/j.ijantimicag.2023.106726] [Reference Citation Analysis]
|
| 47 |
Wong DK, Inoue T, Mak LY, Hui RW, Fung J, Cheung KS, Seto WK, Tanaka Y, Yuen MF. A longitudinal study to detect hepatitis B surface and core-related antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays. J Clin Virol 2023;160:105375. [PMID: 36623378 DOI: 10.1016/j.jcv.2022.105375] [Reference Citation Analysis]
|
| 48 |
Ho JCL, Mak JWY, Yip TCF, Lam HM, Cheng TY, Lam TO, Tam LS, Law MF, Cheung CKM, Ng SC, Wong VWS, Wong GLH. Risk of alanine aminotransferase flare in patients with previous hepatitis B virus exposure on biological modifier therapies-A population-based study. Liver Int 2023;43:588-98. [PMID: 36516362 DOI: 10.1111/liv.15499] [Reference Citation Analysis]
|
| 49 |
Crespo J, Cabezas J, Aguilera A, Berenguer M, Buti M, Forns X, García F, García-samaniego J, Hernández-guerra M, Jorquera F, Lazarus JV, Lens S, Martró E, Antonio Pineda J, Prieto M, Rodríguez-frías F, Rodríguez M, Ángel Serra M, Turnes J, Domínguez-hernández R, Ángel Casado M, Calleja JL. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction. Gastroenterología y Hepatología (English Edition) 2023. [DOI: 10.1016/j.gastre.2022.09.001] [Reference Citation Analysis]
|
| 50 |
Yoshida O, Akbar SMF, Imai Y, Sanada T, Tsukiyama-Kohara K, Miyazaki T, Kamishita T, Miyake T, Tokumoto Y, Hikita H, Tsuge M, Shimizu M, Al Mahtab M, Aguilar JC, Guillen G, Kohara M, Hiasa Y. Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study. Hepatol Res 2023;53:196-207. [PMID: 36399406 DOI: 10.1111/hepr.13851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 51 |
Ludwig H, Kumar S. Prevention of infections including vaccination strategies in multiple myeloma. Am J Hematol 2023;98 Suppl 2:S46-62. [PMID: 36251367 DOI: 10.1002/ajh.26766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 52 |
Burm R, Van Houtte F, Verhoye L, Mesalam AA, Ciesek S, Roingeard P, Wedemeyer H, Leroux-Roels G, Meuleman P. A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection. JHEP Rep 2023;5:100646. [PMID: 36748051 DOI: 10.1016/j.jhepr.2022.100646] [Reference Citation Analysis]
|
| 53 |
Karakousis ND, Chrysavgis L, Papatheodoridi A, Legaki A, Lembessis P, Cholongitas E, Chatzigeorgiou A, Papatheodoridis G. Significance of Circulating Cell-Free DNA Biomarkers in HBeAg-Negative Chronic Hepatitis B Virus Infection and Their Changes after Treatment Initiation. Pathogens 2023;12:394. [DOI: 10.3390/pathogens12030394] [Reference Citation Analysis]
|
| 54 |
Choi WM, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Cant H, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Lim YS. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol 2023;78:534-42. [PMID: 36572349 DOI: 10.1016/j.jhep.2022.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 55 |
Yip TC, Wong VW, Lai MS, Lai JC, Hui VW, Liang LY, Tse YK, Chan HL, Wong GL. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss. J Hepatol 2023;78:524-33. [PMID: 36463985 DOI: 10.1016/j.jhep.2022.11.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Wang J, Zhang X, Han J, Zhou P, Yu X, Shen Z, Mao R, Lu M, Huang Y, Zhang J. MicroRNA-124 expression in Kupffer cells modulates liver injury by targeting IL-6/STAT3 signaling. Antiviral Res 2023;211:105510. [PMID: 36581048 DOI: 10.1016/j.antiviral.2022.105510] [Reference Citation Analysis]
|
| 57 |
Zhang S, Wang C, Liu B, Lu Q, Shang J, Zhou Y, Jia J, Xu X, Rao H, Han B, Zhao T, Chen L, Xie M, Cui J, Du J, zeng J, huang N, Liu Y, Zhang L, Zhuang H, Cui F. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation. The Lancet Regional Health - Western Pacific 2023. [DOI: 10.1016/j.lanwpc.2023.100738] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 58 |
Hang LTT, Trinh HKT, An LB, Tuyet NT, Tho PV, Huy NT, Hoa PTL. Dysregulation of T Cell Differentiation and the IL17A(+)Foxp3(+)Treg Subset in Chronic Hepatitis B Patients with Hepatitis Flare. Viral Immunol 2023;36:127-35. [PMID: 36857742 DOI: 10.1089/vim.2022.0140] [Reference Citation Analysis]
|
| 59 |
Cochrane Hepato-Biliary Group, Jing Wu, Shitong Xie, Yanfang Ma, Xiaoning He, Xinyue Dong, Qianling Shi, Qiangqiang Guo, Qi Wang, Meixuan Li, Naijuan Yao, Liang Yao. Entecavir for children and adults with chronic hepatitis B. Cochrane Database Syst Rev 2023;2023:CD015536. [ DOI: 10.1002/14651858.CD015536] [Reference Citation Analysis]
|
| 60 |
Tan YW, Wang JM, Zhou XB. Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease. World J Hepatol 2023;15:237-54. [PMID: 36926239 DOI: 10.4254/wjh.v15.i2.237] [Reference Citation Analysis]
|
| 61 |
Nguyen TK, Van Le D. Resistant mutations within the hepatitis B virus reverse transcriptase sequence in treatment failure patients with chronic HBV infection in Vietnam. J Glob Antimicrob Resist 2023;33:35-41. [PMID: 36849052 DOI: 10.1016/j.jgar.2023.02.013] [Reference Citation Analysis]
|
| 62 |
Gao Y, Zhu L, Xiao H, Yang C, Xu J, Mou F, Tang Y. Clinical study of the value of shear wave elastography in evaluating the degree of liver fibrosis in children. Abdom Radiol (NY) 2023. [PMID: 36811726 DOI: 10.1007/s00261-023-03837-w] [Reference Citation Analysis]
|
| 63 |
Zeng Y, Huang J, Pang J, Wu Y, Li B, Jie Y, Li X, Chong Y. PD-1 Inhibitor-based Therapies Could Lead to A Diversity of Viral Kinetics in Cancer Patients with Concomitant HBV Infection.. [DOI: 10.21203/rs.3.rs-2573373/v1] [Reference Citation Analysis]
|
| 64 |
Zhao Y, Gong C, Xu J, Chen D, Yang B, Chen Z, Wei L. Research Progress of Fecal Microbiota Transplantation in Liver Diseases. J Clin Med 2023;12. [PMID: 36836218 DOI: 10.3390/jcm12041683] [Reference Citation Analysis]
|
| 65 |
Fabrizi F, Donato MF, Tripodi F, Regalia A, Lampertico P, Castellano G. The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights. Pathogens 2023;12. [PMID: 36839612 DOI: 10.3390/pathogens12020340] [Reference Citation Analysis]
|
| 66 |
Kim D, Choi Y, Rhu J, Hwang S, You YK, Kim D, Nah YW, Kim B, Cho JY, Kang KJ, Yang JD, Choi D, Joo DJ, Kim MS, Ryu JH, Lee JG. Entecavir versus tenofovir on recurrence of hepatitis B virus–related hepatocellular carcinoma in liver transplantation.. [DOI: 10.21203/rs.3.rs-2568480/v1] [Reference Citation Analysis]
|
| 67 |
Liu J, Kam LY, Huang DQ, Henry L, Cheung R, Nguyen MH. Racial and Ethnic Disparities in Characteristics and Care Patterns of Chronic Hepatitis B Patients in the United States. Clin Gastroenterol Hepatol 2023:S1542-3565(23)00102-7. [PMID: 36781005 DOI: 10.1016/j.cgh.2023.01.035] [Reference Citation Analysis]
|
| 68 |
Hong X, Xiao Y, Xu L, Liu L, Mo H, Mo H. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. Immun Inflamm Dis 2023;11:e780. [PMID: 36840482 DOI: 10.1002/iid3.780] [Reference Citation Analysis]
|
| 69 |
Nardone A, Nerlander L, Duffell E, Valenciano M, Buti M, Marcos-Fosch C, Nemeth-Blažić T, Popovici O, Vince A, Filip PV, Filipec T, Kosanović Ličina ML, Luksic B, Nonković D, Pop CS, Radu F, Teodorescu I, Topan AV. A pilot sentinel surveillance system to monitor treatment and treatment outcomes of chronic hepatitis B and C infections in clinical centres in three European countries, 2019. Euro Surveill 2023;28. [PMID: 36757314 DOI: 10.2807/1560-7917.ES.2023.28.6.2200184] [Reference Citation Analysis]
|
| 70 |
Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet 2023:S0140-6736(22)01468-4. [PMID: 36774930 DOI: 10.1016/S0140-6736(22)01468-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 71 |
Watanabe M, Toyoda H, Kawabata T. Rapid quantification assay of hepatitis B virus DNA in human serum and plasma by Fully Automated Genetic Analyzer μTASWako g1. PLoS One 2023;18:e0278143. [PMID: 36758029 DOI: 10.1371/journal.pone.0278143] [Reference Citation Analysis]
|
| 72 |
Wong RJ, Kaufman HW, Niles JK, Kapoor H, Gish RG. Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination. Clin Infect Dis 2023;76:e791-800. [PMID: 35594550 DOI: 10.1093/cid/ciac385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 73 |
Mazzaro C, Bomben R, Visentini M, Gragnani L, Quartuccio L, Saccardo F, Sebastiani M, Filippini D, Lauletta G, Monti G, Gattei V. Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature. Front Oncol 2023;13:1095780. [PMID: 36824142 DOI: 10.3389/fonc.2023.1095780] [Reference Citation Analysis]
|
| 74 |
Liu Z, Li W, Zhu Z, Wen H, Li MD, Hou C, Shen H, Huang B, Luo Y, Wang W, Chen X. A deep learning model with data integration of ultrasound contrast-enhanced micro-flow cines, B-mode images, and clinical parameters for diagnosing significant liver fibrosis in patients with chronic hepatitis B. Eur Radiol 2023. [PMID: 36735040 DOI: 10.1007/s00330-023-09436-z] [Reference Citation Analysis]
|
| 75 |
Freeland C, Cohen C. The impact of a hepatitis B diagnosis. Gastrointestinal Nursing 2023;21:S8-S10. [DOI: 10.12968/gasn.2023.21.sup1.s8] [Reference Citation Analysis]
|
| 76 |
Langat B, Muge EK, Night D, Okoth F, Ochwedo KO, Songok EM. Sero-prevalence of hepatitis B virus and compliance with hepatitis B vaccination schedules among outpatient clinic attendees in Nairobi. PLoS One 2023;18:e0281256. [PMID: 36730277 DOI: 10.1371/journal.pone.0281256] [Reference Citation Analysis]
|
| 77 |
Jachs M, Reiberger T, Ferenci P. Letter: chronic HDV infection-is ignorance bliss? Authors' reply. Aliment Pharmacol Ther 2023;57:359-60. [PMID: 36641789 DOI: 10.1111/apt.17355] [Reference Citation Analysis]
|
| 78 |
Hasan I, Loho IM, Setiawan PB, Djumhana A, Purnomo HD, Siregar L, Gani RA, Sulaiman AS, Lesmana CRA. Indonesian consensus on systemic therapies for hepatocellular carcinoma. Asia Pac J Clin Oncol 2023;19:263-74. [PMID: 35599455 DOI: 10.1111/ajco.13768] [Reference Citation Analysis]
|
| 79 |
Blaney H, Khalid M, Heller T, Koh C. Epidemiology, presentation, and therapeutic approaches for hepatitis D infections. Expert Rev Anti Infect Ther 2023;21:127-42. [PMID: 36519386 DOI: 10.1080/14787210.2023.2159379] [Reference Citation Analysis]
|
| 80 |
Feng Y, Yao N, Shi L, Zhu Y, Liu J, He Y, Zhao Y, Chen T. Efficacy and safety of long-term postpartum antiviral therapy in hepatitis B virus-infected mothers receiving prophylactic tenofovir disoproxil fumarate treatment. Eur J Gastroenterol Hepatol 2023;35:212-8. [PMID: 36574312 DOI: 10.1097/MEG.0000000000002476] [Reference Citation Analysis]
|
| 81 |
Lee HA, Kim SU, Seo YS, Ahn SH, Rim CH. Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis. Hepatol Commun 2023;7:e0011. [PMID: 36691962 DOI: 10.1097/HC9.0000000000000011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 82 |
Niemann G, Germer M, Hauf M, Poelsler G, Röder J, Schüttrumpf J. Hyperimmunplasma: Gewinnung, Verarbeitung und therapeutische Anwendungen. Transfusionsmedizin 2023;13:18-29. [DOI: 10.1055/a-1894-1146] [Reference Citation Analysis]
|
| 83 |
Pawlotsky JM. New hepatitis B drug development disillusions: time to reset? Lancet Gastroenterol Hepatol 2023;8:192-7. [PMID: 36343654 DOI: 10.1016/S2468-1253(22)00341-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 84 |
Jindal A, Sarin SK. Hepatitis B: "Treat all" or "Treat select". Hepatol Int 2023;17:38-41. [PMID: 36316600 DOI: 10.1007/s12072-022-10441-5] [Reference Citation Analysis]
|
| 85 |
Shui LP, Zhu Y, Duan XQ, Chen YT, Yang L, Tang XQ, Zhang HB, Xiao Q, Wang L, Liu L, Luo XH. HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy. J Med Virol 2023;95:e28549. [PMID: 36734081 DOI: 10.1002/jmv.28549] [Reference Citation Analysis]
|
| 86 |
Chen CH, Jeng WJ, Hu TH, Liu YC, Wang JH, Hung CH, Lu SN, Chien RN. HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide. Dig Liver Dis 2023:S1590-8658(23)00165-2. [PMID: 36737315 DOI: 10.1016/j.dld.2023.01.154] [Reference Citation Analysis]
|
| 87 |
Durantel D. Therapies against chronic hepatitis B infections: The times they are a-changin', but the changing is slow! Antiviral Res 2023;210:105515. [PMID: 36603773 DOI: 10.1016/j.antiviral.2022.105515] [Reference Citation Analysis]
|
| 88 |
Hu M, Liao G, Wei S, Qian Z, Chen H, Xia M, Xie Q, Peng J. Effective Analysis of Antiviral Treatment in Patients with HBeAg-Seropositive Chronic Hepatitis B with ALT < 2 Upper Limits of Normal: A Multi-center Retrospective Cohort Study. Infect Dis Ther 2023;12:637-47. [PMID: 36633817 DOI: 10.1007/s40121-022-00757-y] [Reference Citation Analysis]
|
| 89 |
Piscitani L, Leone S, Di Biase J, Salvati L, Sirolli V, Tunno M, Bonomini M. Efficacy of hemoperfusion with Seraph-100 in series with single pass albumin dialysis in acute hepatitis B infection: A case report. Int J Artif Organs 2023;46:81-4. [PMID: 36482663 DOI: 10.1177/03913988221143142] [Reference Citation Analysis]
|
| 90 |
Dezan MGF, Cavalcante LN, Cotrim HP, Lyra AC. Hepatobiliary disease after bone marrow transplant. Expert Rev Gastroenterol Hepatol 2023;17:129-43. [PMID: 36655915 DOI: 10.1080/17474124.2023.2169671] [Reference Citation Analysis]
|
| 91 |
Luo H, Hu X, Li Y, Lei D, Tan G, Zeng Y, Qin B. The antiviral activity of tripartite motif protein 38 in hepatitis B virus replication and gene expression and its association with treatment responses during PEG-IFN-α antiviral therapy. Virology 2023;579:84-93. [PMID: 36623352 DOI: 10.1016/j.virol.2022.12.014] [Reference Citation Analysis]
|
| 92 |
Brakenhoff SM, Hoekstra R, Honkoop P, Roomer R, den Hollander JG, Bezemer G, de Knegt RJ, Sonneveld MJ, de Man RA. Patients treated with rituximab are poorly screened for hepatitis B infection: Data from a low-incidence country. Eur J Intern Med 2023;108:68-73. [PMID: 36462966 DOI: 10.1016/j.ejim.2022.11.024] [Reference Citation Analysis]
|
| 93 |
Etienne S, Vosbeck J, Bernsmeier C, Osthoff M. Prevention of Hepatitis B Reactivation in Patients Receiving Immunosuppressive Therapy: a Case Series and Appraisal of Society Guidelines. J Gen Intern Med 2023;38:490-501. [PMID: 36138278 DOI: 10.1007/s11606-022-07806-9] [Reference Citation Analysis]
|
| 94 |
Liu Y, Wu Y, Jiang X, Chen B, Lu J, Cai Z, Fu B, Zheng W, Wu R, Chen G, Tian S, Ren J. Apolipoprotein H induces sex-specific steatohepatitis and gut dysbiosis during chronic hepatitis B infection. iScience 2023;26:106100. [PMID: 36852272 DOI: 10.1016/j.isci.2023.106100] [Reference Citation Analysis]
|
| 95 |
El Messaoudi S, Lemenuel-Diot A, Gonçalves A, Guedj J. A Semi-mechanistic Model to Characterize the Long-Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon. Clin Pharmacol Ther 2023;113:390-400. [PMID: 36408671 DOI: 10.1002/cpt.2798] [Reference Citation Analysis]
|
| 96 |
Robinson A, Wong R, Gish RG. Chronic Hepatitis B Virus and Hepatitis D Virus: New Developments. Clin Liver Dis 2023;27:17-25. [PMID: 36400464 DOI: 10.1016/j.cld.2022.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 97 |
Crespo J, Cabezas J, Aguilera A, Berenguer M, Buti M, Forns X, García F, García-Samaniego J, Hernández-Guerra M, Jorquera F, Lazarus JV, Lens S, Martró E, Pineda JA, Prieto M, Rodríguez-Frías F, Rodríguez M, Serra MÁ, Turnes J, Domínguez-Hernández R, Casado MÁ, Calleja JL. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction. Gastroenterol Hepatol 2023;46:150-62. [PMID: 36257502 DOI: 10.1016/j.gastrohep.2022.09.009] [Reference Citation Analysis]
|
| 98 |
Li H, Niu X, Zhang Y, Zhang D, Zhang Y, Wang L, Miao Y, Jiang Y, Ji J, Chen Q, Wu X, Ediage EN, Kakuda TN, Biermer M. Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants. Clin Pharmacol Drug Dev 2023;12:175-80. [PMID: 36415122 DOI: 10.1002/cpdd.1197] [Reference Citation Analysis]
|
| 99 |
Suda G, Baba M, Yamamoto Y, Sho T, Ogawa K, Kimura M, Hosoda S, Yoshida S, Kubo A, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Kobayashi T, Tsunematsu I, Sakamoto N. Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis. J Med Virol 2023;95:e28452. [PMID: 36597900 DOI: 10.1002/jmv.28452] [Reference Citation Analysis]
|
| 100 |
Howell J, Van H, Pham MD, Sawhney R, Li F, Bhat P, Lubel J, Kemp W, Bloom S, Majumdar A, McCaughan GW, Hall S, Spelman T, Doyle JS, Hellard M, Visvanathan K, Thompson A, Drummer HE, Anderson D. Validation of a novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study. Liver Int 2023. [PMID: 36719055 DOI: 10.1111/liv.15531] [Reference Citation Analysis]
|
| 101 |
Ouyang S, Chen Z, Peng T, Geng Y, Qiu J, Xiao Z, Pan CQ. Incidence and predictors of elevated postpartum alanine aminotransferase in chronic hepatitis B mothers.. [DOI: 10.21203/rs.3.rs-2501080/v1] [Reference Citation Analysis]
|
| 102 |
Bi X, Xie S, Wu S, Cao W, Lin Y, Yang L, Jiang T, Deng W, Wang S, Liu R, Gao Y, Shen G, Chang M, Hao H, Xu M, Chen X, Hu L, Lu Y, Zhang L, Xie Y, Li M. Changes of natural killer cells' phenotype in patients with chronic hepatitis B in intermittent interferon therapy. Front Immunol 2023;14:1116689. [PMID: 36793722 DOI: 10.3389/fimmu.2023.1116689] [Reference Citation Analysis]
|
| 103 |
Liu M, Liu X, Pan M, Zhang Y, Tang X, Liu W, Zhao M, Ma J, Zhou N, Jiang Y, Wang W, Liu M. Characterization and microRNA Expression Analysis of Serum-Derived Extracellular Vesicles in Severe Liver Injury from Chronic HBV Infection. Life (Basel) 2023;13. [PMID: 36836704 DOI: 10.3390/life13020347] [Reference Citation Analysis]
|
| 104 |
Lazarevic I, Banko A, Miljanovic D, Cupic M. Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas. Viruses 2023;15. [PMID: 36851587 DOI: 10.3390/v15020373] [Reference Citation Analysis]
|
| 105 |
Karaoglu DA, Uner M, Simsek C, Gure AO, Demirkol-Canli S. Transcriptomic Analysis of Hepatitis B Infected Liver for Prediction of Hepatocellular Carcinoma. Biology (Basel) 2023;12. [PMID: 36829466 DOI: 10.3390/biology12020188] [Reference Citation Analysis]
|
| 106 |
Makokha GN, Zhang P, Hayes CN, Songok E, Chayama K. The burden of Hepatitis B virus infection in Kenya: A systematic review and meta-analysis. Front Public Health 2023;11:986020. [PMID: 36778557 DOI: 10.3389/fpubh.2023.986020] [Reference Citation Analysis]
|
| 107 |
Janssen HLA, Hou J, Asselah T, Chan HLY, Zoulim F, Tanaka Y, Janczewska E, Nahass RG, Bourgeois S, Buti M, Lampertico P, Lenz O, Verbinnen T, Vandenbossche J, Talloen W, Kalmeijer R, Beumont M, Biermer M, Shukla U. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut 2023:gutjnl-2022-328041. [PMID: 36697207 DOI: 10.1136/gutjnl-2022-328041] [Reference Citation Analysis]
|
| 108 |
Liu Y, Fu S, Yu X, Zhang J, Zhu S, Yang Y, Huang J, Luo H, Tang K, Zheng Y, Zhao Y, Chen X, Zhan M, He X, Li Q, Duan C, Chen Y, Lu L. Model containing sarcopenia and visceral adiposity can better predict the survival of hepatocellular carcinoma: A multicenter study.. [DOI: 10.21203/rs.3.rs-2438953/v1] [Reference Citation Analysis]
|
| 109 |
Burdette D, Hyrina A, Song Z, Beran RK, Cheung T, Gilmore S, Kobayashi T, Li L, Liu Y, Niedziela-Majka A, Medley J, Mehra U, Morganelli P, Novikov N, Niu C, Tam D, Tang J, Wang J, Yue Q, Fletcher SP, Holdorf MM, Delaney WE 4th, Feierbach B, Lazerwith S. Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection. Antimicrob Agents Chemother 2023;67:e0134822. [PMID: 36519892 DOI: 10.1128/aac.01348-22] [Reference Citation Analysis]
|
| 110 |
Han K, Ito H, Elston R, Cremer J, Hood S, Paff M, Theodore D. Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region. Antimicrob Agents Chemother 2023;67:e0090022. [PMID: 36507675 DOI: 10.1128/aac.00900-22] [Reference Citation Analysis]
|
| 111 |
Wang WX, Jia R, Jin XY, Li X, Zhou SN, Zhang XN, Zhou CB, Wang FS, Fu J. Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients. Front Immunol 2023;14:1121778. [PMID: 36756119 DOI: 10.3389/fimmu.2023.1121778] [Reference Citation Analysis]
|
| 112 |
Stephan AS, Kosinska AD, Mück-Häusl M, Muschaweckh A, Jäger C, Röder N, Heikenwälder M, Dembek C, Protzer U. Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice. Vaccines (Basel) 2023;11. [PMID: 36851121 DOI: 10.3390/vaccines11020245] [Reference Citation Analysis]
|
| 113 |
Lee HA, Lee YS, Jung YK, Kim JH, Yim HJ, Yeon JE, Seo YS, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA. J Gastroenterol Hepatol 2023. [PMID: 36681856 DOI: 10.1111/jgh.16132] [Reference Citation Analysis]
|
| 114 |
Surial B, Ramírez Mena A, Roumet M, Limacher A, Smit C, Leleux O, Mocroft A, van der Valk M, Bonnet F, Peters L, Rockstroh JK, Günthard HF, Berzigotti A, Rauch A, Wandeler G; Swiss HIV Cohort Study, ATHENA Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection. J Hepatol 2023:S0168-8278(23)00011-9. [PMID: 36690280 DOI: 10.1016/j.jhep.2022.12.029] [Reference Citation Analysis]
|
| 115 |
Schmit N, Nayagam S, Lemoine M, Ndow G, Shimakawa Y, Thursz MR, Hallett TB. Cost-effectiveness of different monitoring strategies in a screening and treatment programme for hepatitis B in The Gambia. J Glob Health 2023;13:04004. [PMID: 36655869 DOI: 10.7189/jogh.13.04004] [Reference Citation Analysis]
|
| 116 |
Kuznetsov NI, Moiseeva IE. Modern principles of etiotropic therapy for chronic hepatitis B and C. Russian Family Doctor 2023;26:7-15. [DOI: 10.17816/rfd112383] [Reference Citation Analysis]
|
| 117 |
Congly SE, Syed A, Haylock-jacobs S, Israelson H, Pinto J, Williams S, Lee SS, Coffin CS. A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B. Canadian Liver Journal 2023. [DOI: 10.3138/canlivj-2022-0043] [Reference Citation Analysis]
|
| 118 |
Shao J, Wang Y, Hu L, Zhang L, Lyu C. Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-naïve chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants. Clin Exp Med 2023. [PMID: 36648567 DOI: 10.1007/s10238-023-00990-w] [Reference Citation Analysis]
|
| 119 |
Zhang Q, Niu S, Yang L, Zhu B, Shi K, Zhang X, Zhang Y, Bi Y, Mu Y, Wang X. A novel prognostic model for predicting the risk of first variceal hemorrhage in patients with HBV-related cirrhosis. Front Cell Infect Microbiol 2023;13:1062172. [PMID: 36733609 DOI: 10.3389/fcimb.2023.1062172] [Reference Citation Analysis]
|
| 120 |
Lee Y, Bae S, Kim JH, Kwak M, Jeon SY, Kim T, Yim SY, Lee YS, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS. Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study. J Clin Med 2023;12. [PMID: 36675640 DOI: 10.3390/jcm12020712] [Reference Citation Analysis]
|
| 121 |
Zhao Y, Song Y, Zhang H, Qu T, Axinbai M, Yang Y, Zhang L. Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis. Front Oncol 2022;12:1050714. [PMID: 36727050 DOI: 10.3389/fonc.2022.1050714] [Reference Citation Analysis]
|
| 122 |
Shen C, Jiang X, Li M, Luo Y. Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances. Cancers (Basel) 2023;15. [PMID: 36672482 DOI: 10.3390/cancers15020533] [Reference Citation Analysis]
|
| 123 |
Reiberger T, Hofer BS. The Baveno VII concept of cirrhosis recompensation. Dig Liver Dis 2023:S1590-8658(22)00860-X. [PMID: 36646527 DOI: 10.1016/j.dld.2022.12.014] [Reference Citation Analysis]
|
| 124 |
Pimkova Polidarova M, Vanekova L, Brehova P, Dejmek M, Vavrina Z, Birkus G, Brazdova A. Synthetic Stimulator of Interferon Genes (STING) Agonists Induce a Cytokine-Mediated Anti-Hepatitis B Virus Response in Nonparenchymal Liver Cells. ACS Infect Dis 2023;9:23-32. [PMID: 36472628 DOI: 10.1021/acsinfecdis.2c00424] [Reference Citation Analysis]
|
| 125 |
Wen C, Dong Z, Wang Y, Ye G, Ma Y, Yi X, Zhou Y, Li X, Zheng X, Hou J, Li Y, Tang L. CTLA4(+)CD4(+)CXCR5(-)FOXP3(+) T cells associate with unfavorable outcome in patients with chronic HBV infection. BMC Immunol 2023;24:3. [PMID: 36635631 DOI: 10.1186/s12865-022-00537-w] [Reference Citation Analysis]
|
| 126 |
Conway Morris A, Smielewska A. Viral infections in critical care: a narrative review. Anaesthesia 2023. [PMID: 36633460 DOI: 10.1111/anae.15946] [Reference Citation Analysis]
|
| 127 |
Shuaib BI, Mohammed M, Usman AR, Bola BT, Audu O, Hamid MA, Abidemi MM, Pius OO, Daud A, Umeche IE, Latifat L, Isah SS, Adeiza MA. Evaluation of some Haematological and Immunologic Parameters as Adjunct marker to Viral Load in HBV Management in a Resource-Constrained Setting.. [DOI: 10.21203/rs.3.rs-2377152/v1] [Reference Citation Analysis]
|
| 128 |
Wong NS, Chan DPC, Poon CM, Chan CP, Lau LHW, Yeoh EK, Lee SS. Hepatitis B burden and population immunity in a high endemicity city - a geographically random household epidemiology study for evaluating achievability of elimination. Epidemiol Infect 2023;151:e22. [PMID: 36628568 DOI: 10.1017/S095026882300002X] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 129 |
Teng J, Du Y, Visalath P, Zhou T, Du B, Zhang Q, Cai W. A noninvasive model discriminating significant histological changes in treatment-naive chronic hepatitis B patients with normal ALT. Virol J 2023;20:7. [PMID: 36631824 DOI: 10.1186/s12985-023-01963-x] [Reference Citation Analysis]
|
| 130 |
Kushner T. Delta hepatitis epidemiology and the global burden of disease. J Viral Hepat 2023. [PMID: 36625781 DOI: 10.1111/jvh.13797] [Reference Citation Analysis]
|
| 131 |
Majeed NA, Hitawala AA, Heller T, Koh C. Diagnosis of HDV: From virology to non-invasive markers of fibrosis. Liver Int 2023. [PMID: 36621853 DOI: 10.1111/liv.15515] [Reference Citation Analysis]
|
| 132 |
Manso T, de Salazar A, Rodríguez-Velasco M, García F, Aguilera A. Detection and quantification of HBV and HCV in plasma samples by means of different molecular assays: Comparative study. Enferm Infecc Microbiol Clin (Engl Ed) 2023:S2529-993X(22)00298-2. [PMID: 36624027 DOI: 10.1016/j.eimce.2022.12.007] [Reference Citation Analysis]
|
| 133 |
Dusheiko G, Agarwal K, Maini MK. New Approaches to Chronic Hepatitis B. N Engl J Med 2023;388:55-69. [PMID: 36599063 DOI: 10.1056/NEJMra2211764] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 134 |
Zeng Z, Liu R, Cao W, Yang L, Lin Y, Bi X, Jiang T, Deng W, Wang S, Lu H, Sun F, Shen G, Chang M, Lu Y, Wu S, Hao H, Xu M, Chen X, Hu L, Zhang L, Wan G, Xie Y, Li M. Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative. Front Immunol 2022;13:1113070. [PMID: 36685494 DOI: 10.3389/fimmu.2022.1113070] [Reference Citation Analysis]
|
| 135 |
Duah A, Nartey YA. Clinical Profile and Limitations in the Management of HBV Patients Attending Clinic at a District Hospital in Ghana. Int J Hepatol 2023;2023:4424718. [PMID: 36643337 DOI: 10.1155/2023/4424718] [Reference Citation Analysis]
|
| 136 |
Johannessen A, Stockdale AJ, Henrion MYR, Okeke E, Seydi M, Wandeler G, Sonderup M, Spearman CW, Vinikoor M, Sinkala E, Desalegn H, Fall F, Riches N, Davwar P, Duguru M, Maponga T, Taljaard J, Matthews PC, Andersson M, Mboup S, Sombie R, Shimakawa Y, Lemoine M. Systematic review and individual-patient-data meta-analysis of non-invasive fibrosis markers for chronic hepatitis B in Africa. Nat Commun 2023;14:45. [PMID: 36596805 DOI: 10.1038/s41467-022-35729-w] [Reference Citation Analysis]
|
| 137 |
Hansi NK, Suddle AR. Hematology. The Liver in Systemic Disease 2023. [DOI: 10.1002/9781119802181.ch15] [Reference Citation Analysis]
|
| 138 |
Sheng LP, Zhang JC, Zhong ZQ, Sheng XH, Ren J, Wang GQ. High-potency nucleos(t)ide analogues alone or plus immunoglobulin for HBV prophylaxis after liver transplantation: a meta-analysis. Hepatol Int 2023. [PMID: 36592270 DOI: 10.1007/s12072-022-10466-w] [Reference Citation Analysis]
|
| 139 |
Santos M, Corma-Gómez A, Fernandez-Fuertes M, González-Serna A, Rincón P, Real LM, Pineda JA, Macías J. Burden of significant liver damage in people living with HIV after microelimination of the hepatitis C virus. J Infect 2023;86:41-6. [PMID: 36410455 DOI: 10.1016/j.jinf.2022.11.004] [Reference Citation Analysis]
|
| 140 |
Inoue T, Tanaka Y. Noninvasive assessments of liver disease severity based on biomarkers. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00009-4] [Reference Citation Analysis]
|
| 141 |
Indolfi G, Nicastro E. Hepatitis during childhood. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00031-8] [Reference Citation Analysis]
|
| 142 |
Ito T, Nguyen MH. Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes. J Hepatocell Carcinoma 2023;10:413-28. [PMID: 36926055 DOI: 10.2147/JHC.S347959] [Reference Citation Analysis]
|
| 143 |
Yan R, Cai D, Zong Y, Guo L, Zhou Y, Tang A, Li L, Huang Q, Colonno R, Walker MA. Preclinical characterization of ABI-H2158, an HBV core inhibitor with dual mechanisms of action. Antiviral Res 2023;209:105485. [PMID: 36509208 DOI: 10.1016/j.antiviral.2022.105485] [Reference Citation Analysis]
|
| 144 |
Downs LO, Campbell C, Yonga P, Githinji G, Ansari MA, Matthews PC, Etyang AO. A systematic review of Hepatitis B virus (HBV) prevalence and genotypes in Kenya: Data to inform clinical care and health policy. PLOS Glob Public Health 2023;3:e0001165. [PMID: 36963057 DOI: 10.1371/journal.pgph.0001165] [Reference Citation Analysis]
|
| 145 |
Mak LY, Seto WK, Yuen MF. Correspondence on Editorial regarding "HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB". Clin Mol Hepatol 2023;29:191-3. [PMID: 36417889 DOI: 10.3350/cmh.2022.0410] [Reference Citation Analysis]
|
| 146 |
Zhang C, Li J, Cheng Y, Meng F, Song JW, Fan X, Fan H, Li J, Fu YL, Zhou MJ, Hu W, Wang SY, Fu YJ, Zhang JY, Xu RN, Shi M, Hu X, Zhang Z, Ren X, Wang FS. Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients. Gut 2023;72:153-67. [PMID: 35361683 DOI: 10.1136/gutjnl-2021-325915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 147 |
Lu H, Cao W, Zhang L, Yang L, Bi X, Lin Y, Deng W, Jiang T, Sun F, Zeng Z, Lu Y, Zhang L, Liu R, Gao Y, Wu S, Hao H, Chen X, Hu L, Xu M, Xiong Q, Dong J, Song R, Li M, Xie Y. Effects of hepatitis B virus infection and strategies for preventing mother-to-child transmission on maternal and fetal T-cell immunity. Front Immunol 2023;14:1122048. [PMID: 36875136 DOI: 10.3389/fimmu.2023.1122048] [Reference Citation Analysis]
|
| 148 |
Guo Y, Han J, Zhang Y, Jin C, Zhang Y, He J, Chen S, Guo Y, Lin Y, Li F, Yang F, Shen Z, Mao R, Zhu H, Zhang J. End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation. Front Cell Infect Microbiol 2023;13:1120300. [PMID: 36909726 DOI: 10.3389/fcimb.2023.1120300] [Reference Citation Analysis]
|
| 149 |
Volinsky I. Mathematical Analysis of Hepatitis B Virus Combination Treatment. Springer Proceedings in Mathematics & Statistics 2023. [DOI: 10.1007/978-3-031-21484-4_22] [Reference Citation Analysis]
|
| 150 |
Squires KE, Ogilvie L, Jucov A, Anastasiy I, Ghicavii N, Huguet J, Melara R, Constantineau M, De La Rosa A, Mayers DL. A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection. J Viral Hepat 2023;30:19-28. [PMID: 36201354 DOI: 10.1111/jvh.13753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 151 |
Kim-jun Teh K, Pik-eu Chang J, Boon-bee Goh G. Noninvasive assessment of liver disease severity: image-related. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00014-8] [Reference Citation Analysis]
|
| 152 |
Umami RN, Anwar RI, Murtiyaningsih H, Mustopa AZ. Cloning and Expression of HBcAg Using Food Grade Vector pNZ8149 in Lactococcus Lactis for the Development of HBV Therapeutic Vaccine. Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022) 2023. [DOI: 10.2991/978-94-6463-112-8_76] [Reference Citation Analysis]
|
| 153 |
Mak L, Yuen M. Hepatitis B: treatment. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00001-x] [Reference Citation Analysis]
|
| 154 |
van der Spek DPC, Katwaroe WK, van Kleef LA, Brakenhoff S, de Man RA, de Knegt RJ, van der Meer AJ, Sonneveld MJ. Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980-2020. Eur J Intern Med 2023;107:86-92. [PMID: 36396524 DOI: 10.1016/j.ejim.2022.11.012] [Reference Citation Analysis]
|
| 155 |
Shen Y, Wu SD, Chen Y, Li XY, Zhu Q, Nakayama K, Zhang WQ, Weng CZ, Zhang J, Wang HK, Wu J, Jiang W. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response. Gut Microbes 2023;15:2155018. [PMID: 36519342 DOI: 10.1080/19490976.2022.2155018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 156 |
Stockdale AJ. Hepatitis D. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00027-6] [Reference Citation Analysis]
|
| 157 |
Seto MT, Cheung KW. Hepatitis during pregnancy. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00032-x] [Reference Citation Analysis]
|
| 158 |
Kirino S, Tamaki N, Kurosaki M, Kaneko S, Inada K, Tanaka Y, Ishido S, Yamashita K, Nobusawa T, Matsumoto H, Hayakawa Y, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B. Hepatol Res 2023;53:35-42. [PMID: 36117296 DOI: 10.1111/hepr.13839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 159 |
Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study. Eur J Intern Med 2023;107:66-72. [PMID: 36347739 DOI: 10.1016/j.ejim.2022.10.026] [Reference Citation Analysis]
|
| 160 |
Dieterich D, Graham C, Wang S, Kwo P, Lim Y, Liu C, Agarwal K, Sulkowski M. It Is Time for a Simplified Approach to Hepatitis B Elimination. Gastro Hep Advances 2023;2:209-218. [DOI: 10.1016/j.gastha.2022.10.004] [Reference Citation Analysis]
|
| 161 |
Gusmao C, Tanesi MY, Gomes N, Sheridan SL, Sarmento N, Oakley T, David M, Wapling J, Alves L, Amaral S, Draper AD, Cruz B, Coelho D, Guterres H, Fancourt NS, Yan J, Macartney K, Francis JR, Arkell P. Seroprevalence and prevention of hepatitis B, measles and rubella among healthcare workers in Dili, Timor-Leste. The Lancet Regional Health - Southeast Asia 2023. [DOI: 10.1016/j.lansea.2022.100133] [Reference Citation Analysis]
|
| 162 |
Gillespie IA, Chan KA, Liu Y, Hsieh SF, Schindler C, Cheng W, Chang R, Kap E, Morais E, Duh MS, Park S, Ketz M, Jenner S, Boxall N, Kendrick S, Theodore D. Characteristics, Treatment Patterns, and Clinical Outcomes of Chronic Hepatitis B Across 3 Continents: Retrospective Database Study. Adv Ther 2023;40:425-44. [PMID: 36350533 DOI: 10.1007/s12325-022-02284-1] [Reference Citation Analysis]
|
| 163 |
Ramadan HK, Hassan W, Elossily NA. Hepatitis B Virus Reactivation After COVID-19 Vaccination. Infect Dis Clin Pract 2023;31. [DOI: 10.1097/ipc.0000000000001207] [Reference Citation Analysis]
|
| 164 |
Giordano C, Picardi M, Pugliese N, Vincenzi A, Abagnale DP, De Fazio L, Giannattasio ML, Fatigati C, Ciriello M, Salemme A, Muccioli Casadei G, Vigliar E, Mascolo M, Troncone G, Pane F. Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21. Front Oncol 2023;13:1130899. [PMID: 36890828 DOI: 10.3389/fonc.2023.1130899] [Reference Citation Analysis]
|
| 165 |
Lok J, Veloz MFG, Agarwal K. Hepatitis C: treatment. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00017-3] [Reference Citation Analysis]
|
| 166 |
Choi W, Choi J, Lim Y. Hepatitis B: epidemiology, natural history, and diagnosis. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00007-0] [Reference Citation Analysis]
|
| 167 |
Mak LY, Wong D, Kuchta A, Hilfiker M, Hamilton A, Chow N, Mao X, Seto WK, Yuen MF. Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B. Clin Mol Hepatol 2023;29:146-62. [PMID: 35989092 DOI: 10.3350/cmh.2022.0172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 168 |
Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin IG, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp FA, Port K, Haag M, Schwab M, Zur Wiesch JS, Cornberg M, Haefeli WE, Dandri M, Alexandrov A, Urban S. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis 2023;23:117-29. [PMID: 36113537 DOI: 10.1016/S1473-3099(22)00318-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 169 |
Kaneko S, Kurosaki M, Mashiba T, Marusawa H, Kondo M, Kojima Y, Uchida Y, Fujii H, Akahane T, Yagisawa H, Kusakabe A, Kobashi H, Abe T, Yoshida H, Ogawa C, Furuta K, Tamaki N, Tsuji K, Matsushita T, Izumi N; Japanese Red Cross Liver Study Group. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B. J Med Virol 2023;95:e28210. [PMID: 36222204 DOI: 10.1002/jmv.28210] [Reference Citation Analysis]
|
| 170 |
Yardeni D, Chang KM, Ghany MG. Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure. Gastroenterology 2023;164:42-60.e6. [PMID: 36243037 DOI: 10.1053/j.gastro.2022.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 171 |
Pawlotsky J. Antivirals against hepatitis viruses: basic mechanisms. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00008-2] [Reference Citation Analysis]
|
| 172 |
Kong JH, Jang JY, Ko TH, Kang SH, Kim Y. High rate of hepatitis B reactivation during tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia in Korea. Blood Res 2022;57:290-3. [PMID: 36419239 DOI: 10.5045/br.2022.2022099] [Reference Citation Analysis]
|
| 173 |
Li Y, Chen W, Jin C, Wang T, Yao T, Feng S, Wang B, Feng Y, Wang S. Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine. Hum Vaccin Immunother 2022;18:2029259. [PMID: 35296227 DOI: 10.1080/21645515.2022.2029259] [Reference Citation Analysis]
|
| 174 |
Fischer J, Long S, Koukoulioti E, Müller T, Fueloep B, Heyne R, Eslam M, George J, Finkelmeier F, Waidmann O, Berg T, van Bömmel F. Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B. Pathogens 2022;12. [PMID: 36678401 DOI: 10.3390/pathogens12010054] [Reference Citation Analysis]
|
| 175 |
Hall SAL, Burns GS, Mooney BJ, Millen R, Morris R, Vogrin S, Sundararajan V, Ratnam D, Levy MT, Lubel JS, Nicoll AJ, Strasser SI, Sievert W, Desmond PV, Ngu MC, Angus P, Sinclair M, Meredith C, Matthews G, Revill PA, Jackson K, Littlejohn M, Bowden S, Locarnini SA, Thompson AJ, Visvanathan K. Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways. J Infect Dis 2022;227:123-32. [PMID: 36108079 DOI: 10.1093/infdis/jiac375] [Reference Citation Analysis]
|
| 176 |
Yun B, Oh J, Ahn SH, Yoon JH, Kim BK. Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study. Am J Gastroenterol 2022. [PMID: 36288330 DOI: 10.14309/ajg.0000000000002074] [Reference Citation Analysis]
|
| 177 |
Faenko AP, Filippova AA, Golosova SA, Glazov YN, Ivanova IV, Klyueva EA, Kasatkin MA. The introduction of Laboratory testing for anti-HBcore in blood donors. Gematologiâ i transfuziologiâ 2022;67:525-534. [DOI: 10.35754/0234-5730-2022-67-4-525-534] [Reference Citation Analysis]
|
| 178 |
Gridneva GI, Belov BS, Aronova ES. Chronic viral hepatitis B and rheumatic diseases: Modern view on problem. Medicinskij alfavit 2022. [DOI: 10.33667/2078-5631-2022-29-20-28] [Reference Citation Analysis]
|
| 179 |
Barreira Díaz A, Rando A, Feliu-Prius A, Palom A, Rodríguez-Frías F, Vargas-Accarino E, Vico-Romero J, Palomo N, Riveiro-Barciela M, Esteban R, Buti M. LINK-B: study protocol of a retrospective and prospective project for identification and linkage to care of people living with hepatitis B in a large health area of Barcelona. BMJ Open 2022;12:e062680. [PMID: 36564118 DOI: 10.1136/bmjopen-2022-062680] [Reference Citation Analysis]
|
| 180 |
Li H, Liang S, Liu L, Zhou D, Liu Y, Zhang Y, Chen X, Zhang J, Cao Z. Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon. Front Immunol 2022;13:1091786. [PMID: 36618361 DOI: 10.3389/fimmu.2022.1091786] [Reference Citation Analysis]
|
| 181 |
Chen DY, Chen HH, Chang SH, Chen YM, Huang PH, Hsieh CW, Lan JL, Tang KT. The Impact of b/tsDMARD Dose Reduction on Chronic Hepatitis B in Rheumatoid Arthritis Patients: A Two-Center Long-Term Safety Analysis. J Clin Med 2022;12. [PMID: 36614890 DOI: 10.3390/jcm12010086] [Reference Citation Analysis]
|
| 182 |
Tschäpe J, Cobernuss-Rahn A, Boyle S, Parkin N, LaBrot B, Aslam S, Young S, Gohl P. Multisite Performance Evaluation of the cobas 5800 System and Comparison to the cobas 6800/8800 Systems for Quantitative Measurement of HBV, HCV, and HIV-1 Viral Load. Microbiol Spectr 2022;10:e0312522. [PMID: 36314963 DOI: 10.1128/spectrum.03125-22] [Reference Citation Analysis]
|
| 183 |
Dey D, Pal S, Chakraborty BC, Baidya A, Bhadra S, Ghosh R, Banerjee S, Ahammed SKM, Chowdhury A, Datta S. Multifaceted Defects in Monocytes in Different Phases of Chronic Hepatitis B Virus Infection: Lack of Restoration after Antiviral Therapy. Microbiol Spectr 2022;10:e0193922. [PMID: 36445121 DOI: 10.1128/spectrum.01939-22] [Reference Citation Analysis]
|
| 184 |
Roy A, Roy M, Gacem A, Datta S, Zeyaullah M, Muzammil K, Farghaly TA, Abdellattif MH, Yadav KK, Simal-Gandara J. Role of bioactive compounds in the treatment of hepatitis: A review. Front Pharmacol 2022;13:1051751. [PMID: 36618936 DOI: 10.3389/fphar.2022.1051751] [Reference Citation Analysis]
|
| 185 |
Xu S, Huang J, Xun Z, Li S, Fu Y, Lin N, Wu W, Chen T, Liu C, Ou Q. IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro. Microbiol Spectr 2022;10:e0155722. [PMID: 36314949 DOI: 10.1128/spectrum.01557-22] [Reference Citation Analysis]
|
| 186 |
Asselah T. Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus. J Viral Hepat 2022. [PMID: 36529713 DOI: 10.1111/jvh.13789] [Reference Citation Analysis]
|
| 187 |
Chen JW, Cao XY, Qi X, Zhang JM. Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey. Medicine (Baltimore) 2022;101:e31980. [PMID: 36550809 DOI: 10.1097/MD.0000000000031980] [Reference Citation Analysis]
|
| 188 |
Jin X, Bi J. Prospects for NK-based immunotherapy of chronic HBV infection. Front Immunol 2022;13:1084109. [PMID: 36591230 DOI: 10.3389/fimmu.2022.1084109] [Reference Citation Analysis]
|
| 189 |
Fisicaro P. Engineered IFN-α and anti-PDL1 containing compounds to target the liver and restore antiviral protection for HBV cure. Gut 2022:gutjnl-2022-328902. [PMID: 36591618 DOI: 10.1136/gutjnl-2022-328902] [Reference Citation Analysis]
|
| 190 |
Wang CR, Liu XQ, Li H, Zhang Q, Zhong GC, Tang Q, Chang Y, Wang JS, Duan YQ, Hu P. PgRNA kinetics predict HBsAg reduction in pregnant chronic hepatitis B carriers after treatment cessation. Front Cell Infect Microbiol 2022;12:1055774. [PMID: 36579348 DOI: 10.3389/fcimb.2022.1055774] [Reference Citation Analysis]
|
| 191 |
Lourenço J, McNaughton AL, Pley C, Obolski U, Gupta S, Matthews PC. Polymorphisms predicting phylogeny in hepatitis B virus. Virus Evol 2023;9:veac116. [PMID: 36628296 DOI: 10.1093/ve/veac116] [Reference Citation Analysis]
|
| 192 |
Melkonyan NS, Hovhannisyan HS, Badalyan AR. Impact of HBsAg Serological Testing in Pregnant Women for Improvement of Hepatitis B Vaccinations in Newborns in Armenia. Medical Science of Armenia 2022. [DOI: 10.54503/0514-7484-2022-62.4-114] [Reference Citation Analysis]
|
| 193 |
Ananchuensook P, Suksawatamnauy S, Thaimai P, Sriphoosanaphan S, Thanapirom K, Teerapakpinyo C, Pooworawan Y, Komolmit P. The association between vitamin D receptor polymorphism and phases of chronic hepatitis B infection in HBV carriers in Thailand. PLoS One 2022;17:e0277907. [PMID: 36490235 DOI: 10.1371/journal.pone.0277907] [Reference Citation Analysis]
|
| 194 |
Xie Y, Zhu H, Guo Y, Ma Z, Qi X, Yang F, Mao R, Zhang J. Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study. Can J Gastroenterol Hepatol 2022;2022:4325352. [PMID: 36531834 DOI: 10.1155/2022/4325352] [Reference Citation Analysis]
|
| 195 |
Aguilar JC, Aguiar JA, Akbar SMF. Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B. Vaccines (Basel) 2022;10. [PMID: 36560498 DOI: 10.3390/vaccines10122087] [Reference Citation Analysis]
|
| 196 |
Akgul F, Arslan Y, Celik M, Karasahin O, Celen MK. The Effects of the COVID-19 Pandemic on Clinical and Laboratory Follow-up of Patients Diagnosed With Chronic Hepatitis B: A Multicenter, Prospective, Observational Study. Hepat Mon 2022;22. [DOI: 10.5812/hepatmon-132174] [Reference Citation Analysis]
|
| 197 |
Suzuki T, Matsuura K, Urakabe K, Okumura F, Kawamura H, Sobue S, Matoya S, Miyaki T, Kimura Y, Kato D, Kusakabe A, Tanaka Y, Ozasa A, Nagura Y, Fujiwara K, Nojiri S, Hagiwara S, Kusumoto S, Inoue T, Tanaka Y, Kataoka H. Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation. Hepatol Res 2022. [PMID: 36461885 DOI: 10.1111/hepr.13864] [Reference Citation Analysis]
|
| 198 |
Koffas A, Mak LY, Kennedy PTF. Hepatitis delta virus: Disease assessment and stratification. J Viral Hepat 2022. [PMID: 36458851 DOI: 10.1111/jvh.13777] [Reference Citation Analysis]
|
| 199 |
Guo X, Ji T, Xin S, Xu J, Yu Y. A case report of hepatitis B virus reactivation 19 months after cessation of chemotherapy with rituximab. Front Immunol 2022;13:1083862. [PMID: 36532005 DOI: 10.3389/fimmu.2022.1083862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 200 |
Zeng QL, Zhang HX, Zhang JY, Huang S, Li WZ, Li GM, Pan YJ, Feng YH, Li ZQ, Zhang GF, Xu JH, Lin WB, Xu GH, Liu N, Zhang GQ, Li GT, Li W, Zeng YL, Song N, Wang M, Zhang DW, Chen ZM, Cui GL, Li J, Lv J, Liu YM, Liang HX, Sun CY, Zhou YH, Yu ZJ, Wang FS. Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study. Clin Gastroenterol Hepatol 2022;20:2826-2837.e9. [PMID: 34902570 DOI: 10.1016/j.cgh.2021.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 201 |
Ji D, Chen Y, Bi J, Shang Q, Liu H, Wang JB, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Wang X, Chen D, Li Z, Dong Z, Yang Y. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. J Hepatol 2022;77:1515-24. [PMID: 35985545 DOI: 10.1016/j.jhep.2022.07.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 202 |
Khanna D, Kar P. Can the diagnostics of hepatitis in pregnant patients be improved? Expert Rev Mol Diagn 2022;22:1053-5. [PMID: 36462167 DOI: 10.1080/14737159.2022.2153039] [Reference Citation Analysis]
|
| 203 |
Kam LY, Huang DQ, Tobias AF, Poon K, Henry L, Kwo P, Cheung R, Nguyen MH. Impact of advanced practice providers on characteristics and quality of care of patients with chronic hepatitis B. Aliment Pharmacol Ther 2022;56:1591-601. [PMID: 36266768 DOI: 10.1111/apt.17254] [Reference Citation Analysis]
|
| 204 |
Manzia TM, Trapani S, Nardi A, Ricci A, Lenci I, Milana M, Angelico R, De Feo TM, Agnes S, Andorno E, Baccarani U, Carraro A, Cescon M, Cillo U, Colledan M, De Carlis L, De Simone P, Di Benedetto F, Ettorre GM, Gruttadauria S, Lupo LG, Mazzaferro V, Romagnoli R, Rossi G, Rossi M, Spada M, Vennarecci G, Vivarelli M, Zamboni F, Tisone G, Cardillo M, Angelico M. Temporal trends of waitlistings for liver transplantation in Italy: The ECALITA (Evolution of IndiCAtion in LIver transplantation in ITAly) registry study. Dig Liver Dis 2022;54:1664-71. [PMID: 36096992 DOI: 10.1016/j.dld.2022.08.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 205 |
Ishtiaq SM, Arshad MI, Khan JA. PPARγ signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications. Pharmacol Ther 2022;240:108298. [PMID: 36243148 DOI: 10.1016/j.pharmthera.2022.108298] [Reference Citation Analysis]
|
| 206 |
Elghannam MT, Hassanien MH, Ameen YA, Elattar GM, Elray AA, Turky EA, Eltalkawy MD. COVID-19 and liver diseases. Egypt Liver Journal 2022;12:43. [DOI: 10.1186/s43066-022-00202-2] [Reference Citation Analysis]
|
| 207 |
Kang CK, Brennan PN, Dillon JF. How to Effectively Monitor Aging Patients with Chronic Hepatitis B: A Review. CIA 2022;Volume 17:1811-1820. [DOI: 10.2147/cia.s366255] [Reference Citation Analysis]
|
| 208 |
Xu X, Jiang J, Song C, Yu C, Zhu L, Qian J, Tian T, Ding Y, Zhu F, Hu Z, Zhai X. Association of dynamic changes in serum levels of HBV DNA and risk of hepatocellular carcinoma. Curr Med 2022;1:5. [DOI: 10.1007/s44194-022-00008-9] [Reference Citation Analysis]
|
| 209 |
Ohlendorf V, Wübbolding M, Gineste P, Höner Zu Siederdissen C, Bremer B, Wedemeyer H, Cornberg M, Maasoumy B. Low anti-HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen-negative patients. Liver Int 2022;42:2674-82. [PMID: 36152268 DOI: 10.1111/liv.15433] [Reference Citation Analysis]
|
| 210 |
Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, Kao JH, Terrault N, Lok AS, Reddy KR. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol 2022;77:1670-89. [PMID: 35850281 DOI: 10.1016/j.jhep.2022.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 211 |
Degasperi E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Scholtes C, Facchetti F, Loglio A, Monico S, Fraquelli M, Costantino A, Ceriotti F, Zoulim F, Lampertico P. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. J Hepatol 2022;77:1525-31. [PMID: 35973578 DOI: 10.1016/j.jhep.2022.07.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 212 |
Han G, Zhou G, Sun T, Luo X, Xu J, Chen C, Xu W, Jiang S, Wang C. Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: a multi-center, prospective study. J Matern Fetal Neonatal Med 2022;35:10551-8. [PMID: 36253882 DOI: 10.1080/14767058.2022.2134771] [Reference Citation Analysis]
|
| 213 |
Martin P, Awan AA, Berenguer MC, Bruchfeld A, Fabrizi F, Goldberg DS, Jia J, Kamar N, Mohamed R, Pessôa MG, Pol S, Sise ME, Balk EM, Gordon CE, Adam G, Cheung M, Earley A, Jadoul M. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int 2022;102:1228-37. [PMID: 36411019 DOI: 10.1016/j.kint.2022.07.012] [Reference Citation Analysis]
|
| 214 |
Zhang C, Liu Y, Zhao H, Wang G. Global Patterns and Trends in Total Burden of Hepatitis B from 1990 to 2019 and Predictions to 2030. CLEP 2022;Volume 14:1519-1533. [DOI: 10.2147/clep.s389853] [Reference Citation Analysis]
|
| 215 |
Feld JJ, Lawitz E, Nguyen T, Lalezari J, Hassanein T, Martin P, Han S, Dieterich D, Giard J, De La Rosa G, Ahmad A, Luo E, Conery AL, Adda N. EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B. Antiviral Therapy 2022;27:135965352211278. [DOI: 10.1177/13596535221127848] [Reference Citation Analysis]
|
| 216 |
Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int 2022;102:S129-205. [PMID: 36410841 DOI: 10.1016/j.kint.2022.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 217 |
Tortajada P, Doamba R, Cano L, Ghallab M, Allard MA, Ciacio O, Pittau G, Salloum C, Cherqui D, Adam R, Sa Cunha A, Azoulay D, Pascale A, Vibert E, Golse N. Resectable and transplantable hepatocellular carcinoma: Integration of liver stiffness assessment in the decision-making algorithm. Surgery 2022;172:1704-11. [PMID: 36241470 DOI: 10.1016/j.surg.2022.08.012] [Reference Citation Analysis]
|
| 218 |
Davidov Y, Abu Baker F, Israel A, Ben Ari Z. Real-world hepatitis B antiviral treatment trends and adherence to practice guidelines: a large cohort study. Acta Clinica Belgica 2022. [DOI: 10.1080/17843286.2022.2152566] [Reference Citation Analysis]
|
| 219 |
Chang KC, Lin MT, Wang JH, Hung CH, Chen CH, Chiu SY, Hu TH. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral. Viruses 2022;14. [PMID: 36560675 DOI: 10.3390/v14122671] [Reference Citation Analysis]
|
| 220 |
Zhou L, Li X, Shi J, Hu Q, Zhou X, Gan D, Zhang L, Chen W, Li P. Serum Gasdermin-D and CHB-Related biochemical indicators as potential biomarkers for predicting the natural phases of Chronic HBV infection.. [DOI: 10.21203/rs.3.rs-2283736/v1] [Reference Citation Analysis]
|
| 221 |
Yan Y, Sun H, Chang L, Ji H, Jiang X, Song S, Xiao Y, Feng K, Nuermaimaiti A, Lu Z, Wang L. Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection. Front Microbiol 2022;13. [DOI: 10.3389/fmicb.2022.1063616] [Reference Citation Analysis]
|
| 222 |
Oh JH, Park DA, Ko MJ, Yoo JJ, Yim SY, Ahn JH, Jun DW, Ahn SB. Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis. J Pers Med 2022;12. [PMID: 36556178 DOI: 10.3390/jpm12121957] [Reference Citation Analysis]
|
| 223 |
Sun F, Li Z, Hu L, Deng W, Jiang T, Wang S, Bi X, Lu H, Yang L, Lin Y, Zeng Z, Shen G, Liu R, Chang M, Wu S, Gao Y, Hao H, Xu M, Chen X, Zhang L, Lu Y, Dong J, Xie Y, Li M. Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection. Front Immunol 2022;13:1082091. [PMID: 36505492 DOI: 10.3389/fimmu.2022.1082091] [Reference Citation Analysis]
|
| 224 |
Shilib Al-shimmery AH, Abdul-abbas Bayram A, Obayes Al Mammori R, Al-khafaji NS, O.m. Al-dahmoshi H. Combined Interferon-Antiviral therapy effectiveness against Hepatitis B viral infection in Babylon Province. RJPT 2022. [DOI: 10.52711/0974-360x.2022.00830] [Reference Citation Analysis]
|
| 225 |
Zeng Z, Hao H, Bi X, Lin Y, Yang L, Wang S, Shen G, Chang M, Jiang T, Deng W, Lu H, Sun F, Lu Y, Gao Y, Liu R, Xu M, Chen X, Hu L, Zhang L, Li M, Xie Y. Study on liver histopathology of chronic HBV infected patients with different normal ALT values. Front Immunol 2022;13:1069752. [PMID: 36483546 DOI: 10.3389/fimmu.2022.1069752] [Reference Citation Analysis]
|
| 226 |
Cao W, Lu H, Zhang L, Wang S, Deng W, Jiang T, Lin Y, Yang L, Bi X, Lu Y, Zhang L, Shen G, Liu R, Chang M, Wu S, Gao Y, Hao H, Xu M, Chen X, Hu L, Xie Y, Li M. Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy. Front Immunol 2022;13:1067362. [PMID: 36479104 DOI: 10.3389/fimmu.2022.1067362] [Reference Citation Analysis]
|
| 227 |
Thomas DL, Kiser JJ, Baum MM. Long-Acting Treatments for Hepatitis B. Clin Infect Dis 2022;75:S517-24. [PMID: 36410388 DOI: 10.1093/cid/ciac718] [Reference Citation Analysis]
|
| 228 |
Song Y, Zhang X, Liu M, Zhai X, Liu J, Li Y, Li L, Xiao Y, Duan Z, Jiang J, Ding F, Zhu L, Jiang J, Zou H, Zhuang H, Wang J, Li J. A booster hepatitis B vaccine for children with maternal HBsAg positivity before 2 years of age could effectively prevent vaccine breakthrough infections. BMC Infect Dis 2022;22:863. [DOI: 10.1186/s12879-022-07854-w] [Reference Citation Analysis]
|
| 229 |
Ricco G, Coco B, Colombatto P, Oliveri F, Cavallone D, Bleve P, Vianello B, Romagnoli V, Salvati A, Surace L, Bonino F, Brunetto MR. Highly dynamic changes of regional HBV epidemiology over two decades. Dig Liver Dis 2022:S1590-8658(22)00779-4. [PMID: 36404234 DOI: 10.1016/j.dld.2022.11.003] [Reference Citation Analysis]
|
| 230 |
Zheng J, Wang Z, Feng B. Hepatitis B functional cure and immune response. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1075916] [Reference Citation Analysis]
|
| 231 |
Elbadry M, Moussa AM, Eltabbakh M, Al Balakosy A, Abdalgaber M, Abdeen N, El Sheemy RY, Afify S, El-kassas M. The art of managing hepatitis C virus in special population groups: a paradigm shift. Egypt Liver Journal 2022;12:61. [DOI: 10.1186/s43066-022-00226-8] [Reference Citation Analysis]
|
| 232 |
Kim MN, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Jang SY, Tak WY, Kweon YO, Park SY, Kim SU. ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis. Clin Gastroenterol Hepatol 2022:S1542-3565(22)01050-3. [PMID: 36375797 DOI: 10.1016/j.cgh.2022.10.035] [Reference Citation Analysis]
|
| 233 |
Suslov A, Heim MH, Wieland S. Studying Hepatitis Virus-Host Interactions in Patient Liver Biopsies. Viruses 2022;14. [PMID: 36366588 DOI: 10.3390/v14112490] [Reference Citation Analysis]
|
| 234 |
Huang X, Yan M, Deng Z, Yao L, Han D, Sun L. Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study. BMC Gastroenterol 2022;22:452. [DOI: 10.1186/s12876-022-02541-1] [Reference Citation Analysis]
|
| 235 |
Ferenci P, Reiberger T, Jachs M. Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An Update. Cells 2022;11. [PMID: 36428959 DOI: 10.3390/cells11223531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 236 |
Zhang W, Li YY, Shang QH, Qi L, Sun MM, Chen G, An Y, Li JX, Jia WP, Sun ZA, Xu HB, Gao QM, Tang L, Wang XW, Zhang JY, Mu YM, Wang FS. Randomised controlled trial: effect of metformin add-on therapy on functional cure in entecavir-treated patients with chronic hepatitis B. Ann Hepatol 2022;27:100745. [PMID: 35964909 DOI: 10.1016/j.aohep.2022.100745] [Reference Citation Analysis]
|
| 237 |
Nakanishi A, Okumura H, Hashita T, Yamashita A, Nishimura Y, Watanabe C, Kamimura S, Hayashi S, Murakami S, Ito K, Iwao T, Ikeda A, Hirose T, Sunazuka T, Tanaka Y, Matsunaga T. Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2. Viruses 2022;14. [PMID: 36366568 DOI: 10.3390/v14112468] [Reference Citation Analysis]
|
| 238 |
Qian Z, Hu M, Wu H, Chen H, Liao G, Kang Z, Lin X, Peng J. The Efficacy of Antiviral Treatment for Chronic Hepatitis B Patients with Normal ALT Levels: A Systematic Review and Meta-analysis. Hepat Mon 2022;22. [DOI: 10.5812/hepatmon-129836] [Reference Citation Analysis]
|
| 239 |
Mitchell T, Nayagam JS, Dusheiko G, Agarwal K. Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries. JHEP Rep 2023;5:100623. [PMID: 36636709 DOI: 10.1016/j.jhepr.2022.100623] [Reference Citation Analysis]
|
| 240 |
Papatheodoridi M, Papatheodoridis GV. State-of-the-art and emerging antivirals for chronic hepatitis B infection. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2144219] [Reference Citation Analysis]
|
| 241 |
Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, Atzeni F, Behrens GM, Bijlsma JW, Böhm P, Constantinou CA, Garcia-diaz S, Kapetanovic MC, Lauper K, Luís M, Morel J, Nagy G, Poleverino E, van Rompay J, Sebastiani M, Strangfeld A, de Thurah A, Galloway J, Hyrich KL. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2022. [DOI: 10.1136/ard-2022-223335] [Reference Citation Analysis]
|
| 242 |
Lian J, Kuang W, Jia H, Lu Y, Zhang X, Ye C, Gu J, Lv Y, Yu J, Zhang Y, Lu X, Zhao Y, Yang D, Wang K, Zhao P, Yu Y, Bai L, Zhang J, Zhang X, Yang Y. Pegylated interferon-α-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study. J Med Virol 2022;94:5475-83. [PMID: 35836102 DOI: 10.1002/jmv.28003] [Reference Citation Analysis]
|
| 243 |
Liem KS, Chi H, Fung S, Wong DK, Yim C, Noureldin S, Chen J, de Man RA, Sarowar A, Feld JJ, Hansen BE, Hou J, Peng J, Janssen HLA. Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B. J Viral Hepat 2022;29:986-93. [PMID: 36048970 DOI: 10.1111/jvh.13742] [Reference Citation Analysis]
|
| 244 |
Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, Testoni B, Van Bömmel F, Andrisani O, Beumont-Mauviel M, Block TM, Chan HLY, Cloherty GA, Delaney WE, Geretti AM, Gehring A, Jackson K, Lenz O, Maini MK, Miller V, Protzer U, Yang JC, Yuen MF, Zoulim F, Revill PA. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol 2022;19:727-45. [PMID: 35859026 DOI: 10.1038/s41575-022-00649-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 245 |
Hu Q, Qi X, Yu Y, Gao Y, Zhang X, Wang Q, Zhang X, Zhuo Y, Li J, Zhang J, Chen L, Huang Y. The efficacy and safety of adding on or switching to peginterferon α-2b in HBeAg-positive chronic hepatitis B patients with long-term entecavir treatment: a multicentre randomised controlled trial. Aliment Pharmacol Ther 2022;56:1394-407. [PMID: 36128636 DOI: 10.1111/apt.17222] [Reference Citation Analysis]
|
| 246 |
Peng CW, Jeng WJ, Yang HI, Liu YC, Chien RN, Liaw YF. A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study. J Gastroenterol Hepatol 2022;37:2164-72. [PMID: 35869752 DOI: 10.1111/jgh.15966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 247 |
Aliabadi E, Urbanek-Quaing M, Maasoumy B, Bremer B, Grasshoff M, Li Y, Niehaus CE, Wedemeyer H, Kraft ARM, Cornberg M. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut 2022;71:2300-12. [PMID: 34702717 DOI: 10.1136/gutjnl-2021-324646] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 248 |
Yamada R, Morikawa K, Hotta K, Iwami D, Tanabe T, Murai S, Shinohara N, Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Kimura M, Yamamoto K, Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Sakamoto N. Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection. J Viral Hepat 2022;29:976-85. [PMID: 36031873 DOI: 10.1111/jvh.13740] [Reference Citation Analysis]
|
| 249 |
Carreras-Abad C, Oliveira-Souto I, Pou-Ciruelo D, Pujol-Morro JM, Soler-Palacín P, Soriano-Arandes A, Sulleiro E, Treviño-Maruri B, Broto-Cortés C, Esperalba J, García-Salgado G, Zarzuela F, Serre-Delcor N, Espiau M. Health and Vaccination Status of Unaccompanied Minors After Arrival in a European Border Country: A Cross-sectional Study (2017-2020). Pediatr Infect Dis J 2022;41:872-7. [PMID: 36102691 DOI: 10.1097/INF.0000000000003670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 250 |
Deng R, Liu S, Shen S, Guo H, Sun J. Circulating HBV RNA: From biology to clinical applications. Hepatology 2022;76:1520-30. [PMID: 35342969 DOI: 10.1002/hep.32479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 251 |
Papatheodoridi M, Papachristou E, Moschidis Z, Hadziyannis E, Rigopoulou E, Zachou K, Villeret F, Magiorkinis G, Lyberopoulou A, Gatselis N, Vlachogiannakos I, Manolakopoulos S, Dalekos GN, Zoulim F, Paraskevis D, Papatheodoridis GV. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy. J Viral Hepat 2022;29:948-57. [PMID: 35789515 DOI: 10.1111/jvh.13729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 252 |
Yuen MF, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, Thompson AJ, Given BD, Schluep T, Hamilton J, Biermer M, Kalmeijer R, Beumont M, Lenz O, De Ridder F, Cloherty G, Ka-Ho Wong D, Schwabe C, Jackson K, Lai CL, Gish RG, Gane E. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol 2022;77:1287-98. [PMID: 35870702 DOI: 10.1016/j.jhep.2022.07.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 253 |
Spearman CW, Dusheiko G, Jonas E, Abdo A, Afihene M, Cunha L, Desalegn H, Kassianides C, Katsidzira L, Kramvis A, Lam P, Lesi OA, Micah EA, Musabeyezu E, Ndow G, Nnabuchi CV, Ocama P, Okeke E, Rwegasha J, Shewaye AB, Some FF, Tzeuton C, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2022;7:1036-48. [PMID: 35810766 DOI: 10.1016/S2468-1253(22)00041-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 254 |
Meng CY, Sun S, Liang Y, Xu H, Zhang C, Zhang M, Wang FS, Fu YX, Peng H. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut 2022:gutjnl-2022-327059. [PMID: 36316098 DOI: 10.1136/gutjnl-2022-327059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 255 |
Lazar A, Sporea I, Popa A, Lupusoru R, Gherhardt D, Mare R, Apostu A, Hnatiuc M, Șirli R. Dynamic Changes in Liver Stiffness in Patients with Chronic Hepatitis B Undergoing Antiviral Therapy. Diagnostics (Basel) 2022;12. [PMID: 36359490 DOI: 10.3390/diagnostics12112646] [Reference Citation Analysis]
|
| 256 |
Degasperi E, Anolli MP, Lampertico P. Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies. Viruses 2022;14. [PMID: 36366502 DOI: 10.3390/v14112404] [Reference Citation Analysis]
|
| 257 |
Wu W, Yuan X, Zhang W, Zhou H, Kong X, He Z, Fu T, Zhang W, Jia W, Liang C, Tang H, Wang F, Ye Y, Shao Z, Ji Z. Clinical significance of novel biomarkers to predict the natural course of hepatitis B infection. Front Public Health 2022;10:1037508. [PMID: 36388269 DOI: 10.3389/fpubh.2022.1037508] [Reference Citation Analysis]
|
| 258 |
Yin GQ, Chen KP, Gu XC. Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment. World J Gastroenterol 2022; 28(40): 5784-5800 [DOI: 10.3748/wjg.v28.i40.5784] [Reference Citation Analysis]
|
| 259 |
Ren S, Wang W, Lu J, Wang K, Ma L, Zheng Y, Zheng S, Chen X. Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1035923] [Reference Citation Analysis]
|
| 260 |
Chen S, Liu X, Liu H, Lou J. The incidence rate, serological characteristics and cytokines profile of occult HBV infection in clinic.. [DOI: 10.21203/rs.3.rs-2171086/v1] [Reference Citation Analysis]
|
| 261 |
Mazzaro C, Adinolfi LE, Pozzato G, Nevola R, Zanier A, Serraino D, Andreone P, Fenoglio R, Sciascia S, Gattei V, Roccatello D. Extrahepatic Manifestations of Chronic HBV Infection and the Role of Antiviral Therapy. JCM 2022;11:6247. [DOI: 10.3390/jcm11216247] [Reference Citation Analysis]
|
| 262 |
Amie Ceesay, Khaled Bouherrou, Boun Kim Tan, Maud Lemoine, Gibril Ndow, Barbara Testoni, Isabelle Chemin. Viral Diagnosis of Hepatitis B and Delta: What We Know and What Is Still Required? Specific Focus on Low- and Middle-Income Countries. Microorganisms 2022;10:2096. [PMID: 36363693 DOI: 10.3390/microorganisms10112096] [Reference Citation Analysis]
|
| 263 |
Yu X, Huang H, Jiao Y, Li J, Fan X, Zhang D, Wang F. Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study.. [DOI: 10.21203/rs.3.rs-2180135/v1] [Reference Citation Analysis]
|
| 264 |
Bresalier RS, Coronel ES, Zhang HC. Gastrointestinal and Hepatic Complications in Cancer Patients. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm135.pub2] [Reference Citation Analysis]
|
| 265 |
Mhlanga A, Zakh R, Churkin A, Reinharz V, Glenn JS, Etzion O, Cotler SJ, Yurdaydin C, Barash D, Dahari H. Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients. Mathematics 2022;10:3917. [DOI: 10.3390/math10203917] [Reference Citation Analysis]
|
| 266 |
Bollerup S, Engsig F, Hallager S, Mocroft A, Roege BT, Christensen PB, Laursen AL, Krarup H, Clausen MR, Thielsen P, Madsen LG, Noerregaard L, Barfod TS, Balslev U, Tarp B, Hansen JB, Mygind LH, Gerstoft J, Weis N. Incidence of Hepatocellular Carcinoma and Decompensated Liver Cirrhosis and Prognostic Accuracy of the PAGE-B HCC Risk Score in a Low Endemic Hepatitis B Virus Infected Population. J Hepatocell Carcinoma 2022;9:1093-104. [PMID: 36281336 DOI: 10.2147/JHC.S372571] [Reference Citation Analysis]
|
| 267 |
Luo H, Hu X, Li Y, Lei D, Tan G, Zeng Y, Qin B. The Antiviral Activity of Triple Motif Protein 38 In Hepatitis B Virus Replication and Gene Expression and Its Association with Treatment Responses During PEG-IFN-α Antiviral Therapy.. [DOI: 10.21203/rs.3.rs-2147174/v1] [Reference Citation Analysis]
|
| 268 |
Thanapirom K, Suksawatamnuay S, Thaimai P, Treeprasertsuk S, Komolmit P, Tangkijvanich P. Assessment and validation of the TREAT-B score to assess the treatment eligibility of patients with chronic hepatitis B virus infection. Front Med 2022;9:995857. [DOI: 10.3389/fmed.2022.995857] [Reference Citation Analysis]
|
| 269 |
Wang X, Song A, Lin X, Lu J, Zheng S, Ma L, Ren S, Zheng Y, Chen X. Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases. Front Immunol 2022;13:1031291. [DOI: 10.3389/fimmu.2022.1031291] [Reference Citation Analysis]
|
| 270 |
Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study. Cancers (Basel) 2022;14. [PMID: 36291786 DOI: 10.3390/cancers14205002] [Reference Citation Analysis]
|
| 271 |
Gabr AK, Hawash NI, Abd-elsalam S, Badawi R, Soliman HH. Diagnostic Accuracy of Red Cell Distribution Width to Platelet Ratio for Detection of Liver Fibrosis Compared with Fibroscan in Chronic Hepatitis B Egyptian patients. TOBIOMJ 2022;12. [DOI: 10.2174/18753183-v12-e2208150] [Reference Citation Analysis]
|
| 272 |
Xu B, Liu A, Liu Y, Han T, Guo H, Ding X, Xiang H. Correlations between serum hepatitis B core-related antigen and hepatitis B surface antigen in patients with hepatitis B cirrhosis and a hepatitis B virus-DNA-negative status: a retrospective study. J Int Med Res 2022;50:3000605221130714. [PMID: 36224762 DOI: 10.1177/03000605221130714] [Reference Citation Analysis]
|
| 273 |
Yuan X, Fu T, Xiao L, He Z, Ji Z, Seery S, Zhang W, Ye Y, Zhou H, Kong X, Zhang S, Zhou Q, Lin Y, Jia W, Liang C, Tang H, Wang F, Zhang W, Shao Z. Describing immune factors associated with Hepatitis B surface antigen loss: A nested case-control study of a Chinese sample from Wuwei City. Front Immunol 2022;13:1025654. [DOI: 10.3389/fimmu.2022.1025654] [Reference Citation Analysis]
|
| 274 |
Katwaroe WK, Brakenhoff SM, van der Spek DPC, de Knegt RJ, van Kleef LA, de Man RA, van der Meer AJP, Sonneveld MJ, The Icarus Study Group. Assessment of Adherence to Clinical Guidelines in Patients with Chronic Hepatitis B. Viruses 2022;14. [PMID: 36298784 DOI: 10.3390/v14102229] [Reference Citation Analysis]
|
| 275 |
Masset C, Le Turnier P, Bressollette-Bodin C, Renaudin K, Raffi F, Dantal J. Virus-Associated Nephropathies: A Narrative Review. Int J Mol Sci 2022;23:12014. [PMID: 36233315 DOI: 10.3390/ijms231912014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 276 |
Howell J, Van H, Pham M, Sawhney R, Li F, Bhat P, Lubel J, Kemp W, Bloom S, Majumdar A, McCaughan G, Hall S, Spelman T, Doyle JS, Hellard M, Visvanathan K, Thompson AJ, Drummer HE, Anderson D. Validation of novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study. Clin Liver Dis (Hoboken) 2022;20:136-9. [PMID: 36245683 DOI: 10.1002/cld.1261] [Reference Citation Analysis]
|
| 277 |
Wang L, Zhang G, Sun Y, Wu Z, Ren C, Zhang Z, Peng X, Zhang Y, Zhao Y, Li C, Gao L, Liang X, Sun H, Cui J, Ma C. Enhanced Delivery of TLR7/8 Agonists by Metal-Organic Frameworks for Hepatitis B Virus Cure. ACS Appl Mater Interfaces 2022. [PMID: 36206454 DOI: 10.1021/acsami.2c11203] [Reference Citation Analysis]
|
| 278 |
Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. World J Clin Cases 2022; 10(28): 10085-10096 [DOI: 10.12998/wjcc.v10.i28.10085] [Reference Citation Analysis]
|
| 279 |
Metin O, Zeybel M, Yurdaydin C. Treatment endpoints for chronic hepatitis D. Liver Int 2022. [PMID: 36196680 DOI: 10.1111/liv.15447] [Reference Citation Analysis]
|
| 280 |
Yuen MF, Berliba E, Sukeepaisarnjaroen W, Ahn SH, Tanwandee T, Lim YS, Kim YJ, Poovorawan K, Tangkijvanich P, Schwabe C, Eley T, Brown J, Lee ACH, Thi EP, Paratala B, Mani N, Sofia MJ, Picchio G, Sims KD, Gane EJ. Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B. Hepatol Commun 2022;6:3457-72. [PMID: 36194181 DOI: 10.1002/hep4.2095] [Reference Citation Analysis]
|
| 281 |
Mak LY, Beasley I, Kennedy PTF. Chronic Viral Hepatitis in Elite Athletes: Approaches to Risk Assessment, Prevention and Management. Sports Med Open 2022;8:123. [PMID: 36192563 DOI: 10.1186/s40798-022-00517-9] [Reference Citation Analysis]
|
| 282 |
Tseng C, Chen T, Wu J, Lee T, Borghi JA, Lin J, Nguyen MH, Hsu Y. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100617] [Reference Citation Analysis]
|
| 283 |
Yoo S, Kim JY, Lim YS, Han S, Choi J. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. J Hepatol 2022;77:939-46. [PMID: 35643206 DOI: 10.1016/j.jhep.2022.05.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 284 |
Yuen MF, Heo J, Kumada H, Suzuki F, Suzuki Y, Xie Q, Jia J, Karino Y, Hou J, Chayama K, Imamura M, Lao-Tan JY, Lim SG, Tanaka Y, Xie W, Yoon JH, Duan Z, Kurosaki M, Park SJ, Labio ME, Kumar R, Kweon YO, Yim HJ, Tao Y, Cremer J, Elston R, Davies M, Baptiste-Brown S, Han K, Campbell FM, Paff M, Theodore D. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J Hepatol 2022;77:967-77. [PMID: 35714812 DOI: 10.1016/j.jhep.2022.05.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 285 |
Mazzaro C, Bomben R, Gragnani L, Visentini M, Pozzato G, Pozzo F, Zucchetto A, Gattei V. Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy. Semin Hematol 2022;59:177-82. [PMID: 36805885 DOI: 10.1053/j.seminhematol.2022.11.003] [Reference Citation Analysis]
|
| 286 |
Xu JH, Fan YN, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Zhang DZ, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. 240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C. J Viral Hepat 2022;29:862-7. [PMID: 35737855 DOI: 10.1111/jvh.13724] [Reference Citation Analysis]
|
| 287 |
Mokhtari F, Kaboosi H, Mohebbi SR, Asadzadeh Aghdaei H, Zali MRZ, Department of Microbiology, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran, Department of Microbiology, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Evaluation of Circulating MicroRNA-222 in Patients with Chronic Hepatitis B virus Infection as a Potential Noninvasive Diagnostic Biomarker. Iran J Med Microbiol 2022;16:543-550. [DOI: 10.30699/ijmm.16.6.543] [Reference Citation Analysis]
|
| 288 |
Shata MTM, Hetta HF, Sharma Y, Sherman KE. Viral hepatitis in pregnancy. J Viral Hepat 2022;29:844-61. [PMID: 35748741 DOI: 10.1111/jvh.13725] [Reference Citation Analysis]
|
| 289 |
Han K, Theodore D, McMullen G, Swayze E, McCaleb M, Billioud G, Wieland S, Hood S, Paff M, Bennett CF, Kwoh TJ. Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses. Clin Pharmacol Drug Dev 2022;11:1191-202. [PMID: 35971951 DOI: 10.1002/cpdd.1154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 290 |
Akbar SMF, Mahtab MA, Khan S, Yoshida O, Hiasa Y. Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection. Vaccines (Basel) 2022;10. [PMID: 36298512 DOI: 10.3390/vaccines10101644] [Reference Citation Analysis]
|
| 291 |
Sato K, Inoue J, Akahane T, Kobayashi T, Sato S, Kisara N, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Onuki M, Masamune A. Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study. Medicine (Baltimore) 2022;101:e30630. [PMID: 36181074 DOI: 10.1097/MD.0000000000030630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 292 |
Lee S, Kwon M, Lee S, Kim J. Lactic Acidosis Adverse Drug Reaction Reporting Aspect Evaluation of Hepatitis B Treatment Using Korea Adverse Event Reporting System. Journal of Pharmacoepidemiology and Risk Management 2022;14:144-148. [DOI: 10.56142/jperm.22.0012] [Reference Citation Analysis]
|
| 293 |
Shang H, Hu Y, Guo H, Lai R, Fu Y, Xu S, Zeng Y, Xun Z, Liu C, Wu W, Guo J, Ou Q, Chen T. Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon-α monotherapy. J Clin Lab Anal 2022;:e24667. [PMID: 36181316 DOI: 10.1002/jcla.24667] [Reference Citation Analysis]
|
| 294 |
Schmidt D, Kollan C, Bartmeyer B, Bremer V, Schikowski T, Friebe M, Schellberg S, Scholten S, Bickel M, Hanhoff N, Rüsenberg R, Schewe K; NEPOS study group. Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany. Infection 2022. [PMID: 36168098 DOI: 10.1007/s15010-022-01919-3] [Reference Citation Analysis]
|
| 295 |
Lee I, Lan K, Su C, Li C, Chao Y, Lin H, Hou M, Huang Y. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. IJMS 2022;23:11335. [DOI: 10.3390/ijms231911335] [Reference Citation Analysis]
|
| 296 |
Spera AM. Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment. World J Virol 2022; 11(5): 275-282 [DOI: 10.5501/wjv.v11.i5.275] [Reference Citation Analysis]
|
| 297 |
Lin X, Zheng Y, Li H, Lu J, Ren S, Liu Y, Wang X, Zheng S, Ma L, Cao Z, Chen X. Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance. Front Immunol 2022;13:1028921. [DOI: 10.3389/fimmu.2022.1028921] [Reference Citation Analysis]
|
| 298 |
Roca TP, Villar LM, Nogueira Lima FS, Vasconcelos MPA, Borzacov LMP, Silva EDCE, Lago BVD, Silva MTLD, Botelho Souza LF, Salcedo JMV, Santos ADOD, Vieira DS. Genomic Variability of Hepatitis B Virus Circulating in Brazilian Western Amazon. Viruses 2022;14:2100. [DOI: 10.3390/v14102100] [Reference Citation Analysis]
|
| 299 |
Li YN, Kang NL, Jiang JJ, Zhu YY, Liu YR, Zeng DW, Wang F. Gut microbiota of hepatitis B virus-infected patients in the immune-tolerant and immune-active phases and their implications in metabolite changes. World J Gastroenterol 2022; 28(35): 5188-5202 [DOI: 10.3748/wjg.v28.i35.5188] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 300 |
Cheng R, Xu X. Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis. J Hepatocell Carcinoma 2022;9:987-97. [PMID: 36117526 DOI: 10.2147/JHC.S377435] [Reference Citation Analysis]
|
| 301 |
Li M, Gao Y, Yang L, Lin Y, Deng W, Jiang T, Bi X, Lu Y, Zhang L, Shen G, Liu R, Wu S, Chang M, Xu M, Hu L, Song R, Jiang Y, Yi W, Xie Y. Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B. Front Immunol 2022;13:1024333. [DOI: 10.3389/fimmu.2022.1024333] [Reference Citation Analysis]
|
| 302 |
Tan YW. Risk stratification of primary liver cancer. World J Clin Cases 2022; 10(26): 9545-9549 [DOI: 10.12998/wjcc.v10.i26.9545] [Reference Citation Analysis]
|
| 303 |
Begré L, Béguelin C, Boyd A, Peters L, Rockstroh J, Günthard HF, Bernasconi E, Cavassini M, Lacombe K, Mocroft A, Wandeler G, Rauch A. Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection. Front Med 2022;9. [DOI: 10.3389/fmed.2022.988356] [Reference Citation Analysis]
|
| 304 |
Tian Z, Xu C, Yang P, Lin Z, Wu W, Zhang W, Ding J, Ding R, Zhang X, Dou K. Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma. Front Immunol 2022;13:984728. [DOI: 10.3389/fimmu.2022.984728] [Reference Citation Analysis]
|
| 305 |
Fasano M, Poliseno MC, Fiore JR, Lo Caputo S, D’arminio Monforte A, Santantonio TA. Management of Chronic Hepatitis B in HIV-Coinfected Patients. Viruses 2022;14:2022. [DOI: 10.3390/v14092022] [Reference Citation Analysis]
|
| 306 |
Lempp FA, Volz T, Cameroni E, Benigni F, Zhou J, Rosen LE, Noack J, Zatta F, Kaiser H, Bianchi S, Lombardo G, Jaconi S, Imam H, Soriaga LB, Passini N, Belnap DM, Schulze A, Lütgehetmann M, Telenti A, Cathcart AL, Snell G, Purcell LA, Hebner CM, Urban S, Dandri M, Corti D, Schmid MA. The potent broadly neutralizing antibody VIR-3434 controls Hepatitis B and D Virus infection and reduces HBsAg in humanized mice.. [DOI: 10.1101/2022.09.09.507326] [Reference Citation Analysis]
|
| 307 |
Yao N, Fu S, Wu Y, Tian Z, Feng Y, Li J, Luo X, Yang Y, Ji F, Chen Y, Liu J, Zhao Y, Chen T. Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2022;101:1197-206. [PMID: 36082797 DOI: 10.1111/aogs.14448] [Reference Citation Analysis]
|
| 308 |
Zhu M, Wang H, Lou T, Xiong P, Zhang J, Li L, Sun Y, Wu Y. Current treatment of chronic hepatitis B: Clinical aspects and future directions. Front Microbiol 2022;13:975584. [DOI: 10.3389/fmicb.2022.975584] [Reference Citation Analysis]
|
| 309 |
Batskikh S, Morozov S, Dorofeev A, Borunova Z, Kostyushev D, Brezgin S, Kostyusheva A, Chulanov V. Previous hepatitis B viral infection–an underestimated cause of pancreatic cancer. World J Gastroenterol 2022; 28(33): 4812-4822 [DOI: 10.3748/wjg.v28.i33.4812] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 310 |
Yang X, Zhang K, Xu Q, Shu X, Mo Z, Xie D, Gao Z, Deng H. Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg. Front Immunol 2022;13:997608. [DOI: 10.3389/fimmu.2022.997608] [Reference Citation Analysis]
|
| 311 |
Yip TC, Lai JC, Liang LY, Hui VW, Wong VW, Wong GL. Risk of HCC in Patients with HBV, Role of Antiviral Treatment. Curr Hepatology Rep 2022. [DOI: 10.1007/s11901-022-00588-y] [Reference Citation Analysis]
|
| 312 |
Su WC, Chen TT, Yang SS, Shih LN, Liu CK, Wang CC, Wu CH. The effect of a pay-for-performance program on health-related quality of life for patients with hepatitis in Taiwan. Health Qual Life Outcomes 2022;20:130. [PMID: 36064530 DOI: 10.1186/s12955-022-02038-1] [Reference Citation Analysis]
|
| 313 |
Yang Z, Xuan J, Yang F, Qi Y, Yang M, Xu H, Jiang M, Shen S, Lu M, Shi H, Jiang K, Tao H, Liu Y, Wang F. Timing of endoscopic intervention in patients with cirrhosis with acute variceal haemorrhage (TEACH trial): protocol for a randomised clinical trial (RCT). BMJ Open 2022;12:e060290. [PMID: 36691157 DOI: 10.1136/bmjopen-2021-060290] [Reference Citation Analysis]
|
| 314 |
Bezuglova LV, Osipova LP, Sergeeva EI, Deliy IV, Tabikhanova LE, Netesov SV, Netesova IG. Markers of Viral Hepatitis B in Blood–Plasma Samples of the Indigenous Population of the Far North of Russia. HBV Genotypes and HBsAg Subtypes. Mol Genet Microbiol Virol 2022;37:146-152. [DOI: 10.3103/s0891416822030041] [Reference Citation Analysis]
|
| 315 |
Yang H, Bae SH, Nam H, Lee HL, Lee SW, Yoo SH, Song MJ, Kwon JH, Nam SW, Choi JY, Yoon SK, Jang JW. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol 2022;77:632-41. [PMID: 35398462 DOI: 10.1016/j.jhep.2022.03.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 316 |
Chu JH, Huang Y, Xie DY, Deng H, Wei J, Guan YJ, Li GJ, Zeng YL, Yang JH, Chen XY, Shang J, Li JB, Gao N, Gao ZL. Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients. J Viral Hepat 2022;29:765-76. [PMID: 35718996 DOI: 10.1111/jvh.13722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 317 |
Wang X, Gao X, Wu R, Chi X, Xu H, Guan Y, Jin Q, Niu J. Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients. J Gastroenterol Hepatol 2022;37:1806-14. [PMID: 35509262 DOI: 10.1111/jgh.15881] [Reference Citation Analysis]
|
| 318 |
Liang L, Jiang YJ, Zhang LC, Liu H, Li YF, Li CM, Huang CZ. Rational fabrication of a DNA walking nanomachine on graphene oxide surface for fluorescent bioassay. Biosensors and Bioelectronics 2022;211:114349. [DOI: 10.1016/j.bios.2022.114349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 319 |
Lim SZ, Chuah KH, Rajaram RB, Stanley K, Shahrani S, Chan WK, Ho SH, Hilmi IN, Goh KL, Mahadeva S. Epidemiological trends of gastrointestinal and liver diseases in Malaysia: A single-center observational study. J Gastroenterol Hepatol 2022;37:1732-40. [PMID: 35637160 DOI: 10.1111/jgh.15905] [Reference Citation Analysis]
|
| 320 |
Broquetas T, Carrión JA. Author's reply: Nucleo(s)tide analogue withdrawal in chronic hepatitis B virus infection. Beyond the HBsAg loss. Dig Liver Dis 2022;54:1283-4. [PMID: 35581131 DOI: 10.1016/j.dld.2022.04.020] [Reference Citation Analysis]
|
| 321 |
Chang JI, Sinn DH, Cho H, Kim S, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. Dig Dis Sci 2022;67:4565-73. [PMID: 34800218 DOI: 10.1007/s10620-021-07312-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 322 |
Perrillo R, Lin HS, Schwarz KB, Rosenthal P, Lisker-Melman M, Chung RT, Prokunina-Olsson L, Cloherty G, Feld J; Hepatitis B Research Network (HBRN). Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. Hepatology 2022;76:775-87. [PMID: 35188674 DOI: 10.1002/hep.32400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 323 |
Lok J, Dusheiko G, Carey I, Agarwal K. Review article: novel biomarkers in hepatitis B infection. Aliment Pharmacol Ther 2022;56:760-76. [PMID: 35770458 DOI: 10.1111/apt.17105] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 324 |
Pal S, Dey D, Chakraborty BC, Nandi M, Khatun M, Banerjee S, Santra A, Ghosh R, Ahammed SM, Chowdhury A, Datta S. Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV-specific T-cell response and homing. Hepatology 2022;76:759-74. [PMID: 35000202 DOI: 10.1002/hep.32331] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 325 |
Osman HA, Hetta HF, El-adly AM, Meshaal AK, Mekky MA. Detectability of Hepatitis B Virus in Peripheral Blood Mononuclear Cells Among Naive Chronic Hepatitis B Patients With Negative Viremia: A Multicenter Study. Infect Dis Clin Pract 2022;30. [DOI: 10.1097/ipc.0000000000001153] [Reference Citation Analysis]
|
| 326 |
Yuen MF, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Sulkowski MS. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. J Hepatol 2022;77:642-52. [PMID: 35460726 DOI: 10.1016/j.jhep.2022.04.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 327 |
Howell J, Hellard M. Making child's play of tolerance: Defining the immune-viral interplay during combination entecavir and pegylated interferon therapy for immune-tolerant hepatitis B infection. Hepatology 2022;76:554-7. [PMID: 35262950 DOI: 10.1002/hep.32450] [Reference Citation Analysis]
|
| 328 |
Upadhyay P, Lal BB, Sood V, Khanna R, Gupta E, Rastogi A, Alam S. Incidence and Predictors of Relapse After Stopping Antiviral Therapy in Pediatric Chronic Hepatitis B. Pediatr Infect Dis J 2022;41:714-9. [PMID: 35703278 DOI: 10.1097/INF.0000000000003602] [Reference Citation Analysis]
|
| 329 |
Chevaliez S, Roudot-thoraval F, Brouard C, Gordien E, Zoulim F, Brichler S, Brodard V, Pioche C, Pawlotsky J, Leroy V. Clinical and virological features of chronic hepatitis B in the French National Surveillance Program, 2008-2012. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100593] [Reference Citation Analysis]
|
| 330 |
Lim J, Lee JB, An J, Song GW, Kim KM, Lee HC, Shim JH. Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study. J Viral Hepat 2022;29:756-64. [PMID: 35718999 DOI: 10.1111/jvh.13721] [Reference Citation Analysis]
|
| 331 |
Ogawa E. Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply. Aliment Pharmacol Ther 2022;56:1092-3. [PMID: 35995743 DOI: 10.1111/apt.17173] [Reference Citation Analysis]
|
| 332 |
Wu S, Zhou J, Wu X, Sun Y, Wang B, Kong Y, Zhan S, Jia J, Yang HI, You H. Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints. Am J Gastroenterol 2022;117:1444-53. [PMID: 35973147 DOI: 10.14309/ajg.0000000000001865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 333 |
Massironi S, Pirola L, Mulinacci G, Ciaccio A, Viganò C, Palermo A, Zilli A, Invernizzi P, Danese S. Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks. Inflamm Bowel Dis 2022:izac189. [PMID: 36040402 DOI: 10.1093/ibd/izac189] [Reference Citation Analysis]
|
| 334 |
Bui HH, Vo VH, Nguyen CD, Phan ST, Quach PT, Nguyen DB. Diagnostic Performance of Acoustic Radiation Force Impulse Imaging in Evaluating Liver Fibrosis in Patients with Chronic Hepatitis B Infection: A Cross-Sectional Study. Indian J Radiol Imaging. [DOI: 10.1055/s-0042-1755251] [Reference Citation Analysis]
|
| 335 |
Chang M, Chien R, Liaw Y. Evidence-Based Management of Oral Nucleos(t)ide Analogue Withdrawal in Virally Suppressed Patients with Chronic HBV Infection. Curr Hepatology Rep 2022. [DOI: 10.1007/s11901-022-00587-z] [Reference Citation Analysis]
|
| 336 |
Li J, Fan P, Xu Z, Dong Y, Wang F, Hong W, Zhao J, Gao Y, Yan J, Cao L, Zhang C, Zhu S, Zhong Y, Wang F, Zhang M. Early initiation of antiviral therapy improves cure of chronic hepatitis B in immune tolerant children: a real-world study.. [DOI: 10.21203/rs.3.rs-1987955/v1] [Reference Citation Analysis]
|
| 337 |
Downes TJ, Manship TA, Bathgate A. Infectious hepatitis. InnovAiT 2022. [DOI: 10.1177/17557380221118945] [Reference Citation Analysis]
|
| 338 |
Shin SH, Park SH. Viral Hepatitis in Patients with Inflammatory Bowel Disease. Korean J Gastroenterol 2022;80:51-59. [DOI: 10.4166/kjg.2022.096] [Reference Citation Analysis]
|
| 339 |
Alshuwaykh O, Daugherty T, Cheung A, Goel A, Dhanasekaran R, Ghaziani TT, Ahmed A, Dronamraju D, Kumari R, Kwong A, Nguyen M, Kim WR, Kwo PY. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy. Hepatol Commun 2022;6:3052-61. [PMID: 36004713 DOI: 10.1002/hep4.2064] [Reference Citation Analysis]
|
| 340 |
Hu Y, Wu X, Ye Y, Ye L, Han S, Wang X, Yu H. Liver Histology of Treatment-Naïve Children with Chronic Hepatitis B Virus Infection in Shanghai China. Int J Infect Dis 2022:S1201-9712(22)00487-8. [PMID: 36028208 DOI: 10.1016/j.ijid.2022.08.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 341 |
Nuersulitan R, Li M, Mi L, Wu M, Ji X, Liu Y, Zhao H, Wang G, Song Y, Zhu J, Liu W. Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era. Front Oncol 2022;12:989258. [DOI: 10.3389/fonc.2022.989258] [Reference Citation Analysis]
|
| 342 |
Panda K, Lal BB, Sood V, Khanna R, Alam S. Adequate Chelation and Cupriuresis in Hepatic Wilson disease patients under Combination (Chelator + Zinc) therapy at 2 years of follow up.. [DOI: 10.21203/rs.3.rs-1941777/v1] [Reference Citation Analysis]
|
| 343 |
Wei S, Hu M, Chen H, Xie Q, Wang P, Li H, Peng J. Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study. BMC Gastroenterol 2022;22:387. [PMID: 35978283 DOI: 10.1186/s12876-022-02471-y] [Reference Citation Analysis]
|
| 344 |
Xiong J, Jiang Y, Zhang J, Chen Y, Hu Y. CK1α upregulates the IFNAR1 expression to prompt the anti-HBV effect of type I IFN in hepatoma carcinoma cells. Virol Sin 2022;37:894-903. [PMID: 35985475 DOI: 10.1016/j.virs.2022.08.004] [Reference Citation Analysis]
|
| 345 |
Kim JH, Kim JH, Choe WH, Kwon SY, Yoo BC, Yoon EL, Kang SH. Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers. Antimicrob Agents Chemother 2022;66:e0027522. [PMID: 35867571 DOI: 10.1128/aac.00275-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 346 |
Lalana Garcés M, Ortiz Pastor O, Solé Enrech G, Guerra-ruiz AR, Casals Mercadal G, Almería Lafuente A, Ballesteros Vizoso MA, Medina PG, Salgüero Fernández S, Zamora Trillo A, Aured de la Serna I, Hurtado JC, Pérez-del-pulgar S, Forns X, Morales Ruiz M. Control of occult hepatitis B virus infection. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2022;0. [DOI: 10.1515/almed-2022-0065] [Reference Citation Analysis]
|
| 347 |
Yin X, Li J, Hao Z, Ding R, Qiao Y. A systematic study of traditional Chinese medicine treating hepatitis B virus-related hepatocellular carcinoma based on target-driven reverse network pharmacology. Front Cell Infect Microbiol 2022;12:964469. [DOI: 10.3389/fcimb.2022.964469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 348 |
Araujo-Neto JM, Guimarães GS, Fernandes FF, Soares MA. Hepatitis B Surface Antibody (Anti-HBs) Kinetics during Rituximab Chemotherapy and Performance of Hepatitis B Vaccine before Immunosuppression: Two Prospective Studies. Viruses 2022;14. [PMID: 36016402 DOI: 10.3390/v14081780] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 349 |
Da BL. Clinical trials in hepatitis D virus: Measuring success. Hepatology 2022. [PMID: 35969089 DOI: 10.1002/hep.32732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 350 |
Lalana Garcés M, Pastor OO, Solé Enrech G, Guerra-ruiz AR, Mercadal GC, Almería Lafuente A, Ballesteros Vizoso MA, Medina PG, Salgüero Fernández S, Zamora Trillo A, Aured de la Serna I, Hurtado JC, Pérez-del-pulgar S, Forns X, Morales Ruiz M. Revisión de la infección oculta por el virus de la hepatitis B. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2022;0. [DOI: 10.1515/almed-2021-0084] [Reference Citation Analysis]
|
| 351 |
Ravaioli F, Pivetti A, Di Marco L, Chrysanthi C, Frassanito G, Pambianco M, Sicuro C, Gualandi N, Guasconi T, Pecchini M, Colecchia A. Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease. Int J Mol Sci 2022;23:9016. [PMID: 36012285 DOI: 10.3390/ijms23169016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 352 |
Desmares M, Delphin M, Chardès B, Pons C, Riedinger J, Michelet M, Rivoire M, Verrier B, Salvetti A, Lucifora J, Durantel D. Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes. Antiviral Res 2022;206:105386. [PMID: 35963549 DOI: 10.1016/j.antiviral.2022.105386] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 353 |
Degasperi E, Anolli MP, Lampertico P. Bulevirtide for patients with compensated chronic hepatitis delta: A review. Liver Int 2022. [PMID: 35942695 DOI: 10.1111/liv.15389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 354 |
Huang X, Yan M, Deng Z, Yao L, Han D, Sun L. Natural history of hepatitis B virus-associated decompensated cirrhosis with low-level viremia: a retrospective study.. [DOI: 10.21203/rs.3.rs-1924955/v1] [Reference Citation Analysis]
|
| 355 |
Tschäpe J, Cobernuss-rahn A, Boyle S, Parkin N, Labrot B, Aslam S, Young S, Gohl P. Multi-site Performance Evaluation of the cobas 5800 System and Comparison to the cobas 6800/8800 Systems for Quantitative Measurement of HBV, HCV, and HIV-1 Viral Load.. [DOI: 10.1101/2022.08.09.503351] [Reference Citation Analysis]
|
| 356 |
Feng B, Zheng JR. Importance of quantitative HBsAg detection in whole course management of patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2022; 30(15): 655-660 [DOI: 10.11569/wcjd.v30.i15.655] [Reference Citation Analysis]
|
| 357 |
Yang W, Tian X, Liang J. A Comprehensive Nursing Model Combined with High-Quality Nursing Intervention for Antiviral Therapy in Patients with Chronic Hepatitis B. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-7. [DOI: 10.1155/2022/6244637] [Reference Citation Analysis]
|
| 358 |
Volinsky I. Mathematical Model of Hepatitis B Virus Treatment with Support of Immune System. Mathematics 2022;10:2821. [DOI: 10.3390/math10152821] [Reference Citation Analysis]
|
| 359 |
He J, Wu J, Chen J, Zhang S, Guo Y, Zhang X, Han J, Zhang Y, Guo Y, Lin Y, Yu W, Kong Y, Shen Z, Mao R, Zhang J. Identification of Estradiol Benzoate as an Inhibitor of HBx Using Inducible Stably Transfected HepG2 Cells Expressing HiBiT Tagged HBx. Molecules 2022;27:5000. [PMID: 35956950 DOI: 10.3390/molecules27155000] [Reference Citation Analysis]
|
| 360 |
Raslan E, Abdallah M, Soliman S. The prevalence and determinants of hepatitis B among Egyptian adults: a further analysis of a country-representative survey. Egypt Liver Journal 2022;12:46. [DOI: 10.1186/s43066-022-00207-x] [Reference Citation Analysis]
|
| 361 |
Lim YS, Ahn SH, Shim JJ, Razavi H, Razavi-Shearer D, Sinn DH. Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis. Aliment Pharmacol Ther 2022;56:519-28. [PMID: 35614532 DOI: 10.1111/apt.17052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 362 |
Martin P, Nguyen MH, Dieterich DT, Lau DT, Janssen HLA, Peters MG, Jacobson IM. Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. Clin Gastroenterol Hepatol 2022;20:1766-75. [PMID: 34329775 DOI: 10.1016/j.cgh.2021.07.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 363 |
Huang DQ, Li X, Le MH, Le AK, Yeo YH, Trinh HN, Zhang J, Li J, Wong C, Wong C, Cheung RC, Yang HI, Nguyen MH. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. Clin Gastroenterol Hepatol 2022;20:1803-1812.e5. [PMID: 33465482 DOI: 10.1016/j.cgh.2021.01.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 364 |
Hall SAL, Vogrin S, Wawryk O, Burns GS, Visvanathan K, Sundararajan V, Thompson A. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut 2022;71:1629-41. [PMID: 34493592 DOI: 10.1136/gutjnl-2020-323979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 365 |
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Aliment Pharmacol Ther 2022;56:713-22. [PMID: 35735794 DOI: 10.1111/apt.17107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 366 |
Russo FP, Viganò M, Stock P, Ferrarese A, Pugliese N, Burra P, Aghemo A. HBV-positive and HIV-positive organs in transplantation: A clinical guide for the hepatologist. J Hepatol 2022;77:503-15. [PMID: 35398460 DOI: 10.1016/j.jhep.2022.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 367 |
Maslac O, Wagner J, Sozzi V, Mason H, Svarovskaia J, Tan S, Gaggar A, Locarnini S, Yuen L, Littlejohn M, Revill PA. Secreted hepatitis B virus splice variants differ by HBV genotype and across phases of chronic hepatitis B infection. J Viral Hepat 2022;29:604-15. [PMID: 35582878 DOI: 10.1111/jvh.13702] [Reference Citation Analysis]
|
| 368 |
Broquetas T, Hernandez JJ, Garcia-Retortillo M, Canillas L, Puigvehí M, Cañete N, Coll S, Viu A, Garrido E, Mico M, Bessa X, Carrión JA. On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty. Dig Liver Dis 2022;54:1044-51. [PMID: 35063365 DOI: 10.1016/j.dld.2021.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 369 |
Mohareb AM, Larmarange J, Kim AY, Coffie PA, Kouamé MG, Boyd A, Freedberg KA, Hyle EP. Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. The Lancet HIV 2022;9:e585-94. [DOI: 10.1016/s2352-3018(22)00123-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 370 |
Keskin O. Quality of care for hepatitis B patients should include delta hepatitis screening. Intern Med J 2022;52:1457. [PMID: 35973963 DOI: 10.1111/imj.15849] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 371 |
Segeral O, Dim B, Durier C, Nhoueng S, Chhim K, Sovann S, Yom S, Vong C, Yin S, Ros B, Ky V, Pech S, Nem B, Hout K, Guillebaud J, Ear E, Caroupaye-caroupin L, Rekacewicz C, Fernandez L, Laurent D, Yay C, Kim R, Meyer L, Chhun S, Keang C, Khan O, Nang B, Sreng VL, In S, Sun S, Sov L, Nor B, Hing B, Seng S, Soum S, Say L, Ay SS, Thol D, Chhouk C, Piola P, Nouhin J, Roque Afonso A, Duclos Vallee JC, Sann C, Kruy LS, Lemoine M, Mandelbrot L, Blanche S, Diallo A, Paul C, Tiv S, Sar P, Nov L, Vann D, Chea T, Touch B, Neav K, Kong E, Chea R, Ouk C, Meak L, Krouch R, Chhan N, Seang S, Nuon V, Meng L, Tharith SL, Hang S, Som V, Som R, Seng P, Lim M, Srey K, Uch SR, Hou P, Bo S, Ieang E, Korn K, Noun CR, Soy S, Khim T, Sou V, Pol S, Nget S, Sun M, Uon P, Ya KT, Lean K, Eang KE, Ung S, Rith R, Mom C, Keang C, Sam S, Chuong S, Nam C, Khuon S, Cheang S, Lean S, Tarantola A, Fournier I, Rouveau N, Calvo cortez M. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial. The Lancet Infectious Diseases 2022;22:1181-1190. [DOI: 10.1016/s1473-3099(22)00206-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 372 |
Manso T, de Salazar A, Rodríguez-velasco M, García F, Aguilera A. Detección y cuantificación de VHB y VHC en muestras de plasma mediante la utilización de diferentes ensayos moleculares: estudio comparativo. Enfermedades Infecciosas y Microbiología Clínica 2022. [DOI: 10.1016/j.eimc.2022.07.007] [Reference Citation Analysis]
|
| 373 |
Kayes T, Crane H, Symonds A, Dumond J, Cottrell M, Di Girolamo J, Manandhar S, Lim TH, Gane E, Kashuba A, Levy MT. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. Aliment Pharmacol Ther 2022;56:510-8. [PMID: 35599363 DOI: 10.1111/apt.17040] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 374 |
Lee MH. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. Aliment Pharmacol Ther 2022;56:546-7. [PMID: 35804473 DOI: 10.1111/apt.17079] [Reference Citation Analysis]
|
| 375 |
Pollicino T. Global burden of occult hepatitis B virus infection: where we are and what to do. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00238-2] [Reference Citation Analysis]
|
| 376 |
Papatheodoridis GV, Mimidis K, Manolakopoulos S, Gatselis N, Goulis J, Kapatais A, Manesis E, Vasiliadis T, Triantos C, Samonakis D, Sevastianos V, Karatapanis S, Elefsiniotis I, Deutsch M, Mylopoulou T, Papatheodoridi M, Kranidioti H, Agorastou P, Karaoulani T, Kyriazidou A, Zisimopoulos K, Dalekos GN. HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks. Aliment Pharmacol Ther 2022;56:702-12. [PMID: 35736010 DOI: 10.1111/apt.17093] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 377 |
Montanari NR, Ramírez R, Aggarwal A, van Buuren N, Doukas M, Moon C, Turner S, Diehl L, Li L, Debes JD, Feierbach B, Boonstra A. Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection. J Hepatol 2022;77:332-43. [PMID: 35218813 DOI: 10.1016/j.jhep.2022.02.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 378 |
Bonino F, Colombatto P, Brunetto MR. HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History. Viruses 2022;14:1691. [PMID: 36016312 DOI: 10.3390/v14081691] [Reference Citation Analysis]
|
| 379 |
Zappulo E, Giaccone A, Schiano Moriello N, Gentile I. Pharmacological approaches to prevent vertical transmission of HIV and HBV. Expert Rev Clin Pharmacol 2022;:1-14. [PMID: 35876100 DOI: 10.1080/17512433.2022.2105202] [Reference Citation Analysis]
|
| 380 |
Engin İ, Duman AE, Ataoğlu HE, Örmeci AÇ, Poturoğlu Ş. Predictors of eligibility for reimbursement of antiviral treatment in HBe-Ag negative chronic hepatitis B patients with high ALT levels. J Surg Med 2022;6:705-708. [DOI: 10.28982/josam.1012592] [Reference Citation Analysis]
|
| 381 |
Li YG, Yu ZJ, Li A, Ren ZG. Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: Molecular mechanisms and therapeutic inventions. World J Gastroenterol 2022; 28(28): 3555-3572 [DOI: 10.3748/wjg.v28.i28.3555] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 382 |
Dong H, Hong X, He Y, Bao Z, Zhang Y, Shen S, Wang G, Zhang J, Mo R. A carrier-free metal-organic hybrid nanoassembly with combination anti-viral and hepato-protective activity for hepatitis B treatment. Biomater Sci 2022;10:4356-66. [PMID: 35786722 DOI: 10.1039/d2bm00407k] [Reference Citation Analysis]
|
| 383 |
Yan Y, Chang L, Ji H, Han Y, Wang L. Evaluation of the Aptima HBV Quant Assay Compared to Abbott RealTime M2000 HBV Quant Assay and Procleix Ultrio Plus dHBV Assay in Plasma Samples. Microbiol Spectr 2022;:e0176122. [PMID: 35880868 DOI: 10.1128/spectrum.01761-22] [Reference Citation Analysis]
|
| 384 |
Zhang Z, Lu W, Huang D, Zhou X, Ding R, Li X, Wang Y, Lin W, Zeng D, Feng Y. Capabilities of hepatitis B surface antigen are divergent from hepatitis B virus DNA in delimiting natural history phases of chronic hepatitis B virus infection. Front Immunol 2022;13:944097. [DOI: 10.3389/fimmu.2022.944097] [Reference Citation Analysis]
|
| 385 |
Woo HY, Heo J, Tak WY, Lee HJ, Chung WJ, Park JG, Park SY, Park YJ, Lee YR, Hwang JS, Kweon YO. Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial. PLoS ONE 2022;17:e0270716. [DOI: 10.1371/journal.pone.0270716] [Reference Citation Analysis]
|
| 386 |
Yang R, Li K, Zou C, Wee A, Liu J, Liu L, Li M, Wu T, Wang Y, Ma Z, Wang Y, Liu J, Huang A, Sun Y, Chang B, Liang Q, Jia J, Zou Z, Zhao X. Alanine Aminotransferase and Bilirubin Dynamic Evolution Pattern as a Novel Model for the Prediction of Acute Liver Failure in Drug-Induced Liver Injury. Front Pharmacol 2022;13:934467. [DOI: 10.3389/fphar.2022.934467] [Reference Citation Analysis]
|
| 387 |
Sagnelli C, Montella L, Grimaldi P, Pisaturo M, Alessio L, De Pascalis S, Sagnelli E, Coppola N. COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. Pathogens 2022;11:816. [DOI: 10.3390/pathogens11070816] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 388 |
Nieminen T, Salo H, Nurhonen M, Leino T. Health care costs related to hepatitis B in Finland are mostly due to chronic infections: a register-based study. Infect Dis (Lond) 2022;:1-9. [PMID: 35857779 DOI: 10.1080/23744235.2022.2082519] [Reference Citation Analysis]
|
| 389 |
Graupera I, Thiele M, Ma AT, Serra-Burriel M, Pich J, Fabrellas N, Caballeria L, de Knegt RJ, Grgurevic I, Reichert M, Roulot D, Schattenberg JM, Pericas JM, Angeli P, Tsochatzis EA, Guha IN, Garcia-Retortillo M, Morillas RM, Hernández R, Hoyo J, Fuentes M, Madir A, Juanola A, Soria A, Juan M, Carol M, Diaz A, Detlefsen S, Toran P, Fournier C, Llorca A, Newsome PN, Manns M, de Koning HJ, Serra-Burriel F, Cucchietti F, Arslanow A, Korenjak M, van Kleef L, Falcó JL, Kamath PS, Karlsen TH, Castera L, Lammert F, Krag A, Ginès P; LiverScreen Consortium investigators. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries. BMC Public Health 2022;22:1385. [PMID: 35854275 DOI: 10.1186/s12889-022-13724-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 390 |
Cakal B, Atasoy A, Cavus B, Poda M, Bulakci M, Gulluoglu M, Demirci M, Akyuz F. Prevalence of occult hepatitis B infection in liver biopsy sample of patients with nonviral liver disease. Future Virology. [DOI: 10.2217/fvl-2021-0316] [Reference Citation Analysis]
|
| 391 |
Feld JJ, King WC, Ghany MG, Chang KM, Terrault N, Perrillo RP, Khalili M, Hinerman AS, Janssen H, Lok AS; Hepatitis B Research Network (HBRN). Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00653-X. [PMID: 35843468 DOI: 10.1016/j.cgh.2022.06.015] [Reference Citation Analysis]
|
| 392 |
Sun H, Liu Y, Zhang Y, Jie Y, Wu Y, Li Z, Wei X, Li X, Niu B. Finite versus Indefinite Nucleos(t)ide Analogue Therapy of Patients with Chronic Hepatitis B Exhibiting Negative HBsAg Levels after Treatment. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/6069781] [Reference Citation Analysis]
|
| 393 |
Liao H, Li L, Zheng WV, Zou J, Yu G, Si L, Ge F, Zhou T, Ji D, Chen X, Xu D, Cheng G, Liu Y, Chen J, Colangelo L. Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients. Disease Markers 2022;2022:1-13. [DOI: 10.1155/2022/4133283] [Reference Citation Analysis]
|
| 394 |
Li Z, Xie B, Yi N, Cai H, Yi W, Gao X. Efficacy and safety of tenofovir disoproxil fumarate or telbivudine used throughout pregnancy for the prevention of mother-to-child transmission of hepatitis B virus: A cohort study. Eur J Obstet Gynecol Reprod Biol 2022;276:102-6. [PMID: 35853269 DOI: 10.1016/j.ejogrb.2022.07.009] [Reference Citation Analysis]
|
| 395 |
Gan Q, Huang Y, Zhu C, Zhao S, Fu H, Cai M, Wang J, Zhang C, Guo S, Cao Z, Xie Q. qHBsAg for the Identification of Liver Histological Abnormalities in HBeAg-Negative Chronic Hepatitis B Patients with Normal and Mildly Elevated ALT Levels. Can J Gastroenterol Hepatol 2022;2022:8695196. [PMID: 35875362 DOI: 10.1155/2022/8695196] [Reference Citation Analysis]
|
| 396 |
Hu Q, Wang Q, Xu W, Huang C, Tao S, Qi X, Zhang Y, Li X, Jiang X, Song J, Li Q, Chen L, Huang Y. Development and Validation of a Non-invasive Model to Predict Liver Histological Lesions in Chronic Hepatitis B Patients With Persistently Normal Alanine Aminotransferase and Detectable Viremia. Front Med 2022;9. [DOI: 10.3389/fmed.2022.944547] [Reference Citation Analysis]
|
| 397 |
Dai Y, Zhao Z, Liu C. Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. Front Pharmacol 2022;13:942841. [DOI: 10.3389/fphar.2022.942841] [Reference Citation Analysis]
|
| 398 |
Li Z, Meng F, Li J, Wu T. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report. Front Immunol 2022;13:931452. [DOI: 10.3389/fimmu.2022.931452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 399 |
Li T, Li J, Cao S, Wang Y, Wang H, Zhang C, Ke P, Huang X. Patient-based real-time quality control for quantitative hepatitis B virus DNA test using moving rate of positive and negative patient results. Clin Chem Lab Med 2022. [PMID: 35822704 DOI: 10.1515/cclm-2022-0338] [Reference Citation Analysis]
|
| 400 |
Quan M, Liu X, Liu C, Li W, Xing H, Pan JS. Antiviral Therapy for Prevention of Perinatal Hepatitis B Virus Transmission Reduces the Incidence of Postpartum Hepatitis Flare. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/7046955] [Reference Citation Analysis]
|
| 401 |
Liu Y, Park D, Cafiero TR, Bram Y, Chandar V, Tseng A, Gertje HP, Crossland NA, Su L, Schwartz RE, Ploss A. Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses. JHEP Rep 2022;4:100535. [PMID: 36035359 DOI: 10.1016/j.jhepr.2022.100535] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 402 |
Saitta C, Pollicino T, Raimondo G. Occult Hepatitis B Virus Infection: An Update. Viruses 2022;14:1504. [PMID: 35891484 DOI: 10.3390/v14071504] [Reference Citation Analysis]
|
| 403 |
Won J, Lee AR, Dezhbord M, Lee DR, Kim SH, Kim JC, Park S, Kim N, Jae B, Kim K. Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir. Biomedicines 2022;10:1637. [DOI: 10.3390/biomedicines10071637] [Reference Citation Analysis]
|
| 404 |
Lourenço J, Mcnaughton AL, Pley C, Obolski U, Gupta S, Matthews PC. Polymorphisms Predicting Phylogeny in Hepatitis B Virus (HBV).. [DOI: 10.1101/2022.07.05.498824] [Reference Citation Analysis]
|
| 405 |
Lin X, Song A, Lu J, Zheng S, Hu Z, Ma L, Cao Z, Li H, Zheng Y, Ren S, Chen X. Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure. Front Immunol 2022;13:879835. [DOI: 10.3389/fimmu.2022.879835] [Reference Citation Analysis]
|
| 406 |
Wang J, Geng X, Zhang X, Xiao Y, Wang W. Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database. Front Pharmacol 2022;13:921084. [DOI: 10.3389/fphar.2022.921084] [Reference Citation Analysis]
|
| 407 |
Ravindranath A. Chronic Hepatitis B Management in Children. Annals of Pediatric Gastroenterology & Hepatology 2022;1:7-11. [DOI: 10.5005/jp-journals-11009-0033] [Reference Citation Analysis]
|
| 408 |
Umemura M, Ogawa K, Morikawa K, Kubo A, Tokuchi Y, Yamada R, Kitagataya T, Shigesawa T, Shimazaki T, Kimura M, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Suda G, Natsuizaka M, Ono K, Murata K, Sugiyama M, Mizokami M, Sakamoto N. Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients. Hepatol Res 2022;52:586-96. [PMID: 35352445 DOI: 10.1111/hepr.13768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 409 |
Palom A, Rando-segura A, Vico J, Pacín B, Vargas E, Barreira-díaz A, Rodríguez-frías F, Riveiro-barciela M, Esteban R, Buti M. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100547] [Reference Citation Analysis]
|
| 410 |
Lai MW, Chang YL, Cheng PJ, Chueh HY, Chang SC, Yeh CT. Absence of chronicity in infants born to immunized mothers with occult HBV infection in Taiwan. J Hepatol 2022;77:63-70. [PMID: 35176439 DOI: 10.1016/j.jhep.2022.01.030] [Reference Citation Analysis]
|
| 411 |
Xiridou M, Adam P, Meiberg A, Visser M, Matser A, de Wit J, Op de Coul E. The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.06.075] [Reference Citation Analysis]
|
| 412 |
Liu X, Li H, Wei L, Tang Q, Hu P. Optimized cutoffs of gamma-glutamyl transpeptidase-to-platelet ratio, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 scoring systems for exclusion of cirrhosis in patients with chronic hepatitis B. Hepatol Commun 2022;6:1664-72. [PMID: 35312182 DOI: 10.1002/hep4.1938] [Reference Citation Analysis]
|
| 413 |
Yoon EL, Jun DW. Precision medicine in the era of potent antiviral therapy for chronic hepatitis B. J Gastroenterol Hepatol 2022;37:1191-6. [PMID: 35430754 DOI: 10.1111/jgh.15856] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 414 |
Liu N, Steer CJ, Song G. MicroRNA-206 enhances antitumor immunity by disrupting the communication between malignant hepatocytes and regulatory T cells in c-Myc mice. Hepatology 2022;76:32-47. [PMID: 34606648 DOI: 10.1002/hep.32182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 415 |
Taşkın MC, Uyanikoglu A, Cindoglu C. Evaluation of HBsAg Seroclearance in Patients with Hepatitis B. Euroasian J Hepatogastroenterol 2022;12:65-8. [PMID: 36959985 DOI: 10.5005/jp-journals-10018-1352] [Reference Citation Analysis]
|
| 416 |
Lin C, Huang Y, Luo L, Fang F, Zhang J, Xun Z, Fu Y, Shang H, Liu C, Ou Q. Adenosine Triphosphate in Serum as a Promising Biomarker for Differential Diagnosis of Hepatitis B Disease Progression. Front Immunol 2022;13:927761. [DOI: 10.3389/fimmu.2022.927761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 417 |
Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: The promising paths forward. Hepatology 2022;76:233-50. [PMID: 34990029 DOI: 10.1002/hep.32314] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 418 |
Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, Hu J, Wang Y, Tao R, Xiao F, Zhang X, Wang X, Han M, Luo X, Yan W, Ning Q. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol 2022;77:42-54. [PMID: 35149125 DOI: 10.1016/j.jhep.2022.01.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 419 |
Broquetas T, Carrión JA. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. HMER 2022;Volume 14:87-100. [DOI: 10.2147/hmer.s291976] [Reference Citation Analysis]
|
| 420 |
Agarwal K, Lok J, Carey I, Shivkar Y, Biermer M, Berg T, Lonjon-Domanec I. A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'. J Hepatol 2022;77:245-8. [PMID: 35358614 DOI: 10.1016/j.jhep.2022.03.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 421 |
Zhang Y, Tong S, Li S, Wang X, Ren H, Yin W. Increased ILT2 expression contributes to dysfunction of CD56dimCD16+NK cells in chronic hepatitis B virus infection. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105385] [Reference Citation Analysis]
|
| 422 |
Shbaklo N, Tandoi F, Lupia T, Corcione S, Romagnoli R, De Rosa FG. Bacterial and Viral Infections in Liver Transplantation: New Insights from Clinical and Surgical Perspectives. Biomedicines 2022;10:1561. [DOI: 10.3390/biomedicines10071561] [Reference Citation Analysis]
|
| 423 |
Tserashkou DV, Mitsura VM. Chronic hepatitis B virus infection: clinical characteristics and antiviral therapy. jour 2022;19:82-89. [DOI: 10.51523/2708-6011.2022-19-2-10] [Reference Citation Analysis]
|
| 424 |
Besombes J, Souala F, Bouguen G, Guyader D, Grolhier C, Thibault V, Pronier C. Acute hepatitis B virus infection despite vaccination in a patient treated by infliximab: a case report. BMC Gastroenterol 2022;22:322. [PMID: 35768794 DOI: 10.1186/s12876-022-02397-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 425 |
Huang Y, Chen L, Huang R, Zhu C, Shang J, Qian Y, Lian J, Liu L, Jiang J, Liu C, Gui H, Xie Q. Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores. Ther Adv Chronic Dis 2022;13:20406223221102791. [PMID: 35757781 DOI: 10.1177/20406223221102791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 426 |
Phillips S, Jagatia R, Chokshi S. Novel therapeutic strategies for Chronic Hepatitis B. Virulence 2022. [PMID: 35763282 DOI: 10.1080/21505594.2022.2093444] [Reference Citation Analysis]
|
| 427 |
Peng J, Yao X, Yuan C, Liu X, Xia R, He J, Li R, Yao Y. The Investigation of Hepatitis B Vaccine Immune Responses in Occult Hepatitis B Virus-Infected Patients. Front Immunol 2022;13:903685. [PMID: 35747142 DOI: 10.3389/fimmu.2022.903685] [Reference Citation Analysis]
|
| 428 |
Ahmed Z, Shetty A, Victor DW, Kodali S. Viral hepatitis: A narrative review of hepatitis A–E. World J Meta-Anal 2022; 10(3): 99-121 [DOI: 10.13105/wjma.v10.i3.99] [Reference Citation Analysis]
|
| 429 |
Watanabe T, Hayashi S, Tanaka Y. Drug Discovery Study Aimed at a Functional Cure for HBV. Viruses 2022;14:1393. [DOI: 10.3390/v14071393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 430 |
Soriano V, de Mendoza C, Treviño A, Ramos-Rincón JM, Moreno-Torres V, Corral O, Barreiro P. Treatment of hepatitis delta and HIV infection. Liver Int 2022. [PMID: 35748639 DOI: 10.1111/liv.15345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 431 |
Chen YC, Hsu CW, Chien RN, Tai DI. One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study. Medicine (Baltimore) 2022;101:e29269. [PMID: 35758355 DOI: 10.1097/MD.0000000000029269] [Reference Citation Analysis]
|
| 432 |
Loggi E, Gitto S, Gabrielli F, Franchi E, Seferi H, Cursaro C, Andreone P. Virological Treatment Monitoring for Chronic Hepatitis B. Viruses 2022;14:1376. [DOI: 10.3390/v14071376] [Reference Citation Analysis]
|
| 433 |
Jia N, Gao W, Fan X, Gao H, Li X, Mi B, Yang J. Clinical Efficacy of PEG-IFNα-2a and PEG-IFNα-2b in the Treatment of Hepatitis B e Antigen-Positive Hepatitis B and Their Value in Improving Inflammatory Factors and Hemodynamics in Patients: A Comparative Study. Oxid Med Cell Longev 2022;2022:3185320. [PMID: 35726331 DOI: 10.1155/2022/3185320] [Reference Citation Analysis]
|
| 434 |
Zhang WB, Hou SZ, Chen YL, Mao F, Dong Y, Chen JG, Wang WP. Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of α-Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients. Front Oncol 2022;12:862297. [PMID: 35720017 DOI: 10.3389/fonc.2022.862297] [Reference Citation Analysis]
|
| 435 |
Feng M, Lei L, Xu J, Shi Y, Yang W. Platelet-to-Portal Vein Width Ratio and Platelet-to-Spleen Thickness Ratio Can Be Used to Predict Progressive Liver Fibrosis Among Patients With HBV Infection With HBeAg-Negativity and a Normal ALT Level. Front Med 2022;9:837898. [DOI: 10.3389/fmed.2022.837898] [Reference Citation Analysis]
|
| 436 |
Zhao R, Zhao H, Ge YQ, Zhou FF, Wang LS, Yu HZ, Gong XJ. Usefulness of Noncontrast MRI-Based Radiomics Combined Clinic Biomarkers in Stratification of Liver Fibrosis. Can J Gastroenterol Hepatol 2022;2022:2249447. [PMID: 35775068 DOI: 10.1155/2022/2249447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 437 |
Yendewa GA, Lakoh S, Jiba DF, Yendewa SA, Barrie U, Deen GF, Samai M, Jacobson JM, Sahr F, Salata RA. Hepatitis B Virus and Tuberculosis Are Associated with Increased Noncommunicable Disease Risk among Treatment-Naïve People with HIV: Opportunities for Prevention, Early Detection and Management of Comorbidities in Sierra Leone. J Clin Med 2022;11. [PMID: 35743539 DOI: 10.3390/jcm11123466] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 438 |
Gherlan GS. Occult hepatitis B — the result of the host immune response interaction with different genomic expressions of the virus. World J Clin Cases 2022; 10(17): 5518-5530 [DOI: 10.12998/wjcc.v10.i17.5518] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 439 |
Lazarus JV, Al-Rifai A, Sanai FM, Alghamdi AS, Sharara AI, Saad MF, van Selm L, Alqahtani SA. Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: A scoping review. Liver Int 2022. [PMID: 35689428 DOI: 10.1111/liv.15338] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 440 |
Cao W, Xie S, Zhang L, Bi X, Lin Y, Yang L, Lu Y, Liu R, Chang M, Wu S, Shen G, Dong J, Xie Y, Li M. Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN α-2a Treatment. Front Immunol 2022;13:891424. [PMID: 35663955 DOI: 10.3389/fimmu.2022.891424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 441 |
Stella L, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. World J Gastroenterol 2022; 28(21): 2251-2281 [DOI: 10.3748/wjg.v28.i21.2251] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 442 |
Azhari H, Frolkis AD, Shaheen AA, Israelson H, Pinto J, Congly SE, Borman MA, Aspinall AA, Stinton LM, Nguyen HH, Swain MG, Burak KW, Lee SS, Sadler MD, Coffin CS. Real-world tertiary referral centre experience stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B. CanLivJ 2022. [DOI: 10.3138/canlivj-2022-0002] [Reference Citation Analysis]
|
| 443 |
Lai X, Chen W, Wu Y, Gao Y, Zhang Y, Xu X, Fu Y, Wang X, Yang Y, Zhang Y. Effect of mutations across reverse transcriptase region on HBV replication and progression of liver diseases in Chinese patients. J Clin Lab Anal 2022;:e24530. [PMID: 35657116 DOI: 10.1002/jcla.24530] [Reference Citation Analysis]
|
| 444 |
He WQ, Matthews GV, Liu B. Characteristics Associated with Monitoring and Treatment of Chronic Hepatitis B in a Large Cohort of Australian Adults. Dig Dis Sci 2022;67:2600-7. [PMID: 33945063 DOI: 10.1007/s10620-021-07008-z] [Reference Citation Analysis]
|
| 445 |
Hui RW, Chiu KW, Mak LY, Chang HC, Cheung KS, Fung J, Yuen MF, Seto WK. Magnetic resonance imaging metrics and the predictability of adverse outcomes in on-treatment Asian chronic hepatitis B. J Gastroenterol Hepatol 2022;37:1139-47. [PMID: 35368120 DOI: 10.1111/jgh.15846] [Reference Citation Analysis]
|
| 446 |
Bernstein DE, Trinh HN, Schiff ER, Smith CI, Mospan AR, Zink RC, Fried MW, Lok AS. Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. Dig Dis Sci 2022;67:2637-45. [PMID: 34059991 DOI: 10.1007/s10620-021-07033-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 447 |
van Oorschot E, Koc ÖM, Oude Lashof AM, van Loo IH, Ackens R, Posthouwer D, Koek GH. Cascade of care among hepatitis B patients in Maastricht, the Netherlands, 1996 to 2018. Journal of Virus Eradication 2022;8:100075. [DOI: 10.1016/j.jve.2022.100075] [Reference Citation Analysis]
|
| 448 |
Peña-Asensio J, Calvo H, Miquel J, Sanz-de-Villalobos E, González-Praetorius A, Torralba M, Larrubia JR. Model to predict on-treatment restoration of functional HBV-specific CD8(+) cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2022;55:1545-59. [PMID: 35224746 DOI: 10.1111/apt.16850] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 449 |
Lin MH, Li HQ, Zhu L, Su HY, Peng LS, Wang CY, He CP, Liang XE, Wang Y. Liver Fibrosis in the Natural Course of Chronic Hepatitis B Viral Infection: A Systematic Review with Meta-Analysis. Dig Dis Sci 2022;67:2608-26. [PMID: 34008117 DOI: 10.1007/s10620-021-07009-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 450 |
Guo F, Yuan Y, Chen Z, Gao F, Li X, Wang H, Wang X, Bai G. Downregulation of the long non-coding RNA MALAT1 in tenofovir-treated pregnant women with hepatitis B virus infection promotes immune recovery of natural killer cells via the has-miR-155-5p/HIF-1α axis. International Immunopharmacology 2022;107:108701. [DOI: 10.1016/j.intimp.2022.108701] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 451 |
Gane E, Yuen MF, Kakuda TN, Ogawa T, Takahashi Y, Goeyvaerts N, Lonjon-Domanec I, Vaughan T, Schluep T, Hamilton J, Njumbe Ediage E, Hillewaert V, Snoeys J, Lenz O, Talloen W, Biermer M. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B. Antivir Ther 2022;27:13596535221093856. [PMID: 35695169 DOI: 10.1177/13596535221093856] [Reference Citation Analysis]
|
| 452 |
Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 453 |
Deng JJ, Li GP, Lu W, Yan Z, Wang Y. DAZAP1 overexpression promotes growth of HCC cell lines: a primary study using CEUS. Clin Transl Oncol 2022;24:1168-76. [PMID: 35091997 DOI: 10.1007/s12094-021-02758-8] [Reference Citation Analysis]
|
| 454 |
Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, Tang ASP, Lim KE, Lim GEH, Tamaki N, Kim BK, Teng MLP, Fung J, Loomba R, Nguyen MH, Huang DQ. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis. JAMA Netw Open 2022;5:e2219407. [PMID: 35767258 DOI: 10.1001/jamanetworkopen.2022.19407] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 455 |
Watermeyer G, Awuku Y, Fredericks E, Epstein D, Setshedi M, Devani S, Mudombi W, Kassianides C, Katsidzira L. Challenges in the management of inflammatory bowel disease in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00048-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 456 |
Lee J, Lee JG, Hwang S, Lee KW, Kim JM, Ryu JH, Kim BW, Choi DL, You YK, Kim DS, Nah YW, Kang KJ, Cho JY, Yu HC, Hong G, Choi D, Moon JI, Kim MS. Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study. Hepatol Int 2022;16:537-44. [PMID: 35467324 DOI: 10.1007/s12072-022-10320-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 457 |
Huang J, Liu Y, Liu Y. Antiviral therapy in hepatitis B virus-infected with immune-tolerant: A meta-analysis. Gastroenterología y Hepatología 2022. [DOI: 10.1016/j.gastrohep.2022.05.014] [Reference Citation Analysis]
|
| 458 |
Wang J, Zhang X, Geng X, Shi J, Jia X, Dang S, Wang W. Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases. EClinicalMedicine 2022;48:101425. [PMID: 35706497 DOI: 10.1016/j.eclinm.2022.101425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 459 |
Chen Y, Gao WK, Shu YY, Ye J. Clinical treatment of chronic hepatitis B virus infection in indeterminate phase: Current status and future prospects. Shijie Huaren Xiaohua Zazhi 2022; 30(10): 436-443 [DOI: 10.11569/wcjd.v30.i10.436] [Reference Citation Analysis]
|
| 460 |
Oh H, Lee HY, Kim J, Kim YJ. Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail. Cancers (Basel) 2022;14:2617. [PMID: 35681596 DOI: 10.3390/cancers14112617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 461 |
Boglione L, De Benedetto I, Dodaro V, Chiecchio M, De Nicolò A, Di Perri G, D’avolio A. Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B. Arch Virol. [DOI: 10.1007/s00705-022-05466-y] [Reference Citation Analysis]
|
| 462 |
Luo L, Ye J, Shao C, Lin Y, Sun Y, Feng S, Wang W, Zhong B. Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection. Nutrients 2022;14. [PMID: 35631255 DOI: 10.3390/nu14102114] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 463 |
Zhao D, Cao J, Zhang L, Zhang S, Wu S. Targeted Molecular Imaging Probes Based on Magnetic Resonance Imaging for Hepatocellular Carcinoma Diagnosis and Treatment. Biosensors 2022;12:342. [DOI: 10.3390/bios12050342] [Reference Citation Analysis]
|
| 464 |
Magri A, Harris JM, D’arienzo V, Minisini R, Jühling F, Wing PAC, Rapetti R, Leutner M, Testoni B, Baumert TF, Zoulim F, Balfe P, Pirisi M, Mckeating JA. Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease. Viruses 2022;14:1070. [DOI: 10.3390/v14051070] [Reference Citation Analysis]
|
| 465 |
Sagnelli C, Sica A, Creta M, Borsetti A, Ciccozzi M, Sagnelli E. Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. Pathogens 2022;11:567. [DOI: 10.3390/pathogens11050567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 466 |
Pley C, Lourenço J, McNaughton AL, Matthews PC. Spacer Domain in Hepatitis B Virus Polymerase: Plugging a Hole or Performing a Role? J Virol 2022;96:e0005122. [PMID: 35412348 DOI: 10.1128/jvi.00051-22] [Reference Citation Analysis]
|
| 467 |
Sandmann L, Cornberg M. HCC and HBV reactivation-A preventable condition not to be missed. Hepatology 2022;75:1075-7. [PMID: 35007342 DOI: 10.1002/hep.32333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 468 |
Zhao D, Zhang X, Tang Y, Guo P, Ai R, Hou M, Wang Y, Yuan X, Cui L, Zhang Y, Zhao S, Li W, Wang Y, Sun X, Liu L, Dong S, Li L, Zhao W, Nan Y. Identification and Validation of Novel Biomarkers for Hepatocellular Carcinoma, Liver Fibrosis/Cirrhosis and Chronic Hepatitis B via Transcriptome Sequencing Technology. JHC 2022;Volume 9:389-403. [DOI: 10.2147/jhc.s357380] [Reference Citation Analysis]
|
| 469 |
Tsai M, Sytwu H, Hsieh T, Chien W, Lai C, Chen H. Association Between Depression or Anxiety and the Risk of Hepatitis B Flares: A Nationwide Population-Based Cohort Study. JIR 2022;Volume 15:2983-93. [DOI: 10.2147/jir.s355314] [Reference Citation Analysis]
|
| 470 |
Choi HSJ, Tonthat A, Janssen HLA, Terrault NA. Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B. Hepatol Commun 2022;6:935-49. [PMID: 34894108 DOI: 10.1002/hep4.1875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 471 |
Tonthat AV, Zhou K. Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir-a "knock-out" is yet to be delivered. Aliment Pharmacol Ther 2022;55:1342-3. [PMID: 35472182 DOI: 10.1111/apt.16822] [Reference Citation Analysis]
|
| 472 |
Zeng X, Bahabayi A, Tuerhanbayi B, Zheng M, Liu T, Xu L, Long Y, Xia C, Lu S, Song Y, Liu C. The altered HLA-DQ expression in peripheral blood T cells of chronic hepatitis B patients characterizes the function of T cells. J Viral Hepat 2022;29:340-51. [PMID: 35274405 DOI: 10.1111/jvh.13669] [Reference Citation Analysis]
|
| 473 |
Tseng TC, Hosaka T, Liu CJ, Suzuki F, Hong CM, Kumada H, Yang WT, Hsu CY, Su TH, Yang HC, Liu CH, Chen PJ, Chen HH, Kao JH. Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase. Am J Gastroenterol 2022;117:748-57. [PMID: 35191399 DOI: 10.14309/ajg.0000000000001691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 474 |
Xun Z, Yao X, Zhu C, Ye Y, Wu S, Chen T, Zeng Y, Lin C, Yang B, Ou Q, Liu C. Proteomic characterization of the natural history of chronic HBV infection revealed by tandem mass tag-based quantitative proteomics approach. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 475 |
Chen Y, Hua X, Huang B, Karsten S, You Z, Li B, Li Y, Li Y, Liang J, Zhang J, Wei Y, Chen R, Lyu Z, Xiao X, Lian M, Wei J, Fang J, Miao Q, Wang Q, Berglung UW, Tang R, Helleday T, Ma X. MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells. Hepatol Commun 2022;6:1016-31. [PMID: 34894107 DOI: 10.1002/hep4.1862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 476 |
Vyas AK, Jindal A. Concerns and Safety of Add-on Versus Switch Peginterferon Therapy for Chronic Hepatitis B. Clin Gastroenterol Hepatol 2022;20:1190-1. [PMID: 34000379 DOI: 10.1016/j.cgh.2021.05.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 477 |
Yuan BH, Li RH, Huo RR, Li MJ, Papatheodoridis G, Zhong JH. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J Gastroenterol Hepatol 2022;37:782-94. [PMID: 35080052 DOI: 10.1111/jgh.15783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 478 |
Narmada BC, Khakpoor A, Shirgaonkar N, Narayanan S, Kim Aw PP, Singh M, Ong KH, Owino CO, Ng JWT, Yew HC, Binte Mohamed Nasir NS, Au VB, Sng R, Kaliaperumal N, Khine HHTW, Ng HX, Chia SL, Seah CXY, Alnawaz MH, Wai CLY, Tay AYL, Yu W, Connolly JE, Periyasamy G, Lim SG, Dasgupta R. Single cell profiling of functionally cured Chronic Hepatitis B patients reveals the emergence of activated innate and an altered adaptive immune response in the intra-hepatic environment.. [DOI: 10.1101/2022.04.26.489625] [Reference Citation Analysis]
|
| 479 |
Ortonne V, Lucas Q, Garrigou O, Soulier A, Challine D, Pawlotsky JM, Leroy V, Chevaliez S. Alinity m, a Random-Access System, for Hepatitis B Virus DNA Quantification in Plasma and Whole Blood Collected on Dried Blood Spots. mSphere 2022;:e0008222. [PMID: 35477312 DOI: 10.1128/msphere.00082-22] [Reference Citation Analysis]
|
| 480 |
Cortese MF, Riveiro-Barciela M, Tabernero D, Rodriguez-Algarra F, Palom A, Sopena S, Rando-Segura A, Roade L, Kuchta A, Ferrer-Costa R, Quer J, Pacin B, Vila M, Casillas R, Garcia-Garcia S, Esteban R, Pumarola T, Buti M, Rodriguez-Frias F. Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up. Microbiol Spectr 2022;10:e0214921. [PMID: 35377229 DOI: 10.1128/spectrum.02149-21] [Reference Citation Analysis]
|
| 481 |
Asai A, Hirai S, Yokohama K, Nishikawa T, Nishikawa H, Higuchi K. Effect of an Electronic Alert System on Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Drug Therapy. J Clin Med 2022;11:2446. [PMID: 35566572 DOI: 10.3390/jcm11092446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 482 |
Koffas A, Mak LY, Gill US, Kennedy PTF. Early Treatment Consideration in Patients with Hepatitis B 'e' Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift? Viruses 2022;14. [PMID: 35632642 DOI: 10.3390/v14050900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 483 |
Hong YM, Yoon KT. [Definition and Management of the Immune Tolerance Phase in Chronic Hepatitis B]. Korean J Gastroenterol 2022;79:156-60. [PMID: 35473773 DOI: 10.4166/kjg.2022.049] [Reference Citation Analysis]
|
| 484 |
Pan CQ. The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B. Antiviral Therapy 2022;27:135965352210766. [DOI: 10.1177/13596535221076640] [Reference Citation Analysis]
|
| 485 |
Chi X, Jiang L, Yuan Y, Huang X, Yang X, Hochwald S, Liu J, Huang H. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02279-w] [Reference Citation Analysis]
|
| 486 |
Chen W, Fu M, Zhang C, Xing Q, Zhou F, Lin M, Dong X, Huang J, Lin S, Hong M, Zheng Q, Pan J. Deep Learning-Based Universal Expert-Level Recognizing Pathological Images of Hepatocellular Carcinoma and Beyond. Front Med 2022;9:853261. [DOI: 10.3389/fmed.2022.853261] [Reference Citation Analysis]
|
| 487 |
Wong GL, Lok AS. Chronic hepatitis B and D. Yamada's Textbook of Gastroenterology 2022. [DOI: 10.1002/9781119600206.ch87] [Reference Citation Analysis]
|
| 488 |
Akyüz F, Çavuş B, Nizam N, Göktürk S, Baran B, Yazıcı H, Evirgen S, Akyüz Ü, Öbekli T, Karaca Ç, Demir K, Beşışık F, Kaymakoğlu S. Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data. Clin Exp Hepatol 2022;8:7-13. [PMID: 35415260 DOI: 10.5114/ceh.2022.114153] [Reference Citation Analysis]
|
| 489 |
Martini S, Tandoi F, Romagnoli R, Rizzetto M. Liver Transplantation in Hepatitis B/Hepatitis D (Delta) Virus Coinfected Recipients. Transplantation 2022;Publish Ahead of Print. [DOI: 10.1097/tp.0000000000004138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 490 |
Diao Y, Hu D, Hu X, Wang P, Wang X, Luo X, Wang H, Ning Q. The Role of Metabolic Factors and Steatosis in Treatment-Naïve Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase. Infect Dis Ther. [DOI: 10.1007/s40121-022-00629-5] [Reference Citation Analysis]
|
| 491 |
Msomi N, Parboosing R, Wilkinson E, Giandhari J, Govender K, Chimukangara B, Mlisana KP. Persistent Hepatitis B Viraemia with Polymerase Mutations among HIV/HBV Co-Infected Patients on HBV-Active ART in KwaZulu-Natal, South Africa. Viruses 2022;14. [PMID: 35458518 DOI: 10.3390/v14040788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 492 |
Downs LO, Campbell C, Yonga P, Ansari MA, Matthews PC, Etyang AO. A systematic review of Hepatitis B virus (HBV) prevalence and genotypes in Kenya: Data to inform clinical care and health policy.. [DOI: 10.1101/2022.04.08.22273611] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 493 |
Hammond SP, Ho VT, Marty FM. Hepatitis B virus vaccination after allogeneic hematopoietic cell transplantation prevents post-transplant HBV reactivation. Transplant Cell Ther 2022:S2666-6367(22)01197-6. [PMID: 35413458 DOI: 10.1016/j.jtct.2022.04.004] [Reference Citation Analysis]
|
| 494 |
Tseng C, Liu W, Chen C, Chang T, Tseng K. Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07326-1] [Reference Citation Analysis]
|
| 495 |
Wang J, Zhang Q, Ai J, Liu D, Liu C, Xiang H, Gu Y, Guo Y, Lv J, Huang Y, Liu Y, Xu D, Chen S, Li J, Li Q, Liang J, Bian L, Zhang Z, Guo X, Feng Y, Liu L, Zhang X, Zhang Y, Xie F, Jiang S, Qin W, Wang X, Rao W, Zhang Q, Tian Q, Zhu Y, Cong Q, Xu J, Hou Z, Zhang N, Zhang A, Zu H, Wang Y, Yan Z, Du X, Hou A, Yan Y, Qiu Y, Wu H, Hu S, Deng Y, Ji J, Yang J, Huang J, Zhao Z, Zou S, Ji H, Ge G, Zhong L, He S, Yan X, Yangzhen BB, Qu C, Zhang L, Yang S, Gao X, Lv M, Zhu Q, Xu X, Zeng Q, Qi X, Zhang W. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int. [DOI: 10.1007/s12072-022-10332-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 496 |
Luo Y, Xiang K, Liu J, Song J, Feng J, Chen J, Dai Y, Hu Y, Zhuang H, Zhou Y. Inhibition of In Vitro Infection of Hepatitis B Virus by Human Breastmilk. Nutrients 2022;14:1561. [DOI: 10.3390/nu14081561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 497 |
Tan J, Tang X, He Y, Xu X, Qiu D, Chen J, Zhang Q, Zhang L. In-patient Expenditure Between 2012 and 2020 Concerning Patients With Liver Cirrhosis in Chongqing: A Hospital-Based Multicenter Retrospective Study. Front Public Health 2022;10:780704. [PMID: 35350474 DOI: 10.3389/fpubh.2022.780704] [Reference Citation Analysis]
|
| 498 |
Zhang JH, Zhang X, Zhou ZH, Zhu XJ, Zheng C, Li M, Jin SG, Mao DW, Xue JD, Shi WB, Chi XL, Wang XB, Li XD, Li Y, Wang H, Li Q, Zhou DQ, Wang CB, Shi CH, Li CZ, Wu JH, Kong XN, Sun XH, Gao YQ. Bushen Jianpi Formula Combined with Entecavir for the Treatment of HBeAg-Negative Chronic Hepatitis B: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med 2022;2022:6097221. [PMID: 35368769 DOI: 10.1155/2022/6097221] [Reference Citation Analysis]
|
| 499 |
Fang Z, Zhang Y, Zhu Z, Wang C, Hu Y, Peng X, Zhang D, Zhao J, Shi B, Shen Z, Wu M, Xu C, Chen J, Zhou X, Xie Y, Yu H, Zhang X, Li J, Hu Y, Kozlowski M, Bertoletti A, Yuan Z. Monocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV. J Exp Med 2022;219:e20211838. [PMID: 35254403 DOI: 10.1084/jem.20211838] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 500 |
Chon YE, Park SY, Kim SU, Hong HP, Lee JS, Lee HW, Kim MN, Park JY, Kim DY, Ahn SH, Kim BK. Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study. J Viral Hepat 2022;29:289-96. [PMID: 35152517 DOI: 10.1111/jvh.13656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 501 |
Scholtès C, Hamilton AT, Plissonnier M, Charre C, Scott B, Wang L, Berby F, French J, Testoni B, Blair A, Subic M, Hoppler M, Lankenau A, Grubenmann A, Levrero M, Heil ML, Zoulim F. Performance of the cobas® HBV RNA Automated Investigational Assay for the Detection and Quantification of Circulating HBV RNA in Chronic HBV Patients. Journal of Clinical Virology 2022. [DOI: 10.1016/j.jcv.2022.105150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 502 |
Feng M, Liu K, Zhao G, Lou S, An B, Lin L, Ding Y, Bao S, Wang H. A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105315] [Reference Citation Analysis]
|
| 503 |
Pollicino T. The Impact of Nucleos(t)ide Analogs on Hepatitis B Virus DNA Integration: Hype or Reality? Gastroenterology 2022;162:1030-3. [PMID: 35120915 DOI: 10.1053/j.gastro.2022.01.039] [Reference Citation Analysis]
|
| 504 |
Hsu YC, Suri V, Nguyen MH, Huang YT, Chen CY, Chang IW, Tseng CH, Wu CY, Lin JT, Pan DZ, Gaggar A, Podlaha O. Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation. Gastroenterology 2022;162:1160-1170.e1. [PMID: 34995536 DOI: 10.1053/j.gastro.2021.12.286] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 505 |
Liao G, Liu Z, Xia M, Chen H, Wu H, Li B, Yu T, Cai S, Zhang X, Peng J. Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued. IDR 2022;Volume 15:2347-57. [DOI: 10.2147/idr.s360202] [Reference Citation Analysis]
|
| 506 |
Park J, Le AK, Tseng TC, Yeh ML, Jun DW, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung KS, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH. Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. Clin Gastroenterol Hepatol 2022;20:874-885.e4. [PMID: 34089852 DOI: 10.1016/j.cgh.2021.05.062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 507 |
Lim YS, Seto WK, Kurosaki M, Fung S, Kao JH, Hou J, Gordon SC, Flaherty JF, Yee LJ, Zhao Y, Agarwal K, Lampertico P. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther 2022;55:921-43. [PMID: 35178711 DOI: 10.1111/apt.16788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 508 |
Li G, Wang Y, De Clercq E. Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharm Sin B 2022;12:1567-90. [PMID: 35847492 DOI: 10.1016/j.apsb.2021.11.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 509 |
Yoo S, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Yoo C, Ryoo BY, Choi J. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment. Clin Gastroenterol Hepatol 2022;20:898-907. [PMID: 34182151 DOI: 10.1016/j.cgh.2021.06.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 510 |
Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Tak WY, Park JY, Kweon YO, Kim DY, Ahn SH, Jang SY, Park SY, Kim SU. Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. Clin Gastroenterol Hepatol 2022;20:e794-807. [PMID: 34091048 DOI: 10.1016/j.cgh.2021.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 511 |
Zhang N, Tao D, Lei H, Shao Q, Liu Y, Long H, Zeng X. HBV Infection Status Does Not Influence the Initial Metastatic Pattern and the Prognosis of Breast Cancer Patients with de novo and Relapsed Metastatic Disease. JIR 2022;Volume 15:2509-21. [DOI: 10.2147/jir.s355301] [Reference Citation Analysis]
|
| 512 |
Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B; CREATE Study Group. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). Clin Gastroenterol Hepatol 2022;20:e784-93. [PMID: 33309804 DOI: 10.1016/j.cgh.2020.12.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 513 |
Pan CQ, Dai E, Duan Z, Han G, Zhao W, Wang Y, Zhang H, Zhu B, Jiang H, Zhang S, Zhang X, Zou H, Chen X, Chen Y. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China. Gut 2022;71:798-806. [PMID: 33789963 DOI: 10.1136/gutjnl-2020-322719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 514 |
Yardeni D, Ghany MG. Review article: hepatitis B-current and emerging therapies. Aliment Pharmacol Ther 2022;55:805-19. [PMID: 35224760 DOI: 10.1111/apt.16828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 515 |
Lebray P, Delignat S, Frelicot A, Carrette M, Gautier A, Jamet N, Lecefel C, Houot M, Bourguignon S, Thabut D, Conti F, Liou A. Hepatitis B or Delta liver transplant patients at risk of recurrence: Long-term effectiveness and budget impact of low-dose subcutaneous anti-hepatitis B immunoglobulin plus patient education program. Journal of Liver Transplantation 2022. [DOI: 10.1016/j.liver.2022.100088] [Reference Citation Analysis]
|
| 516 |
Usai C, Gill US, Riddell AC, Asselah T, Kennedy PT. Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus. Aliment Pharmacol Ther 2022;55:978-93. [PMID: 35292991 DOI: 10.1111/apt.16807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 517 |
Luo M, Zhou B, Hou J, Jiang D. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients. Hepatol Res 2022;52:337-51. [PMID: 35089634 DOI: 10.1111/hepr.13749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 518 |
Lim YS, Lampertico P. Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B? Authors' reply. Aliment Pharmacol Ther 2022;55:1044-5. [PMID: 35362138 DOI: 10.1111/apt.16886] [Reference Citation Analysis]
|
| 519 |
Jung CY, Kim HW, Ahn SH, Kim SU, Kim BS. Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol 2022;20:956-958.e2. [PMID: 34029751 DOI: 10.1016/j.cgh.2021.05.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 520 |
Winckelmann A, Fahnøe U, Bajpai P, Dalegaard MI, Lundh A, Ryom L, Bukh J, Weis N. Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment. Journal of Clinical Virology 2022. [DOI: 10.1016/j.jcv.2022.105159] [Reference Citation Analysis]
|
| 521 |
Costa APDM, da Silva MACN, Castro RS, Sampaio ALDO, Alencar Júnior AM, da Silva MC, Ferreira ADSP. PAGE-B and REACH-B Predicts the Risk of Developing Hepatocellular Carcinoma in Chronic Hepatitis B Patients from Northeast, Brazil. Viruses 2022;14:732. [DOI: 10.3390/v14040732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 522 |
Zhou L, He Q, Liu X, Yang X, Ou X, Situ B, Li Y, Pan X, Xu Q. Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse. Med Sci Monit 2022;28:e934785. [PMID: 35351845 DOI: 10.12659/MSM.934785] [Reference Citation Analysis]
|
| 523 |
Xia F, Zhu P, Chen XP, Zhang BX, Zhang MY. Prognostic Analysis of Postoperative Survival for Ruptured Hepatocellular Carcinoma with or without Cirrhosis. J Oncol 2022;2022:7531452. [PMID: 35342424 DOI: 10.1155/2022/7531452] [Reference Citation Analysis]
|
| 524 |
Lee TH, Hunt CM, Maier MM, Lowy E, Beste LA. Hepatitis B Virus-Related Care Quality In Patients With Hepatitis B/Hiv Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study. Clin Infect Dis 2022:ciac227. [PMID: 35349635 DOI: 10.1093/cid/ciac227] [Reference Citation Analysis]
|
| 525 |
Colombatto P, Coco B, Bonino F, Brunetto MR. Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine. Viruses 2022;14:701. [DOI: 10.3390/v14040701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 526 |
Zhao Y, Kong LX, Feng FS, Yang J, Wei G. A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study. BMC Cancer 2022;22:311. [PMID: 35321670 DOI: 10.1186/s12885-022-09433-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 527 |
Moini M, Fung S. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. Viruses 2022;14. [PMID: 35458387 DOI: 10.3390/v14040657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 528 |
Hu Z, Zeng H, Hou J, Wang J, Xu L, Zhang Y, Chen M, Zhou Z. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. Viruses 2022;14. [PMID: 35458386 DOI: 10.3390/v14040656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 529 |
Kmet NG, Poljak M, Zakotnik B, Matičič M. Hepatitis B elimination in children of Slovenian origin born in Slovenia after the introduction of preventive strategies: The results of a national study. Slovenian Journal of Public Health 2022;61:109-14. [DOI: 10.2478/sjph-2022-0015] [Reference Citation Analysis]
|
| 530 |
Durmashkina E, Zeuzem S, Sarrazin C. [Treatment of parenterally transmittable viral hepatitis]. Internist (Berl) 2022. [PMID: 35303130 DOI: 10.1007/s00108-022-01287-y] [Reference Citation Analysis]
|
| 531 |
Johannessen A, Stockdale AJ, Henrion MY, Okeke E, Seydi M, Wandeler G, Sonderup M, Spearman CW, Vinikoor M, Sinkala E, Desalegn H, Fall F, Riches N, Davwar P, Duguru M, Maponga T, Taljaard J, Matthews PC, Andersson M, Sombie R, Shimakawa Y, Lemoine M. Diagnostic performance of non-invasive fibrosis markers for chronic hepatitis B in sub-Saharan Africa: a Bayesian individual patient data meta-analysis.. [DOI: 10.1101/2022.03.18.22272415] [Reference Citation Analysis]
|
| 532 |
Htet NH, Naing C, Vongpunsawad S, Win TT, Poovorawan Y; Cochrane Hepato-Biliary Group. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd014610] [Reference Citation Analysis]
|
| 533 |
Danis N, Salih Akarca U, Turan I, Karasu Z, Ersoz G, Yilmaz F, Nart D, Zeytinoglu A, Selda Erensoy M, Gunsar F. Predictive value of FibroScan in detecting liver fibrosis in HBeAg negative patients with chronic hepatitis B whose HBV DNA 2000-20000 IU/ml with ALT 1-2 times the upper limit of normal and those with HBV DNA >20000 IU/ml and normal ALT. North Clin Istanb 2021;8:568-74. [PMID: 35284786 DOI: 10.14744/nci.2021.35545] [Reference Citation Analysis]
|
| 534 |
Choi YH, Lee HW, Purdy MA. Natural antibody IgG levels are associated with HBeAg-positivity and seroconversion in chronic hepatitis B patients treated with entecavir. Sci Rep 2022;12:4382. [PMID: 35288624 DOI: 10.1038/s41598-022-08457-w] [Reference Citation Analysis]
|
| 535 |
Wang J, Hou H, Mao L, Wang F, Yu J, Luo Y, Lin Q, Sun Z. TIGIT Signaling Pathway Regulates Natural Killer Cell Function in Chronic Hepatitis B Virus Infection. Front Med (Lausanne) 2021;8:816474. [PMID: 35265633 DOI: 10.3389/fmed.2021.816474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 536 |
Tang Y, Yin X, Ma Y. Non-Alcoholic Fatty Liver Disease and Its Potential Therapeutic Strategies. Hepatotoxicity [Working Title] 2022. [DOI: 10.5772/intechopen.103059] [Reference Citation Analysis]
|
| 537 |
Liaw YF, Chien RN. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation". Kaohsiung J Med Sci 2022. [PMID: 35262284 DOI: 10.1002/kjm2.12518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 538 |
Liu X, Chen C, Jiang D, Yan D, Zhou Y, Ding C, Lan L, Huang C, Zhang X, Li L, Yang S. Psychological stress; knowledge, attitude and practice and acceptance of antiviral therapy in pregnant women with hepatitis B in Zhejiang, China: a case comparison study. BMJ Open 2022;12:e055642. [PMID: 35264360 DOI: 10.1136/bmjopen-2021-055642] [Reference Citation Analysis]
|
| 539 |
Chemin I, Pujol FH. Special Issue: “Updates on HBV Infection”. Microorganisms 2022;10:580. [DOI: 10.3390/microorganisms10030580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 540 |
Mayran C, Foulongne V, Van de Perre P, Fournier-Wirth C, Molès JP, Cantaloube JF. Rapid Diagnostic Test for Hepatitis B Virus Viral Load Based on Recombinase Polymerase Amplification Combined with a Lateral Flow Read-Out. Diagnostics (Basel) 2022;12. [PMID: 35328174 DOI: 10.3390/diagnostics12030621] [Reference Citation Analysis]
|
| 541 |
Yip TC, Gill M, Wong GL, Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol Int 2022. [PMID: 35235148 DOI: 10.1007/s12072-022-10306-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 542 |
Liu YC, Jeng WJ, Peng CW, Chien RN, Liaw YF. Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies. Liver Int 2022;42:551-60. [PMID: 34936719 DOI: 10.1111/liv.15140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 543 |
Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong G, Brakenhoff SM, Chien RN, Feld J, Sonneveld MJ, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng WJ, Janssen HLA; RETRACT-B Study Group. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology 2022;162:757-771.e4. [PMID: 34762906 DOI: 10.1053/j.gastro.2021.11.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 544 |
Zhou Y, Li J, Gordon SC, Trudeau S, Rupp LB, Boscarino JA, Daida YG, Schmidt MA, Lu M. Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States. J Viral Hepat 2022;29:189-95. [PMID: 34905259 DOI: 10.1111/jvh.13639] [Reference Citation Analysis]
|
| 545 |
Mustafayev K, Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.02.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 546 |
Dong B, Chen Y, Lyu G, Qin R. Liver stiffness measurement as a quantitative method for liver fibrosis in children with non-alcoholic fatty liver disease: A meta-analysis. J Paediatr Child Health 2022;58:481-90. [PMID: 34554611 DOI: 10.1111/jpc.15751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 547 |
Pol S. Withdrawal of Nucleos(t)ide Analogues in the Treatment of Chronic Hepatitis B: A Cornelian Choice. Gastroenterology 2022;162:698-9. [PMID: 34914942 DOI: 10.1053/j.gastro.2021.12.240] [Reference Citation Analysis]
|
| 548 |
Qiu X, Gao F, Wang K, Zhang Z, Shao C, Xu X. Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment? iLIVER 2022;1:55-64. [DOI: 10.1016/j.iliver.2022.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 549 |
Li C, Li H, Gong M, Wei J. Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate. Clin Case Rep 2022;10:e05641. [PMID: 35356169 DOI: 10.1002/ccr3.5641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 550 |
Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou Α, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, Dalekos G, Kao JH, Hadziyannis S, Papatheodoridis GV. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver Int 2022;42:541-50. [PMID: 34890120 DOI: 10.1111/liv.15128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 551 |
Li M, Sun F, Bi X, Lin Y, Yang L, Lu Y, Zhang L, Wan G, Yi W, Zhao L, Xie Y. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virologica Sinica 2022. [DOI: 10.1016/j.virs.2022.03.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 552 |
Dionne-Odom J, Cozzi GD, Franco RA, Njei B, Tita ATN. Treatment and prevention of viral hepatitis in pregnancy. Am J Obstet Gynecol 2022;226:335-46. [PMID: 34516961 DOI: 10.1016/j.ajog.2021.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 553 |
Lin C, Lin Y, Liang K, Chen L, Chien C, Hu C, Huang T, Shyu Y, Yeh C, Chien R. Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan. Clinical Therapeutics 2022;44:403-417.e6. [DOI: 10.1016/j.clinthera.2022.01.010] [Reference Citation Analysis]
|
| 554 |
Shi Z, Zheng H, Han M, Hu J, Hu Y, Li X, Zhu W, He X, Deng H, Long Q, Huang A. Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.03.003] [Reference Citation Analysis]
|
| 555 |
Roger S, Fontana J, Ducancelle A, Guillou-Guillemette HL, Canivet CM, Lefeuvre C. Acute hepatitis B in pregnancy with surprisingly rapid clearance of serum HBs antigen associated with a favourable outcome. Int J Infect Dis 2022:S1201-9712(22)00134-5. [PMID: 35235825 DOI: 10.1016/j.ijid.2022.02.053] [Reference Citation Analysis]
|
| 556 |
Masetti C, Pugliese N, Aghemo A, Viganò M. Safety of current antiviral drugs for chronic hepatitis B. Expert Opin Drug Saf 2022. [PMID: 35209776 DOI: 10.1080/14740338.2022.2045271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 557 |
Saracco GM, Marzano A, Rizzetto M. Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel? Biomedicines 2022;10:534. [DOI: 10.3390/biomedicines10030534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 558 |
Von den Hoff DW, Berden FAC, Atsma F, Schellekens AFA, Drenth JPH. Against All Odds? Addiction History Associated with Better Viral Hepatitis Care: A Dutch Nationwide Claims Data Study. J Clin Med 2022;11:1146. [PMID: 35207419 DOI: 10.3390/jcm11041146] [Reference Citation Analysis]
|
| 559 |
Chien RN, Liaw YF. Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses 2022;14:434. [PMID: 35216027 DOI: 10.3390/v14020434] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 560 |
Yan Y, Qiu Y, Davgadorj C, Zheng C. Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection. Front Cell Infect Microbiol 2022;12:847539. [DOI: 10.3389/fcimb.2022.847539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 561 |
Suzuki K, Suda G, Yamamoto Y, Abiko S, Kinoshita K, Miyamoto S, Sugiura R, Kimura M, Maehara O, Yamada R, Kitagataya T, Shigesawa T, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS One 2022;17:e0261760. [PMID: 35051189 DOI: 10.1371/journal.pone.0261760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 562 |
Clerico M, Dogliotti I, Ghione P, Zilioli VR, Merli F, Botto B, Al Essa W, Battaglini M, Grimaldi D, Cervi L, Ragaini S, Ferrero S, Peri V, De Luca G, Marzano A, Cavallo F. HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience. JPM 2022;12:285. [DOI: 10.3390/jpm12020285] [Reference Citation Analysis]
|
| 563 |
Cerva C, Salpini R, Alkhatib M, Malagnino V, Piermatteo L, Battisti A, Bertoli A, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Ferrari L, Laura C, Teti E, Cantonetti M, Arcese W, Ceccherini-silberstein F, Perno C, Andreoni M, Svicher V, Sarmati L. Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines 2022;10:443. [DOI: 10.3390/biomedicines10020443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 564 |
Shang D, Wang P, Tang W, Mo R, Lai R, Lu J, Li Z, Wang X, Cai W, Wang H, Zhao G, Xie Q, Xiang X. Genetic Variations of ALDH (rs671) Are Associated With the Persistence of HBV Infection Among the Chinese Han Population. Front Med 2022;9:811639. [DOI: 10.3389/fmed.2022.811639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 565 |
. Stellungnahme der DGVS und der DGIM zum Zeitpunkt des Screenings auf Hepatitis B gemäß Mutterschafts-Richtlinien (Mu-RL). Z Gastroenterol 2022;60:241-4. [DOI: 10.1055/a-1742-4795] [Reference Citation Analysis]
|
| 566 |
Campbell C, Wang T, Smith DA, Freeman O, Noble T, Várnai KA, Harris S, Salih H, Roadknight G, Little S, Glampson B, Mercuri L, Papadimitriou D, Jones CR, Taylor V, Chaudhry A, Phan H, Borca F, Olza J, Warricker F, Romão L, Ramlakhan D, English L, Klenerman P, Andersson MI, Collier J, Nastouli E, Khakoo SI, Gelson W, Cooke GS, Woods K, Davies J, Barnes E, Matthews PC. Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. Wellcome Open Res 2022;7:51. [DOI: 10.12688/wellcomeopenres.17522.1] [Reference Citation Analysis]
|
| 567 |
Jachs M, Hartl L, Bauer D, Simbrunner B, Stättermayer AF, Strassl R, Trauner M, Mandorfer M, Reiberger T. Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression. JPM 2022;12:239. [DOI: 10.3390/jpm12020239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 568 |
Peliganga LB, Horta MAP, Lewis-ximenez LL. Enduring Challenges despite Progress in Preventing Mother-to-Child Transmission of Hepatitis B Virus in Angola. Pathogens 2022;11:225. [DOI: 10.3390/pathogens11020225] [Reference Citation Analysis]
|
| 569 |
Wu Y, Ding Y, Shen C. A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus. Vaccines 2022;10:257. [DOI: 10.3390/vaccines10020257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 570 |
Leoni S, Casabianca A, Biagioni B, Serio I. Viral hepatitis: Innovations and expectations. World J Gastroenterol 2022; 28(5): 517-531 [DOI: 10.3748/wjg.v28.i5.517] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 571 |
El Kassas M, Eltabbakh M, Elbadry M, Tawheed A, Elbaz T. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Curr Med Res Opin 2022;:1-23. [PMID: 35118916 DOI: 10.1080/03007995.2022.2038489] [Reference Citation Analysis]
|
| 572 |
Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, Scholtes C, Holzmann H, van Bömmel F, Borghi M, Perbellini R, Rimondi A, Farina E, Trombetta E, Manunta M, Porretti L, Prati D, Ceriotti F, Zoulim F, Bertoletti A, Lampertico P. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol 2022;76:464-9. [PMID: 34699951 DOI: 10.1016/j.jhep.2021.10.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 573 |
Yim HJ, Kim W, Ahn SH, Jung YK, Um SH, Sohn JH, Jang JY, Kim DJ, Park ES, Jin SY, Kim KH. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. J Gastroenterol Hepatol 2022;37:378-86. [PMID: 34653281 DOI: 10.1111/jgh.15710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 574 |
Chang HL, Wen WH, Lee CN, Chiu YE, Liu CJ, Chang MH, Lin LH, Chen HL. Kinetics of hepatitis B surface antigen in pregnant women with and without tenofovir disoproxil fumarate. J Viral Hepat 2022;29:107-14. [PMID: 34724288 DOI: 10.1111/jvh.13628] [Reference Citation Analysis]
|
| 575 |
Huang Y, Li W, Hu HT, Ruan SM, Xian MF, Xie XY, Lu MD, Kuang M, Chen LD, Wang W. Contrast-enhanced US diagnostic algorithm of hepatocellular carcinoma in patients with occult hepatitis B. Abdom Radiol (NY) 2022;47:608-17. [PMID: 34800160 DOI: 10.1007/s00261-021-03343-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 576 |
Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res 2022;52:153-64. [PMID: 34687121 DOI: 10.1111/hepr.13726] [Reference Citation Analysis]
|
| 577 |
Lu J, Zhang C, He P, Ou M, Xia J, Huang M. Risk factors for very low-level viremia in patients with chronic hepatitis B virus infection: A single-center retrospective study. Liver Research 2022. [DOI: 10.1016/j.livres.2022.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 578 |
Jo AJ, Choi WM, Kim HJ, Choi SH, Han S, Ko MJ, Lim YS. A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study. J Viral Hepat 2022;29:115-23. [PMID: 34762757 DOI: 10.1111/jvh.13631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 579 |
Chang Y, Jeong SW, Jang JY. Hepatitis B Virus Reactivation Associated With Therapeutic Interventions. Front Med (Lausanne) 2021;8:770124. [PMID: 35096867 DOI: 10.3389/fmed.2021.770124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 580 |
Lim SG, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lim K, Lee YM, Lee GH, Tan PS, Wai KL, Phyo WW, Khine HHTW, Lee C, Tay A, Chan E. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clin Gastroenterol Hepatol 2022;20:e228-50. [PMID: 33895361 DOI: 10.1016/j.cgh.2021.04.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 581 |
Giadans CG, Ríos DA, Ameigeiras B, Haddad L, De Matteo EN, Valva P, Preciado MV. Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same. J Viral Hepat 2022;29:124-34. [PMID: 34820942 DOI: 10.1111/jvh.13635] [Reference Citation Analysis]
|
| 582 |
Dai CY, Yeh ML, Yu ML. An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously. J Hepatol 2022;76:478-80. [PMID: 34492252 DOI: 10.1016/j.jhep.2021.08.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 583 |
Lee HW, Park SY, Lee YR, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. Am J Gastroenterol 2022;117:288-94. [PMID: 34506308 DOI: 10.14309/ajg.0000000000001497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 584 |
Cacoub P, Asselah T. Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease. Am J Gastroenterol 2022;117:253-63. [PMID: 34913875 DOI: 10.14309/ajg.0000000000001575] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 585 |
Xiao Y, Ni L, Cui Z, Sun L, Zhou X, Chen X, Li L, Tang C, Yin F, Du J, Liu L, Lu G, Cui X, Quan Y. Discrepant results of hepatitis B virus genotype determination by PCR and DNA sequencing. Journal of Virological Methods 2022. [DOI: 10.1016/j.jviromet.2022.114503] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 586 |
Su S, Wong WC, Zou Z, Cheng DD, Ong JJ, Chan P, Ji F, Yuen M, Zhuang G, Seto W, Zhang L. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. The Lancet Global Health 2022;10:e278-87. [DOI: 10.1016/s2214-109x(21)00517-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 587 |
Liu N, Chang CW, Steer CJ, Wang XW, Song G. MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells. Gastroenterology 2022;162:575-89. [PMID: 34678217 DOI: 10.1053/j.gastro.2021.10.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 588 |
Wang X, Wei Z, Cheng B, Li J, He Y, Lan T, Kemper T, Lin Y, Jiang B, Jiang Y, Meng Z, Lu M. Endoplasmic reticulum stress promotes HBV production by enhancing use of the autophagosome/multivesicular body axis. Hepatology 2022;75:438-54. [PMID: 34580902 DOI: 10.1002/hep.32178] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 589 |
Lee JS, Lee HW, Lim TS, Min IK, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. Cancers 2022;14:711. [DOI: 10.3390/cancers14030711] [Reference Citation Analysis]
|
| 590 |
Nakai M, Yamamoto Y, Baba M, Suda G, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Sho T, Morikawa K, Ogawa K, Furuya K, Sakamoto N. Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. Sci Rep 2022;12:1449. [PMID: 35087141 DOI: 10.1038/s41598-022-05492-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 591 |
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study. Hepatol Int. [DOI: 10.1007/s12072-021-10295-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 592 |
Venner JM, Bernstein CN. Immunomodulators: still having a role? Gastroenterology Report 2022;10. [DOI: 10.1093/gastro/goac061] [Reference Citation Analysis]
|
| 593 |
Zhang Q, Zhong C, Cai S, Yu T, Xu X, Yin J. Risk Factors Associated With Quality of Life in Patients With Hepatitis B Virus Related Cirrhosis. Front Psychol 2021;12:770415. [PMID: 35069349 DOI: 10.3389/fpsyg.2021.770415] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 594 |
Kim TH, Kim M, Yim HJ, Suh SJ, Jung YK, Seo YS, Um SH, Lee JI, Lee SH, Kim SG, Kim IH, Kim HS, Cho EY, Kim TY, Hwang SG. Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.121627] [Reference Citation Analysis]
|
| 595 |
Motolese A, Ceccarelli M, Macca L, Li Pomi F, Ingrasciotta Y, Nunnari G, Guarneri C. Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomedicines 2022;10:228. [DOI: 10.3390/biomedicines10020228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 596 |
Gane EJ, Schwabe C, Berliba E, Tangkijvanich P, Jucov A, Ghicavii N, Verbinnen T, Lenz O, Talloen W, Kakuda TN, Westland C, Patel M, Yogaratnam JZ, Dragone L, Van Remoortere P. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. J Antimicrob Chemother 2022:dkab491. [PMID: 35040959 DOI: 10.1093/jac/dkab491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 597 |
Vasconcelos J, Domingos J, Bastos L, Baptista T, Mansinho K. Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection. Case Rep Infect Dis 2022;2022:3890309. [PMID: 35036013 DOI: 10.1155/2022/3890309] [Reference Citation Analysis]
|
| 598 |
Chen R, Zou J, Long L, Huang H, Zhang M, Fan X, Huang Y. Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B. Front Med 2022;8:796901. [DOI: 10.3389/fmed.2021.796901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 599 |
Huang Y, Gan Q, Lai R, Wang W, Guo S, Sheng Z, Chen L, Guo Q, Cai W, Wang H, Zhao G, Cao Z, Xie Q. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients. Front Cell Infect Microbiol 2022;11:733348. [DOI: 10.3389/fcimb.2021.733348] [Reference Citation Analysis]
|
| 600 |
Kamimura H, Nonaka H, Mori M, Kobayashi T, Setsu T, Kamimura K, Tsuchiya A, Terai S. Use of a Deep Learning Approach for the Sensitive Prediction of Hepatitis B Surface Antigen Levels in Inactive Carrier Patients. J Clin Med 2022;11:387. [PMID: 35054079 DOI: 10.3390/jcm11020387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 601 |
Poortahmasebi V, Alavian SM, Ghaziasadi A, Azadi A, Nasiri Toosi M, Jazayeri SM. Detection and Quantification of Hepatitis B Virus Genomes in Peripheral Blood Mononuclear Cells of Chronic Hepatitis B Virus Infection, Cirrhosis, and Hepatocellular Carcinoma Patients. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.120982] [Reference Citation Analysis]
|
| 602 |
Akdemir Kalkan I, Karasahin O, Sarigul F, Altunisik Toplu S, Aladag M, Akgul F, Mete AO, Golbol A, Nazik S, Kömür S, Merve Oren M, Yildiz Y, Demir Y, Ayhan M, Tasova Y, Bayındır Y, Dal T, Celen MK. Comparison of Tenofovir Alafenamide and Entecavir Therapy in Patients with Chronic Hepatitis B Initially Treated with Tenofovir Disoproxil: A Retrospective Observational Survey. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.118721] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 603 |
Tey TT, Yiu R, Leow WQ. Hepatitis B-Associated Symptomatic Iron Overload, with Complete Resolution after Nucleoside Analogue Treatment. Case Rep Gastrointest Med 2021;2021:8407257. [PMID: 34987872 DOI: 10.1155/2021/8407257] [Reference Citation Analysis]
|
| 604 |
Wu YL, Ke J, Zhang BY, Zhao D. Hepatitis B virus reactivation in rheumatoid arthritis. World J Clin Cases 2022; 10(1): 12-22 [DOI: 10.12998/wjcc.v10.i1.12] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 605 |
Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 606 |
Kozuka R, Enomoto M, Dong MP, Hai H, Thuy LTT, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Tamori A, Kawada N. Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment. Sci Rep 2022;12:105. [PMID: 34996935 DOI: 10.1038/s41598-021-03706-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 607 |
Akbar SMF, Al Mahtab M, Yoshida O, Hiasa Y. Cellular and Molecular Mechanisms Underlying Scope and Limitation of Ongoing and Innovative Therapies for Treating Chronic Hepatitis B. Livers 2022;2:1-14. [DOI: 10.3390/livers2010001] [Reference Citation Analysis]
|
| 608 |
Lee JJ, Chang JM, Yang LJ, Hsu CC, Lin MH, Lin MY. Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: A nationwide survey in 2010-2018. J Formos Med Assoc 2022:S0929-6646(21)00584-2. [PMID: 34996670 DOI: 10.1016/j.jfma.2021.12.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 609 |
Wu Y, Chen Y, Zhu P, Ye B, Lu Y, Shi J, Tan Y, Zhao Y, Yu J, Lai X, Lan J, Si T, Ni L, Huang H, Luo Y. Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantatio:a multi-institutional experience from an HBV endemic area. Ann Hematol. [DOI: 10.1007/s00277-021-04730-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 610 |
Macpherson I, Brennan PN, Dillon JF. Hepatitis B, Hepatitis C and Liver Disease: A Review for the Dental Practitioner. Dent Update 2022;49:26-30. [DOI: 10.12968/denu.2022.49.1.26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 611 |
Russo FP, Zanetto A, Pinto E, Battistella S, Penzo B, Burra P, Farinati F. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Int J Mol Sci 2022;23:500. [PMID: 35008926 DOI: 10.3390/ijms23010500] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 612 |
Calvo Sánchez H, Peña-asensio J, Larrubia Marfil JR. Current challenges in the functional cure of HBe-antigen negative chronic hepatitis B. Rev Esp Enferm Dig 2022;114. [DOI: 10.17235/reed.2022.9052/2022] [Reference Citation Analysis]
|
| 613 |
Man X, Wei R. Advancements in the prevention of hepatitis B recurrence by nucleos(t)ide analogue monotherapies after liver transplantation. Eur J Inflamm 2022;20:1721727X2211392. [DOI: 10.1177/1721727x221139254] [Reference Citation Analysis]
|
| 614 |
Blinov D, Kuhareva E, Tarasova O, Aleksandrova M, Politidis R. Gilbert’s syndrome may predict the favorable outcome of antiviral therapy in patients with HDV infection. Dok gastroenterol 2022;11:5. [DOI: 10.17116/dokgastro2022110115] [Reference Citation Analysis]
|
| 615 |
Kaewdech A, Assawasuwannakit S, Sripongpun P, Chamroonkul N, Tangkijvanich P, Piratvisuth T. Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up. Front Med (Lausanne) 2022;9:859430. [PMID: 35402452 DOI: 10.3389/fmed.2022.859430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 616 |
Kumada T, Toyoda H, Yasuda S, Ito T, Tanaka J. Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population. Hepatol Res 2022;52:81-92. [PMID: 34665918 DOI: 10.1111/hepr.13723] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 617 |
Choi WM, Yip TC, Lim YS, Wong GL, Kim WR. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J Hepatol 2022;76:186-94. [PMID: 34592365 DOI: 10.1016/j.jhep.2021.09.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 618 |
Hansi N, Mak LL, Gill U, Kennedy P. Chronic Hepatitis B. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-10012-3_8] [Reference Citation Analysis]
|
| 619 |
Cohen C, Evans AA, Block TM. Hepatitis Viruses: Hepatitis B and Hepatitis D. Viral Infections of Humans 2022. [DOI: 10.1007/978-1-4939-9544-8_32-1] [Reference Citation Analysis]
|
| 620 |
Walker A, Schwarz T, Brinkmann-Paulukat J, Wisskirchen K, Menne C, Alizei ES, Kefalakes H, Theissen M, Hoffmann D, Schulze Zur Wiesch J, Maini MK, Cornberg M, Kraft AR, Keitel V, Bock HH, Horn PA, Thimme R, Wedemeyer H, Heinemann FM, Luedde T, Neumann-Haefelin C, Protzer U, Timm J. Immune escape pathways from the HBV core(18-27) CD8 T cell response are driven by individual HLA class I alleles. Front Immunol 2022;13:1045498. [PMID: 36439181 DOI: 10.3389/fimmu.2022.1045498] [Reference Citation Analysis]
|
| 621 |
Shenoy P, Nalianda KK. Biologics in Rheumatic Diseases in the Presence of Infection. Handbook of Biologics for Rheumatological Disorders 2022. [DOI: 10.1007/978-981-16-7200-2_19] [Reference Citation Analysis]
|
| 622 |
Ekin N, Ucmak F, Ebik B, Tugba Tuncel E, Kacmaz H, Arpa M, Engin Atay A. GPR, King's Score and S-Index are superior to other non-invasive fibrosis markers in predicting the liver fibrosis in chronic Hepatitis B patients. Acta Gastroenterol Belg 2022;85:62-8. [PMID: 35304995 DOI: 10.51821/85.1.9156] [Reference Citation Analysis]
|
| 623 |
Sharrock KC, Noori T, Axelsson M, Buti M, Diaz A, Fursa O, Hendrickx G, James C, Klavs I, Korenjak M, Maticic M, Mozalevskis A, Peters L, Rigoni R, Rosinska M, Ruutel K, Schatz E, Seyler T, Veldhuijzen I, Duffell E. Monitoring progress towards elimination of hepatitis B and C in the EU/EEA. PLOS Glob Public Health 2022;2:e0000841. [PMID: 36962761 DOI: 10.1371/journal.pgph.0000841] [Reference Citation Analysis]
|
| 624 |
Gambato M, Ferrarese A. Indications to Liver Transplantation for Liver Cirrhosis. Textbook of Liver Transplantation 2022. [DOI: 10.1007/978-3-030-82930-8_2] [Reference Citation Analysis]
|
| 625 |
Burra P, Sciarrone SS, Bo P. Sexual Function, Fertility and Pregnancy in Liver Disease and After Liver Transplantation. Textbook of Liver Transplantation 2022. [DOI: 10.1007/978-3-030-82930-8_32] [Reference Citation Analysis]
|
| 626 |
Mikulska M, Averbuch D. CD19, CD20 and CD52. Infectious Complications in Biologic and Targeted Therapies 2022. [DOI: 10.1007/978-3-031-11363-5_7] [Reference Citation Analysis]
|
| 627 |
Gish RG, Asselah T, Squires K, Mayers D. Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens. Antivir Chem Chemother 2022;30:204020662211387. [DOI: 10.1177/20402066221138705] [Reference Citation Analysis]
|
| 628 |
Loarec A, Nguyen A, Molfino L, Chissano M, Madeira N, Rusch B, Staderini N, Couto A, Ciglenecki I, Antabak NT. Prevention of mother-to-child transmission of hepatitis B virus in antenatal care and maternity services, Mozambique. Bull World Health Organ 2022;100:60-9. [PMID: 35017758 DOI: 10.2471/BLT.20.281311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 629 |
Käser R, Böttler T. Nicht-alkoholische Fettlebererkrankung als Komorbidität chronischer Lebererkrankungen. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_26] [Reference Citation Analysis]
|
| 630 |
Romero Guadix B, Martin Cabrejas B, Castel Segui AB, Saiz Eslava MJ, Peralta Flores S, Monzó Miralles A, Llaneza Coto P, Gaspar Herrero B, Iñarra Velasco MJ, Sanz Pérez C, Casas Marcos AB, Heras Sedano I. Recomendaciones para técnicas de reproducción asistida en pacientes con enfermedades infecciosas transmisibles. Manejo de las parejas serodiscordantes. Medicina Reproductiva y Embriología Clínica 2022;9:100112. [DOI: 10.1016/j.medre.2021.100112] [Reference Citation Analysis]
|
| 631 |
Batskikh S, Morozov S, Vinnitskaya E, Sbikina E, Borunova Z, Dorofeev A, Sandler Y, Saliev K, Kostyushev D, Brezgin S, Kostyusheva A, Chulanov V. May Previous Hepatitis B Virus Infection Be Involved in Etiology and Pathogenesis of Autoimmune Liver Diseases? Adv Ther 2022;39:430-40. [PMID: 34762287 DOI: 10.1007/s12325-021-01983-5] [Reference Citation Analysis]
|
| 632 |
O’riordan A, Ware T. Hepatology and the Kidney. Primer on Nephrology 2022. [DOI: 10.1007/978-3-030-76419-7_36] [Reference Citation Analysis]
|
| 633 |
Mao QG, Liang HQ, Yin YL, Tang JM, Yang JE, Wu CC, Chen Y, Zhang MY, Liu YY, Zheng XT, Zhuang LY, Chen SD. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B. Clin Res Hepatol Gastroenterol 2022;46:101758. [PMID: 34303003 DOI: 10.1016/j.clinre.2021.101758] [Reference Citation Analysis]
|
| 634 |
Chon YE, Kim SU, Seo YS, Lee HW, Lee HA, Kim MN, Roh YH, Park JY, Kim DY, Ahn SH, Tak WY, Park SY, Kim BK. Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. J Gastroenterol Hepatol 2022;37:200-7. [PMID: 34478195 DOI: 10.1111/jgh.15678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 635 |
Kim S, Yoo S, Lee JI, Kim S, Chang HY, Kim D, Jeong SH, Lee KS, Lee HW. Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance. Dig Dis Sci 2022;67:321-8. [PMID: 33517556 DOI: 10.1007/s10620-021-06845-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 636 |
Abdelbary MS, Samir R, El-Nahaas SM, Shahin RMH, El-Sayed M, Gaber Y, Tantawi O, Zayed NA, Yosry A. Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt. J Clin Exp Hepatol 2022;12:1276-84. [PMID: 36157140 DOI: 10.1016/j.jceh.2022.04.020] [Reference Citation Analysis]
|
| 637 |
Bamdad T, Yari A. Hepatitis Viruses. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00078-1] [Reference Citation Analysis]
|
| 638 |
Bird TG, Kiourtis C. Liver diseases fibrosis and cirrhosis. Cellular Senescence in Disease 2022. [DOI: 10.1016/b978-0-12-822514-1.00004-3] [Reference Citation Analysis]
|
| 639 |
Premkumar M, Chawla YK. Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia. J Clin Exp Hepatol 2022;12:144-54. [PMID: 35068795 DOI: 10.1016/j.jceh.2021.08.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 640 |
Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 104] [Cited by in F6Publishing: 66] [Article Influence: 104.0] [Reference Citation Analysis]
|
| 641 |
Erken R, Loukachov VV, de Niet A, Jansen L, Stelma F, Helder JT, Peters MW, Zaaijer HL, Kootstra NA, Willemse SB, Reesink HW. A Prospective Five-Year Follow-up After peg-Interferon Plus Nucleotide Analogue Treatment or no Treatment in HBeAg Negative Chronic Hepatitis B Patients. J Clin Exp Hepatol 2022;12:735-44. [PMID: 35677522 DOI: 10.1016/j.jceh.2021.12.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 642 |
Phoolchund AGS, Rahim MN, Heneghan MA. Fertility and Pregnancy. In Clinical Practice 2022. [DOI: 10.1007/978-3-030-98808-1_20] [Reference Citation Analysis]
|
| 643 |
Bergasa NV. Chronic Hepatitis B. Clinical Cases in Hepatology 2022. [DOI: 10.1007/978-1-4471-4715-2_7] [Reference Citation Analysis]
|
| 644 |
Bezuglova L, Osipova L, Sergeeva E, Deliy I, Tabikhanova L, Netesov S, Netesova I. The Markers of viral hepatitis B in blood plasma samples of the indigenous population of the Far North of Russia. HBV genotypes and HBsAg subtypes. Mol genet mikrobiol virusol 2022;40:41. [DOI: 10.17116/molgen20224003141] [Reference Citation Analysis]
|
| 645 |
Russo FP, Zanetto A. Recurrence of the Primary Liver Disease. Textbook of Liver Transplantation 2022. [DOI: 10.1007/978-3-030-82930-8_22] [Reference Citation Analysis]
|
| 646 |
Xu H, Locarnini S, Wong D, Hammond R, Colledge D, Soppe S, Huynh T, Shaw T, Thompson AJ, Revill PA, Hogarth PM, Wines BD, Walsh R, Warner N. Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. J Hepatol 2022;76:34-45. [PMID: 34371070 DOI: 10.1016/j.jhep.2021.07.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 647 |
Matthews PC, Maponga T, Ghosh I, Lemoine M, Ocama P, Abubakar I, Story A, Flanagan S. Hepatitis B Virus: Infection, liver disease, carcinogen or syndemic threat? Remodelling the clinical and public health response. PLOS Glob Public Health 2022;2:e0001359. [PMID: 36962907 DOI: 10.1371/journal.pgph.0001359] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 648 |
O’gurek DT. Diseases of the Liver. Family Medicine 2022. [DOI: 10.1007/978-3-030-54441-6_97] [Reference Citation Analysis]
|
| 649 |
Visentin A, Rocchi M, Salvadori AG, Del Bravo P, Righi E. Infections and Paraproteinemia. Paraproteinemia and Related Disorders 2022. [DOI: 10.1007/978-3-031-10131-1_18] [Reference Citation Analysis]
|
| 650 |
Khaleel DA, Hason HJ. Hepatitis B surface antibody serum levels among vaccinated children aged 1 to 13 years in Basrah governorate Southern of Iraq. PROCEEDING OF THE 1ST INTERNATIONAL CONFERENCE ON ADVANCED RESEARCH IN PURE AND APPLIED SCIENCE (ICARPAS2021): Third Annual Conference of Al-Muthanna University/College of Science 2022. [DOI: 10.1063/5.0097553] [Reference Citation Analysis]
|
| 651 |
Zeng Q. Anti-HBV Drugs in Liver Cirrhosis. Pharmacotherapy for Liver Cirrhosis and Its Complications 2022. [DOI: 10.1007/978-981-19-2615-0_1] [Reference Citation Analysis]
|
| 652 |
Lohse AW, Huber S. Magen/Darm- und Lebererkrankungen. Arzneiverordnungs-Report 2022 2022. [DOI: 10.1007/978-3-662-66303-5_12] [Reference Citation Analysis]
|
| 653 |
Ye Q, Kam LY, Yeo YH, Dang N, Huang DQ, Cheung R, Nguyen MH. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J Hepatol 2022;76:63-74. [PMID: 34474097 DOI: 10.1016/j.jhep.2021.08.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 654 |
. Viral Hepatitis. Non-Neoplastic Diseases of the Liver 2022. [DOI: 10.55418/9781933477183-2] [Reference Citation Analysis]
|
| 655 |
Shirmast P, Shahri MA, Pashangzadeh S, Mirshahabi H, Samadi E, Motamed N. Detection of occult hepatitis B virus in patients undergoing chemotherapy in Iran. Future Virology 2022;17:29-36. [DOI: 10.2217/fvl-2020-0386] [Reference Citation Analysis]
|
| 656 |
Seong G, Sinn DH, Kang W, Gwak GY, Choi MS, Lee JH, Koh KC, Woon Paik S, Paik YH. Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. Eur J Gastroenterol Hepatol 2022;34:69-75. [PMID: 32925504 DOI: 10.1097/MEG.0000000000001915] [Reference Citation Analysis]
|
| 657 |
Salpini R, D'Anna S, Benedetti L, Piermatteo L, Gill U, Svicher V, Kennedy PTF. Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure. Front Microbiol 2022;13:972687. [PMID: 36118192 DOI: 10.3389/fmicb.2022.972687] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 658 |
Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Khan S, Penton E, Gerardo GN, Hiasa Y. The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial. Vaccines (Basel) 2021;10:45. [PMID: 35062707 DOI: 10.3390/vaccines10010045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 659 |
Jacob R, Danta M. Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection. Expert Opin Pharmacother 2021;:1-8. [PMID: 34937470 DOI: 10.1080/14656566.2021.2019708] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 660 |
Zhang Q, Peng H, Liu X, Wang H, Du J, Luo X, Ren H, Hu P. Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease. J Clin Transl Hepatol 2021;9:850-9. [PMID: 34966648 DOI: 10.14218/JCTH.2021.00046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 661 |
van Buuren N, Ramirez R, Turner S, Chen D, Suri V, Aggarwal A, Moon C, Kim S, Kornyeyev D, Bui N, Bhardwaj N, Chan HL, Marcellin P, Buti M, Wallin J, Gaggar A, Fletcher SP, Diehl L, Li L, Mo H, Feierbach B. Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection. JHEP Rep 2022;4:100388. [PMID: 34950863 DOI: 10.1016/j.jhepr.2021.100388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 662 |
Xie Y, Ma H, Feng B, Song G. Combining the HBcrAg decline and HBV mutations predicts spontaneous HBeAg seroconversion in chronic hepatitis B patients during the immune clearance phase. J Med Virol 2021. [PMID: 34951036 DOI: 10.1002/jmv.27545] [Reference Citation Analysis]
|
| 663 |
Filippidis P, Vionnet J, Manuel O, Mombelli M. Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34854329 DOI: 10.1080/14787210.2022.2013808] [Reference Citation Analysis]
|
| 664 |
Jiang W, Liu CH, Wu D, Wang YJ, Tang H. Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan. Biosci Rep 2021;41:BSR20211769. [PMID: 34918746 DOI: 10.1042/BSR20211769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 665 |
Reeves I, Cromarty B, Deayton J, Dhairyawan R, Kidd M, Taylor C, Thornhill J, Tickell-Painter M, van Halsema C. British HIV Association guidelines for the management of HIV-2 2021. HIV Med 2021;22 Suppl 4:1-29. [PMID: 34927347 DOI: 10.1111/hiv.13204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 666 |
González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 667 |
Abd El-halim JA, Gewaifel GI, Darwish EAF, Ramadan AM, Elsisi GH. Health care resources utilization and costs associated with different clinical stages of chronic hepatitis B in Egypt. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00162-z] [Reference Citation Analysis]
|
| 668 |
Tan N, Luo H, Kang Q, Pan J, Cheng R, Xi H, Chen H, Han Y, Yang Y, Xu X. High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment. Virus Res 2021;309:198660. [PMID: 34929214 DOI: 10.1016/j.virusres.2021.198660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 669 |
Ergen P, Isik B, Arslan F, Karadag FY, Aydin O, Cag Y, Yazici S, Ucisik AC, Vahaboglu MH. Outcomes of Cessation of Antiviral Therapy in Chronic Hepatitis B: A Retrospective Cohort Study. Medeni Med J 2021;36:201-8. [PMID: 34915677 DOI: 10.5222/MMJ.2021.52959] [Reference Citation Analysis]
|
| 670 |
Picchio CA, Lens S, Hernandez-Guerra M, Arenas J, Andrade RJ, Crespo J, García-Samaniego J, Romero-Gómez M, Turnes J, Calleja JL, Simón MÁ, White TM, Riveiro-Barciela M, Pocurull A, Morales-Arraez D, Gómez A, Buti M, Lazarus JV. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. Sci Rep 2021;11:24133. [PMID: 34921156 DOI: 10.1038/s41598-021-01885-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 671 |
Khan IW, Dad Ullah MU, Choudhry M, Ali MJ, Ali MA, Lam SLK, Shah PA, Kaur SP, Lau DTY. Novel Therapies of Hepatitis B and D. Microorganisms 2021;9:2607. [PMID: 34946209 DOI: 10.3390/microorganisms9122607] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 672 |
Nkongolo S, Mahamed D, Kuipery A, Sanchez Vasquez JD, Kim SC, Mehrotra A, Patel A, Hu C, Mcgilvray I, Feld JJ, Fung S, Chen D, Wallin JJ, Gaggar A, Janssen HLA, Gehring AJ. Pathogenic CD8 T cells defined by longitudinal liver sampling in chronic hepatitis B patients starting antiviral therapy.. [DOI: 10.1101/2021.12.16.21267870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 673 |
Cardoso AC, A Villela-Nogueira C, de Figueiredo-Mendes C, Leão Filho H, Pinto Silva RA, Valle Tovo C, Perazzo H, Matteoni AC, de Carvalho-Filho RJ, Lisboa Bittencourt P. Brazilian Society of Hepatology and Brazilian College of Radiology practice guidance for the use of elastography in liver diseases. Ann Hepatol 2021;22:100341. [PMID: 33737252 DOI: 10.1016/j.aohep.2021.100341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 674 |
Wang J, Du L, Tang H. Suppression of Interferon-α Treatment Response by Host Negative Factors in Hepatitis B Virus Infection. Front Med (Lausanne) 2021;8:784172. [PMID: 34901094 DOI: 10.3389/fmed.2021.784172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 675 |
Okamura T, Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Nakano Y, Honda T, Yajima H, Miyazaki O, Kuribayashi Y, Ikeda T, Taura N, Nakao K. Change in tartrate-resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide. Biomed Rep 2022;16:6. [PMID: 34900255 DOI: 10.3892/br.2021.1489] [Reference Citation Analysis]
|
| 676 |
Duan Y, Chen Z, Li H, Shen W, Zeng Y, Peng M, Hu P. Potential Molecular Targets of Tenofovir Disoproxil Fumarate for Alleviating Chronic Liver Diseases via a Non-Antiviral Effect in a Normal Mouse Model. Front Mol Biosci 2021;8:763150. [PMID: 34869594 DOI: 10.3389/fmolb.2021.763150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 677 |
Wagay NA, Rafiq S, Rather MA, Tantray YR, Lin F, Wani SH, El-Sabrout AM, Elansary HO, Mahmoud EA. Secondary Metabolite Profiling, Anti-Inflammatory and Hepatoprotective Activity of Neptunia triquetra (Vahl) Benth. Molecules 2021;26:7353. [PMID: 34885934 DOI: 10.3390/molecules26237353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 678 |
Cliff ERS, Sasadeusz J, Visvanathan K, Grigg A. Very late-onset hepatitis B reactivation following chemoimmunotherapy. Leuk Lymphoma 2021;:1-5. [PMID: 34852722 DOI: 10.1080/10428194.2021.2010066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 679 |
Genshaft AS, Subudhi S, Keo A, Vasquez JDS, Conceição-neto N, Mahamed D, Boeijen LL, Alatrakchi N, Oetheimer C, Vilme M, Drake R, Fleming I, Tran N, Tzouanas C, Joseph-chazan J, Villanueva MA, van de Werken HJG, van Oord GW, Groothuismink ZM, Beudeker BJ, Osmani Z, Nkongolo S, Mehrotra A, Feld J, Chung RT, de Knegt RJ, Janssen HLA, Aerssens J, Bollekens J, Hacohen N, Lauer GM, Boonstra A, Shalek AK, Gehring A. Clinical implementation of single-cell RNA sequencing using liver fine needle aspirate tissue sampling and centralized processing captures compartment specific immuno-diversity.. [DOI: 10.1101/2021.11.30.470634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 680 |
Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, Wang B, Zhan S, Kong Y, Jia J, You H, Yang HI. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clin Gastroenterol Hepatol 2021;19:2499-513. [PMID: 33667678 DOI: 10.1016/j.cgh.2021.02.040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 681 |
Atef M, Zayed N, Salama R, Abdel Alem S, Yousof H, Saber M, Hamed M, Yosry A. Is urinary β2-microglobulin a reliable marker for assessment of renal tubular dysfunction in chronic hepatitis B patients receiving tenofovir therapy? Eur J Gastroenterol Hepatol 2021;33:e992-8. [PMID: 33136729 DOI: 10.1097/MEG.0000000000001977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 682 |
Cheung KW, Seto MTY, Tsui PM, So PL, Wong D, Kong CW, Wang W, Ng EHY. Knowledge, perception and expectation of management of hepatitis B infection among pregnant hepatitis B carriers in Hong Kong. J Viral Hepat 2021;28:1699-709. [PMID: 34467599 DOI: 10.1111/jvh.13609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 683 |
Deterding K. Therapie der Koinfektion mit Hepatitis-B und -D: Mono- oder Kombinationstherapien mit Peginterferon, Nukleos(t)idanaloga und/oder Myrcludex? Gastroenterologe 2021;16:433-441. [DOI: 10.1007/s11377-021-00565-9] [Reference Citation Analysis]
|
| 684 |
Tsuge M. The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection. Liver Int 2021;41:2836-48. [PMID: 34559952 DOI: 10.1111/liv.15065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 685 |
Myers L, Mitra A, Ahn J. Addressing Hepatitis B in the Context of Hepatitis C. Curr Hepatology Rep 2021;20:175-182. [DOI: 10.1007/s11901-021-00578-6] [Reference Citation Analysis]
|
| 686 |
Shu X, Sun H, Yang X, Jia Y, Xu P, Cao H, Zhang K. Correlation of effective hepatic blood flow with liver pathology in patients with hepatitis B virus. Liver Research 2021;5:243-50. [DOI: 10.1016/j.livres.2021.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 687 |
Huang S, Kao J. Management of Hepatitis B in Persons Who Inject Drugs (PWID). Curr Hepatology Rep 2021;20:158-165. [DOI: 10.1007/s11901-021-00574-w] [Reference Citation Analysis]
|
| 688 |
Xiao LL, Wu XX, Chen JJ, Yan D, Shi DY, Huang JR, Xu XW, Li LJ. Progress in hepatitis B virus-related acute-on-chronic liver failure treatment in China: A large, multicenter, retrospective cohort study using a propensity score matching analysis. Hepatobiliary Pancreat Dis Int 2021;20:535-41. [PMID: 34303609 DOI: 10.1016/j.hbpd.2021.05.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 689 |
Erken R, Andre P, Roy E, Kootstra N, Barzic N, Girma H, Laveille C, Radreau-Pierini P, Darteil R, Vonderscher J, Scalfaro P, Tangkijvanich P, Flisiak R, Reesink H. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. J Viral Hepat 2021;28:1690-8. [PMID: 34467593 DOI: 10.1111/jvh.13608] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 690 |
Svicher V, Salpini R, Piermatteo L, Carioti L, Battisti A, Colagrossi L, Scutari R, Surdo M, Cacciafesta V, Nuccitelli A, Hansi N, Ceccherini Silberstein F, Perno CF, Gill US, Kennedy PTF. Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. Gut 2021;70:2337-48. [PMID: 33402415 DOI: 10.1136/gutjnl-2020-323300] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 691 |
Erken R, Zaaijer HL, Willemse SB, Bakker E, Takkenberg BB, Reesink HW, Kootstra NA. Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy. Ann Hepatol 2021;26:100540. [PMID: 34583061 DOI: 10.1016/j.aohep.2021.100540] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 692 |
Lee CK, Jonas MM. Viral Hepatitis B—Management in Children. Curr Hepatology Rep 2021;20:137-143. [DOI: 10.1007/s11901-021-00570-0] [Reference Citation Analysis]
|
| 693 |
Kumada T, Toyoda H, Yasuda S, Ito T, Tanaka J. Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B. Eur J Gastroenterol Hepatol 2021;33:e898-904. [PMID: 35048656 DOI: 10.1097/MEG.0000000000002292] [Reference Citation Analysis]
|
| 694 |
Yang L, Zhang Y, Zhang K, Liu Z, He T, Zheng X, Li L, Arnér ESJ, Zhang Z, Zhang J. Evaluation of dithiothreitol-oxidizing capacity (DOC) as a serum biomarker for chronic hepatitis B in patients exhibiting normal alanine aminotransferase levels: a pilot study towards better monitoring of disease. EClinicalMedicine 2021;42:101180. [PMID: 34765954 DOI: 10.1016/j.eclinm.2021.101180] [Reference Citation Analysis]
|
| 695 |
Kayadibi H, Yilmaz B, Ozgur Yeniova A, Koseoglu H, Simsek Z. Development and evaluation of a novel noninvasive index for predicting significant fibrosis, advanced fibrosis, and cirrhosis in patients with chronic hepatitis B infection. Eur J Gastroenterol Hepatol 2021;33:e121-30. [PMID: 33177385 DOI: 10.1097/MEG.0000000000001973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 696 |
Koutsianas C, Hadziyannis E, Thomas K, Deutsch M, Vassilopoulos D. Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents. J Viral Hepat 2021;28:1710-8. [PMID: 34496105 DOI: 10.1111/jvh.13610] [Reference Citation Analysis]
|
| 697 |
van Bömmel F, Berg T. Hepatitis B: Wann ist eine Beendigung der Therapie mit Nukleos(t)idanaloga gerechtfertigt? Gastroenterologe 2021;16:417-432. [DOI: 10.1007/s11377-021-00572-w] [Reference Citation Analysis]
|
| 698 |
Neumann-haefelin C. HCC-Surveillance bei Patienten mit chronischer Virushepatitis. Gastroenterologe 2021;16:450-454. [DOI: 10.1007/s11377-021-00567-7] [Reference Citation Analysis]
|
| 699 |
Jachs M, Binter T, Schmidbauer C, Hartl L, Strasser M, Laferl H, Hametner-Schreil S, Lindorfer A, Dax K, Stauber RE, Kessler HH, Bernhofer S, Maieron A, Loacker L, Bota S, Santonja I, Munda P, Mandorfer M, Peck-Radosavljevic M, Holzmann H, Gschwantler M, Zoller H, Ferenci P, Reiberger T. Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European Gastroenterol J 2021;9:1119-27. [PMID: 34873866 DOI: 10.1002/ueg2.12163] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 700 |
Furquim d'Almeida A, Ho E, Van Hees S, Vanwolleghem T. Clinical management of chronic hepatitis B: A concise overview. United European Gastroenterol J 2021. [PMID: 34846093 DOI: 10.1002/ueg2.12176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 701 |
Chang Y, Kim SG, Jeong SW, Jang JY, Yoo JJ, Lee SH, Kim YS, Kim HS, Lee HW, Park S. Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study. J Clin Med 2021;10:5628. [PMID: 34884330 DOI: 10.3390/jcm10235628] [Reference Citation Analysis]
|
| 702 |
Zhang Z, Lu W, Zeng D, Huang D, Lin W, Yan L, Feng Y. Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection. J Clin Med 2021;10:5617. [PMID: 34884319 DOI: 10.3390/jcm10235617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 703 |
Kuhns MC, Holzmayer V, McNamara AL, Anderson M, Cloherty GA. Hepatitis B seroconversion revisited: new insights into the natural history of acute hepatitis B virus (HBV) infection from quantitative and highly sensitive assays and novel biomarkers. Virol J 2021;18:235. [PMID: 34844619 DOI: 10.1186/s12985-021-01706-w] [Reference Citation Analysis]
|
| 704 |
Hur MH, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6009. [PMID: 34885118 DOI: 10.3390/cancers13236009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 705 |
Xiao X, Hu Q, Deng X, Shi K, Zhang W, Jiang Y, Ma X, Zeng J, Wang X. Old wine in new bottles: Kaempferol is a promising agent for treating the trilogy of liver diseases. Pharmacol Res 2021;175:106005. [PMID: 34843960 DOI: 10.1016/j.phrs.2021.106005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 706 |
Huang D, Yan W, Han M, Yuan W, Wang P, Chen Y, Wan X, Luo X, Wu D, Ning Q. Insufficient immunity led to virologic breakthrough in NAs-treated chronic hepatitis B patients switching to Peg-IFN-ɑ. Antiviral Res 2021;197:105220. [PMID: 34848218 DOI: 10.1016/j.antiviral.2021.105220] [Reference Citation Analysis]
|
| 707 |
Khanam A, Kottilil S. Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management. Front Med (Lausanne) 2021;8:752875. [PMID: 34820395 DOI: 10.3389/fmed.2021.752875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 708 |
Lempp FA, Roggenbach I, Nkongolo S, Sakin V, Schlund F, Schnitzler P, Wedemeyer H, Le Gal F, Gordien E, Yurdaydin C, Urban S. A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. Viruses 2021;13:2371. [PMID: 34960640 DOI: 10.3390/v13122371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 709 |
Su PY, Su WW, Hsu YC, Huang SP, Yen HH. Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study. PeerJ 2021;9:e12527. [PMID: 34820208 DOI: 10.7717/peerj.12527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 710 |
Sonneveld MJ, Maasoumy B. Prevalence of hepatitis D virus co-infection in Austria - Finding the needle in the haystack. United European Gastroenterol J 2021;9:1105-6. [PMID: 34817935 DOI: 10.1002/ueg2.12177] [Reference Citation Analysis]
|
| 711 |
Álvarez EG, Demeulemeester J, Otero P, Jolly C, García-Souto D, Pequeño-Valtierra A, Zamora J, Tojo M, Temes J, Baez-Ortega A, Rodriguez-Martin B, Oitaben A, Bruzos AL, Martínez-Fernández M, Haase K, Zumalave S, Abal R, Rodríguez-Castro J, Rodriguez-Casanova A, Diaz-Lagares A, Li Y, Raine KM, Butler AP, Otero I, Ono A, Aikata H, Chayama K, Ueno M, Hayami S, Yamaue H, Maejima K, Blanco MG, Forns X, Rivas C, Ruiz-Bañobre J, Pérez-Del-Pulgar S, Torres-Ruiz R, Rodriguez-Perales S, Garaigorta U, Campbell PJ, Nakagawa H, Van Loo P, Tubio JMC. Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. Nat Commun 2021;12:6910. [PMID: 34824211 DOI: 10.1038/s41467-021-26805-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 712 |
Caviglia GP, Zorzi A, Rizzetto M, Mirandola M, Olivero A, Carolo G. Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report. Diagnostics 2021;11:2185. [DOI: 10.3390/diagnostics11122185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 713 |
Lee JS, Lee HW, Lim TS, Shin HJ, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. Cancers (Basel) 2021;13:5892. [PMID: 34885000 DOI: 10.3390/cancers13235892] [Reference Citation Analysis]
|
| 714 |
Song A, Lin X, Lu J, Ren S, Cao Z, Zheng S, Hu Z, Li H, Shen C, Chen X. Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis. Front Immunol 2021;12:779347. [PMID: 34804072 DOI: 10.3389/fimmu.2021.779347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 715 |
Wang CR, Zhong GC, Chen ZW, Hu P. A Nomogram for Predicting Non-Rebound in HBV-Infected Pregnant Women With Mother-to-Child Transmission Prevention. Front Med (Lausanne) 2021;8:746759. [PMID: 34805216 DOI: 10.3389/fmed.2021.746759] [Reference Citation Analysis]
|
| 716 |
Papatheodoridi A, Karakousis N, Lembessis P, Chatzigeorgiou A, Papatheodoridis GV. The Significance of Circulating Cell-Free DNA Markers in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. Pathogens 2021;10:1524. [PMID: 34832679 DOI: 10.3390/pathogens10111524] [Reference Citation Analysis]
|
| 717 |
Neag MA, Mitre AO, Catinean A, Buzoianu AD. Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. World J Gastroenterol 2021; 27(43): 7446-7461 [PMID: 34887642 DOI: 10.3748/wjg.v27.i43.7446] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 718 |
Biondetti P, Saggiante L, Ierardi AM, Iavarone M, Sangiovanni A, Pesapane F, Fumarola EM, Lampertico P, Carrafiello G. Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers (Basel) 2021;13:5797. [PMID: 34830949 DOI: 10.3390/cancers13225797] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 719 |
Xiang T, Liang B, Wang H, Quan X, He S, Zhou H, He Y, Yang D, Wang B, Zheng X. Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection. Cell Mol Immunol 2021;18:2679-81. [PMID: 34782756 DOI: 10.1038/s41423-021-00795-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 720 |
Fang Y, Xu X, Hou F, Jia W. A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients. Antiviral Therapy 2021;26:126-33. [DOI: 10.1177/13596535211059895] [Reference Citation Analysis]
|
| 721 |
Sirilert S, Tongsong T, Kumfu S, Chattipakorn SC, Chattipakorn N. Effects of intrauterine exposure to hepatitis B virus in foetuses. J Med Microbiol 2021;70. [PMID: 34779762 DOI: 10.1099/jmm.0.001455] [Reference Citation Analysis]
|
| 722 |
Liu J, Wang J, Yan X, Xue R, Zhan J, Jiang S, Geng Y, Liu Y, Mao M, Xia J, Yin S, Tong X, Chen Y, Ding W, Huang R, Wu C. Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis. Hepatol Commun 2021. [PMID: 34783181 DOI: 10.1002/hep4.1859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 723 |
Argirion I, Pfeiffer RM, Lam TK, O'Brien TR, Yu K, McGlynn KA, Petrick JL, Pinto L, Chen CJ, Lee MH, Hildesheim A, Yang HI, Koshiol J. Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B. Sci Rep 2021;11:21194. [PMID: 34782638 DOI: 10.1038/s41598-021-00455-8] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 724 |
Lu J, Wang X, Zhu Y, Ma L, Zheng S, Hu Z, Chen X. Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. Gut Liver 2021;15:887-94. [PMID: 34446613 DOI: 10.5009/gnl21001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 725 |
Li J, Cheng L, Jia H, Liu C, Wang S, Liu Y, Shen Y, Wu S, Meng F, Zheng B, Yang C, Jiang W. IFN-γ facilitates liver fibrogenesis by CD161+CD4+ T cells through a regenerative IL-23/IL-17 axis in chronic hepatitis B virus infection. Clin Transl Immunology 2021;10:e1353. [PMID: 34754450 DOI: 10.1002/cti2.1353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 726 |
Campbell C, Wang T, Smith DA, Freeman O, Noble T, Várnai KA, Harris S, Salih H, Roadknight G, Little S, Glampson B, Mercuri L, Papadimitriou D, Jones CR, Taylor V, Chaudhry A, Phan H, Borca F, Olza J, Warricker F, Romão L, Ramlakhan D, English L, Klenerman P, Andersson MI, Collier J, Nastouli E, Khakoo SI, Gelson W, Cooke GS, Woods K, Davies J, Barnes E, Matthews PC. Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK.. [DOI: 10.1101/2021.11.10.21265651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 727 |
Zhang Q, Cai DC, Hu P, Ren H. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. Chin Med J (Engl) 2021;134:2810-7. [PMID: 34759219 DOI: 10.1097/CM9.0000000000001793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 728 |
Jin M, Chen Y, Hu S, Zhu M, Wang Y, Chen M, Peng Z. Association of Virological Response to Antiviral Therapy With Survival in Intermediate-Stage Hepatitis B Virus-Related Hepatocellular Carcinoma After Chemoembolization. Front Oncol 2021;11:751777. [PMID: 34745980 DOI: 10.3389/fonc.2021.751777] [Reference Citation Analysis]
|
| 729 |
Riveiro-Barciela M, Pericàs JM, Buti M. How to interpret viral markers in the management of chronic hepatitis B infection. Clin Microbiol Infect 2021:S1198-743X(21)00622-4. [PMID: 34768018 DOI: 10.1016/j.cmi.2021.10.020] [Reference Citation Analysis]
|
| 730 |
Alqahtani SA, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. Cells 2021;10:3091. [PMID: 34831314 DOI: 10.3390/cells10113091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 731 |
Lim J, Chon YE, Kim MN, Lee JH, Hwang SG, Lee HC, Ha Y. Cirrhosis, Age, and Liver Stiffness-Based Models Predict Hepatocellular Carcinoma in Asian Patients with Chronic Hepatitis B. Cancers (Basel) 2021;13:5609. [PMID: 34830764 DOI: 10.3390/cancers13225609] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 732 |
Yu MW, Lin CL, Liu CJ, Huang YW, Hu JT, Wu WJ, Wu CF. Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors. J Formos Med Assoc 2021:S0929-6646(21)00486-1. [PMID: 34764005 DOI: 10.1016/j.jfma.2021.10.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 733 |
Onorato L, Pisaturo M, Camaioni C, Grimaldi P, Codella AV, Calò F, Coppola N. Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. J Clin Med 2021;10:5201. [PMID: 34768721 DOI: 10.3390/jcm10215201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 734 |
Garcia-Garcia S, Cortese MF, Tabernero D, Gregori J, Vila M, Pacín B, Quer J, Casillas R, Castillo-Ribelles L, Ferrer-Costa R, Rando-Segura A, Trejo-Zahínos J, Pumarola T, Casis E, Esteban R, Riveiro-Barciela M, Buti M, Rodríguez-Frías F. Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA: Different quasispecies? World J Gastroenterol 2021; 27(41): 7144-7158 [PMID: 34887634 DOI: 10.3748/wjg.v27.i41.7144] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 735 |
Zhu B, Lv X, Zhao Z, Chen L, Chen X, Li C, Li S, Dai E. Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus. Medicine (Baltimore) 2021;100:e27695. [PMID: 34871254 DOI: 10.1097/MD.0000000000027695] [Reference Citation Analysis]
|
| 736 |
Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial. Pathogens 2021;10:1440. [PMID: 34832596 DOI: 10.3390/pathogens10111440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 737 |
Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical Updates on Chronic Hepatitis B Virus Infection in 2021. Cureus 2021;13:e19152. [PMID: 34733599 DOI: 10.7759/cureus.19152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 738 |
Tan L, Xu SL, Mo ZS, Liu JR, Gan WQ, Chen JH, Gao ZL, Wu ZQ. The clinical value of serum hepatic parenchyma cell volume-normalized hepatitis B surface antigen levels in hepatitis B e antigen -positive and -negative chronic hepatitis B patients. Ann Transl Med 2021;9:1431. [PMID: 34733983 DOI: 10.21037/atm-21-3846] [Reference Citation Analysis]
|
| 739 |
Gu S, Liu Z, Lin L, Zhong S, Ma Y, Li X, Ye G, Wen C, Li Y, Tang L. Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array. Front Immunol 2021;12:767000. [PMID: 34721439 DOI: 10.3389/fimmu.2021.767000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 740 |
Jo HS, Khan JF, Han JH, Yu YD, Kim DS. Efficacy and Safety of Hepatitis B Virus Vaccination Following Hepatitis B Immunoglobulin Withdrawal After Liver Transplantation. Transplant Proc 2021:S0041-1345(21)00736-3. [PMID: 34740450 DOI: 10.1016/j.transproceed.2021.09.038] [Reference Citation Analysis]
|
| 741 |
Tjønnfjord SKV, Tjønnfjord EB, Konopski Z, Tjønnfjord GE. Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia. Case Rep Hematol 2021;2021:1862446. [PMID: 34721911 DOI: 10.1155/2021/1862446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 742 |
Tout I, Loureiro D, Asselah T. The Changing Demographics of Hepatitis B Virus Infection. Clin Liver Dis 2021;25:673-87. [PMID: 34593147 DOI: 10.1016/j.cld.2021.06.001] [Reference Citation Analysis]
|
| 743 |
Sandmann L, Wedemeyer H. New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. Clin Liver Dis 2021;25:831-9. [PMID: 34593156 DOI: 10.1016/j.cld.2021.06.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 744 |
Charatcharoenwitthaya P, Kaewdech A, Piratvisuth T. Controversies in Treating Chronic HBV: The Role of PEG-interferon-alfa. Clin Liver Dis 2021;25:741-62. [PMID: 34593151 DOI: 10.1016/j.cld.2021.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 745 |
de Almeida NAA, de Paula VS. Occult Hepatitis B virus (HBV) infection and challenges for hepatitis elimination: A literature review. J Appl Microbiol 2021. [PMID: 34724308 DOI: 10.1111/jam.15351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 746 |
Dekker SE, Green EW, Ahn J. Treatment and Prevention of Acute Hepatitis B Virus. Clin Liver Dis 2021;25:711-24. [PMID: 34593149 DOI: 10.1016/j.cld.2021.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 747 |
Airewele NE, Shiffman ML. Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus. Clin Liver Dis 2021;25:817-29. [PMID: 34593155 DOI: 10.1016/j.cld.2021.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 748 |
Kim HL, Kim GA, Park JA, Kang HR, Lee EK, Lim YS. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. Gut 2021;70:2172-82. [PMID: 33239344 DOI: 10.1136/gutjnl-2020-321309] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 749 |
Buti M, Riveiro-Barciela M, Esteban R. Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. Clin Liver Dis 2021;25:725-40. [PMID: 34593150 DOI: 10.1016/j.cld.2021.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 750 |
Wang X, Chen Y, Xu M, Cheng K, Duan X, Liao W, Wang Y, Lu Y, Duan Z, Wang L. Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir. Expert Rev Gastroenterol Hepatol 2021;15:1337-44. [PMID: 34511012 DOI: 10.1080/17474124.2021.1980385] [Reference Citation Analysis]
|
| 751 |
Chi Z, Zhao W, Li JW, Liu H, Shao C, Zhao H, Gui-Qiang W. Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy. Clin Res Hepatol Gastroenterol 2021;45:101563. [PMID: 33272888 DOI: 10.1016/j.clinre.2020.10.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 752 |
Huang DQ, Kew GS, Lim SG. Controversies in Treating Chronic Hepatitis B virus: The Role of Hepatitis B Virus DNA and Surface Antigen Titer. Clin Liver Dis 2021;25:763-84. [PMID: 34593152 DOI: 10.1016/j.cld.2021.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 753 |
Lee WM, King WC, Janssen HLA, Ghany MG, Fontana RJ, Fried M, Sterling RK, Feld JJ, Wang J, Mogul DB, Cooper SL, Bisceglie AMD; Hepatitis B Research Network (HBRN). Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. J Viral Hepat 2021;28:1526-38. [PMID: 34355475 DOI: 10.1111/jvh.13591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 754 |
Tsai HJ, Chuang YW, Yang SS, Chang YZ, Chang HR, Lee TY. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease. J Viral Hepat 2021;28:1579-86. [PMID: 34464999 DOI: 10.1111/jvh.13603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 755 |
Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. J Viral Hepat 2021;28:1570-8. [PMID: 34435412 DOI: 10.1111/jvh.13601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 756 |
Wang L, Zhao J, Liu J, Zhen C, Zhang M, Dong Y, Gan Y, Xu Z, Li Y, Zhu S, Wang FS. Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B. J Viral Hepat 2021;28:1554-62. [PMID: 34448324 DOI: 10.1111/jvh.13598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 757 |
Schmidbauer C, Chromy D, Schmidbauer VU, Schwarz M, Jachs M, Bauer DJM, Binter T, Apata M, Nguyen DT, Mandorfer M, Simbrunner B, Rieger A, Mayer F, Breuer M, Strassl R, Schmidt R, Holzmann H, Trauner M, Gschwantler M, Reiberger T. Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. Liver Int 2021;41:2622-34. [PMID: 34268869 DOI: 10.1111/liv.15018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 758 |
Khemichian S, Kahn J, Terrault NA. Use of Hepatitis B Virus-Positive Organs in Organ Transplantation. Clin Liver Dis 2021;25:841-57. [PMID: 34593157 DOI: 10.1016/j.cld.2021.06.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 759 |
Sarowar A, Hirode G, Janssen HLA, Feld JJ. Controversies in Treating Chronic Hepatitis B Virus Infection: Discordant Serologic Results. Clin Liver Dis 2021;25:805-16. [PMID: 34593154 DOI: 10.1016/j.cld.2021.06.007] [Reference Citation Analysis]
|
| 760 |
Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 761 |
Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Xiao L, Li C, Wu Q, Sun C, Niu J, Hou J; TMF Study Group. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther 2021;54:1134-49. [PMID: 34587302 DOI: 10.1111/apt.16611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 762 |
Zamor PJ, Lane AM. Interpretation of HBV Serologies. Clin Liver Dis 2021;25:689-709. [PMID: 34593148 DOI: 10.1016/j.cld.2021.06.012] [Reference Citation Analysis]
|
| 763 |
Loglio A, Viganò M, Lampertico P. Novel Therapies That May Cure Chronic Hepatitis B Virus. Clin Liver Dis 2021;25:875-99. [PMID: 34593159 DOI: 10.1016/j.cld.2021.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 764 |
Pappas SC. Hepatitis B and Health Care Workers. Clin Liver Dis 2021;25:859-74. [PMID: 34593158 DOI: 10.1016/j.cld.2021.06.010] [Reference Citation Analysis]
|
| 765 |
Zhang YR, Wang H, Zhou N, Zhang YD, Lin Y, Wu LY, Wei SF, Ma YY, Wang CX. A Multidisciplinary Team Approach to the Treatment of Liver Cirrhosis. J Inflamm Res 2021;14:5443-50. [PMID: 34712056 DOI: 10.2147/JIR.S328334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 766 |
Soriano V, Alvarez C, Edagwa B, de Mendoza C, Montoya N, Treviño A, Gendelman H. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. Int J Infect Dis 2021;114:45-50. [PMID: 34728344 DOI: 10.1016/j.ijid.2021.10.052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 767 |
Wang X, Liu X, Wang P, Yu L, Yan F, Yan H, Zhou D, Yang Z. Antiviral Therapy Reduces Mortality in Hepatocellular Carcinoma Patients with Low-Level Hepatitis B Viremia. J Hepatocell Carcinoma 2021;8:1253-67. [PMID: 34708007 DOI: 10.2147/JHC.S330301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 768 |
Zhang C, Li JW, Wu Z, Zhao H, Wang GQ. Significant Histologic Changes Are Not Rare in Treatment-naive Hepatitis B Patients with Normal Alanine Aminotransferase Level: A Meta-analysis. J Clin Transl Hepatol 2021;9:615-25. [PMID: 34722176 DOI: 10.14218/JCTH.2020.00136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 769 |
Liu YC, Hsu CM, Hsiao SY, Hsiao HH. Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. J Pers Med 2021;11:1108. [PMID: 34834460 DOI: 10.3390/jpm11111108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 770 |
Kulkarni AV, Duvvuru NR. Management of hepatitis B and C in special population. World J Gastroenterol 2021; 27(40): 6861-6873 [PMID: 34790011 DOI: 10.3748/wjg.v27.i40.6861] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 771 |
Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 772 |
Gane E, Pastagia M, Schwertschlag U, De Creus A, Schwabe C, Vandenbossche J, Slaets L, Fevery B, Smyej I, Wu LS, Li R, Siddiqui S, Oey A, Musto C, Van Remoortere P. Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults. Antiviral Therapy 2021;26:58-68. [DOI: 10.1177/13596535211056581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 773 |
Liang KH, Chen SF, Lin YH, Chu YD, Lin YH, Lai MW, Lin CL, Yeh CT. Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma. Biomedicines 2021;9:1539. [PMID: 34829768 DOI: 10.3390/biomedicines9111539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 774 |
Wang Z, Chen Y, Deng H, Zhen X, Xiong J, Hu Y. Quantification of intrahepatic cccDNA in HBV associated hepatocellular carcinoma by improved ddPCR method. J Virol Methods 2022;299:114334. [PMID: 34688781 DOI: 10.1016/j.jviromet.2021.114334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 775 |
Zhu S, Wu L, Mei Y, Liu Z, Lin L, Yuan J, Li J, Li X, Peng L. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol. BMJ Open 2021;11:e049104. [PMID: 34697111 DOI: 10.1136/bmjopen-2021-049104] [Reference Citation Analysis]
|
| 776 |
Jang Y, Ahn SH, Lee K, Kwon OY, Kim JH. Development and Pilot Testing of a Smartphone-Based Self-Care Program for Patients with Chronic Hepatitis B. Int J Environ Res Public Health 2021;18:11139. [PMID: 34769658 DOI: 10.3390/ijerph182111139] [Reference Citation Analysis]
|
| 777 |
Lai CY, Yang SS, Lee SW, Tsai HJ, Lee TY. Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation. J Clin Med 2021;10:4883. [PMID: 34768403 DOI: 10.3390/jcm10214883] [Reference Citation Analysis]
|
| 778 |
Hayashi T, Takeshita Y, Hutin YJ, Harmanci H, Easterbrook P, Hess S, van Holten J, Oru EO, Kaneko S, Yurdaydin C, Bulterys M. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response? Arch Public Health 2021;79:180. [PMID: 34663473 DOI: 10.1186/s13690-021-00693-2] [Reference Citation Analysis]
|
| 779 |
MacDonald-Ottevanger MS, Boyd A, Prins M, van der Helm JJ, Zijlmans CWR, Hindori-Mohangoo AD, Harkisoen S, Hermelijn SM, Brinkman K, Codrington J, Roosblad J, Kort SAR, Dams ETM, van de Laar TJW, Vreden SGS. Differences in prevalence of hepatitis B virus infection and genotypes between ethnic populations in Suriname, South America. Virology 2021;564:53-61. [PMID: 34656809 DOI: 10.1016/j.virol.2021.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 780 |
Miao J, Gao P, Li Q, He K, Zhang L, Wang J, Huang L. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int J Mol Sci 2021;22:11227. [PMID: 34681886 DOI: 10.3390/ijms222011227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 781 |
Xie X, Lv H, Liu C, Su X, Yu Z, Song S, Bian H, Tian M, Qin C, Qi J, Zhu Q. HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis. BMC Med 2021;19:247. [PMID: 34649530 DOI: 10.1186/s12916-021-02085-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 782 |
Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, Tami Y, You S, Yates P, Tao Y, Cremer J, Campbell F, Elston R, Theodore D, Paff M, Bennett CF, Kwoh TJ. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med 2021;27:1725-34. [PMID: 34642494 DOI: 10.1038/s41591-021-01513-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 783 |
Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Yao ZA, Qiang R, Chen ST, Zhao X, Liu S, Cao ZM, Xu L, Li GH, Chen J, Wang L. YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial. Trials 2021;22:701. [PMID: 34649610 DOI: 10.1186/s13063-021-05650-6] [Reference Citation Analysis]
|
| 784 |
Hayashi S, Nagaoka K, Tanaka Y. Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins. Int J Mol Sci 2021;22:11051. [PMID: 34681709 DOI: 10.3390/ijms222011051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 785 |
Kuhns MC, Holzmayer V, Anderson M, McNamara AL, Sauleda S, Mbanya D, Duong PT, Dung NTT, Cloherty GA. Molecular and Serological Characterization of Hepatitis B Virus (HBV)-Positive Samples with Very Low or Undetectable Levels of HBV Surface Antigen. Viruses 2021;13:2053. [PMID: 34696483 DOI: 10.3390/v13102053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 786 |
Xu H, Li X, Wu Z, Zhao L, Shen J, Liu J, Qin J, Shen Y, Ke J, Wei Y, Li J, Gao Y. LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB. Front Mol Biosci 2021;8:749648. [PMID: 34631799 DOI: 10.3389/fmolb.2021.749648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 787 |
Linn YH, Ei WW, Myint LMM, Lwin KM. Anti-hepatitis B activities of Myanmar medicinal plants: a narrative review of current evidence. Virusdisease 2021;32:446-66. [PMID: 34631974 DOI: 10.1007/s13337-021-00714-2] [Reference Citation Analysis]
|
| 788 |
Chen P, Wei W, Jin L, Kuai W, Li F, Liu H, Jiang B, Zhu Y. Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naïve patients with chronic hepatitis B. Exp Ther Med 2021;22:1325. [PMID: 34630679 DOI: 10.3892/etm.2021.10760] [Reference Citation Analysis]
|
| 789 |
Dezanet LNC, Miailhes P, Lascoux-Combe C, Chas J, Maylin S, Gabassi A, Rougier H, Delaugerre C, Lacombe K, Boyd A. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study. J Antimicrob Chemother 2021;76:3009-19. [PMID: 34458919 DOI: 10.1093/jac/dkab294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 790 |
Ju YC, Jun DW, Yoon EL, Ahn SB, Kim YJ, Nguyen MH. Nationwide Data on the Characteristics of Linked-to-Care Chronic Hepatitis B in Korea. J Clin Med 2021;10:4633. [PMID: 34682760 DOI: 10.3390/jcm10204633] [Reference Citation Analysis]
|
| 791 |
Shoukry NH, Walker CM. T cell responses during HBV and HCV infections: similar but not quite the same? Curr Opin Virol 2021;51:80-6. [PMID: 34619514 DOI: 10.1016/j.coviro.2021.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 792 |
Sun T, Li R, Qiu Y, Shen S, Wang W. New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram. Int J Gen Med 2021;14:6149-65. [PMID: 34611429 DOI: 10.2147/IJGM.S335400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 793 |
Yeh ML, Liang PC, Trinh S, Huang CI, Huang CF, Hsieh MY, Huang JF, Dai CY, Chuang WL, Nguyen MH, Yu ML. Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide☆. J Formos Med Assoc 2021:S0929-6646(21)00431-9. [PMID: 34625346 DOI: 10.1016/j.jfma.2021.09.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 794 |
Carda JP, Santos L, Mariz JM, Monteiro P, Gonçalves HM, Raposo J, Gomes da Silva M. Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations. Hematology 2021;26:785-98. [PMID: 34605364 DOI: 10.1080/16078454.2021.1980690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 795 |
Wehmeyer MH, Schulze Zur Wiesch J. Editorial: only steps away from prime time? Hepatitis B virus RNA as routine marker to guide HBV treatment decisions. Aliment Pharmacol Ther 2021;54:970-1. [PMID: 34506655 DOI: 10.1111/apt.16560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 796 |
Meier MA, Calabrese D, Suslov A, Terracciano LM, Heim MH, Wieland S. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol 2021;75:840-7. [PMID: 34004216 DOI: 10.1016/j.jhep.2021.04.051] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 797 |
Kaneko S, Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2021;36:2943-51. [PMID: 34057248 DOI: 10.1111/jgh.15563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 798 |
Yip TC, Wong VW, Lui GC, Chow VC, Tse YK, Hui VW, Liang LY, Chan HL, Hui DS, Wong GL. Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. Hepatology 2021;74:1750-65. [PMID: 33961298 DOI: 10.1002/hep.31890] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 799 |
Gu X, Zhou H, Chu Q, Zheng Q, Wang J, Zhu H. Uncovering the Association Between m5C Regulator-Mediated Methylation Modification Patterns and Tumour Microenvironment Infiltration Characteristics in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:727935. [PMID: 34589490 DOI: 10.3389/fcell.2021.727935] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 800 |
Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
|
| 801 |
Lim JH, Yu JH, Suh YJ, Lee JW, Jin YJ. Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir. Medicine (Baltimore) 2021;100:e27417. [PMID: 34596169 DOI: 10.1097/MD.0000000000027417] [Reference Citation Analysis]
|
| 802 |
Li J, Qu L, Sun X, Liu Y, Gong Q, Yu D, Zhang D, Jiang J, Chen J, Wei D, Han Y, Gao Y, Zhang Q, She W, Chen L, Zhang J, Zhang X. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients. J Viral Hepat 2021;28:1381-91. [PMID: 34228855 DOI: 10.1111/jvh.13571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 803 |
van Bömmel F, Berg T. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatol Commun 2021;5:1632-48. [PMID: 34558833 DOI: 10.1002/hep4.1708] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 804 |
Ferrando-Martinez S, Snell Bennett A, Lino E, Gehring AJ, Feld J, Janssen HLA, Robbins SH. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection. Front Immunol 2021;12:648420. [PMID: 34589081 DOI: 10.3389/fimmu.2021.648420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 805 |
Yoo SH, Lim TS, Lee HW, Kim JK, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Lee JI, Lee KS, Kim SU. Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. J Viral Hepat 2021;28:1362-72. [PMID: 34185929 DOI: 10.1111/jvh.13560] [Reference Citation Analysis]
|
| 806 |
Jeng WJ, Lok AS. Should Treatment Indications for Chronic Hepatitis B Be Expanded? Clin Gastroenterol Hepatol 2021;19:2006-14. [PMID: 32434068 DOI: 10.1016/j.cgh.2020.04.091] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 807 |
Gane EJ, Kim HJ, Visvanathan K, Kim YJ, Nguyen AH, Wallin JJ, Chen DY, McDonald C, Arora P, Tan SK, Gaggar A, Roberts SK, Lim YS. Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B. Hepatology 2021;74:1737-49. [PMID: 33704806 DOI: 10.1002/hep.31795] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 808 |
Gane E, Yuen MF, Kim DJ, Chan HL, Surujbally B, Pavlovic V, Das S, Triyatni M, Kazma R, Grippo JF, Buatois S, Lemenuel-Diot A, Krippendorff BF, Mueller H, Zhang Y, Kim HJ, Leerapun A, Lim TH, Lim YS, Tanwandee T, Kim W, Cheng W, Hu TH, Wat C. Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. Hepatology 2021;74:1795-808. [PMID: 34037271 DOI: 10.1002/hep.31920] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 809 |
Du Y, Yang X, Li J, Sokolova V, Zou S, Han M, Yan H, Wey K, Lu M, Dittmer U, Yang D, Epple M, Wu J. Delivery of toll-like receptor 3 ligand poly(I:C) to the liver by calcium phosphate nanoparticles conjugated with an F4/80 antibody exerts an anti-hepatitis B virus effect in a mouse model. Acta Biomater 2021;133:297-307. [PMID: 33540061 DOI: 10.1016/j.actbio.2021.01.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 810 |
Jeong S, Cho Y, Park SM, Kim W. Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:e77-86. [PMID: 33883516 DOI: 10.1097/MCG.0000000000001548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 811 |
Asif B, Koh C. Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials. Expert Opin Investig Drugs 2021;:1-16. [PMID: 34482769 DOI: 10.1080/13543784.2021.1977795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 812 |
Muhammad H, Zaffar D, Tehreem A, Ting P, Simsek C, Gokcan H, Gurakar A, Idilman R. HBV/HDV management after liver transplantation: Review. Journal of Liver Transplantation 2021;4:100046. [DOI: 10.1016/j.liver.2021.100046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 813 |
Lou T, Li B, Xiong P, Jin C, Chen Y. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China. J Viral Hepat 2021;28:1373-80. [PMID: 34218498 DOI: 10.1111/jvh.13569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 814 |
Yu X, Xin L, Rongyong M, Aibing W, Jianzhong C. Clinical efficacy and safety of TCM prescriptions combined with nucleoside (acid) analogues in treating chronic hepatitis B: a meta-analysis. Digital Chinese Medicine 2021;4:170-9. [DOI: 10.1016/j.dcmed.2021.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 815 |
Inada K, Kaneko S, Kurosaki M, Yamashita K, Kirino S, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. JGH Open 2021;5:1085-91. [PMID: 34584979 DOI: 10.1002/jgh3.12636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 816 |
Garteiser P, Pagé G, d'Assignies G, Leitao HS, Vilgrain V, Sinkus R, Van Beers BE. Necro-inflammatory activity grading in chronic viral hepatitis with three-dimensional multifrequency MR elastography. Sci Rep 2021;11:19386. [PMID: 34588519 DOI: 10.1038/s41598-021-98726-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 817 |
Piermatteo L, Alkhatib M, D'Anna S, Malagnino V, Bertoli A, Andreassi E, Basile E, Iuvara A, De Cristofaro M, Cappiello G, Cerva C, Minichini C, Pisaturo M, Starace M, Coppola N, Fontana C, Grelli S, Ceccherini-Silberstein F, Andreoni M, Gill US, Kennedy PTF, Sarmati L, Salpini R, Svicher V. HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. Biomedicines 2021;9:1352. [PMID: 34680469 DOI: 10.3390/biomedicines9101352] [Reference Citation Analysis]
|
| 818 |
Wang M, Qian M, Fu R, Zhang Y, Shen X, Yue D, Wang N, Yang L. The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Front Public Health 2021;9:709220. [PMID: 34568257 DOI: 10.3389/fpubh.2021.709220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 819 |
Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 820 |
Stinco M, Rubino C, Trapani S, Indolfi G. Treatment of hepatitis B virus infection in children and adolescents. World J Gastroenterol 2021; 27(36): 6053-6063 [PMID: 34629819 DOI: 10.3748/wjg.v27.i36.6053] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 821 |
Xu WX, Li YM, Li JG, Mei YY, Chen YM, Li XJ, Lin CS, Deng H, Zhao ZX, Xie DY, Gao ZL, Peng L. The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients. Gastroenterol Rep (Oxf) 2021;9:313-22. [PMID: 34567563 DOI: 10.1093/gastro/goab013] [Reference Citation Analysis]
|
| 822 |
Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021;13:1042-57. [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 823 |
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 137] [Cited by in F6Publishing: 184] [Article Influence: 68.5] [Reference Citation Analysis]
|
| 824 |
Wu X, Feng S, Zhang J, Zhang W, Zhang Y, Zhu M, Triyatni M, Zhao N, Bo Q, Jin Y. Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers. Clin Transl Sci 2021. [PMID: 34562067 DOI: 10.1111/cts.13134] [Reference Citation Analysis]
|
| 825 |
Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol 2021;12:733364. [PMID: 34557195 DOI: 10.3389/fimmu.2021.733364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 826 |
Yilmaz Önal H. Evaluation nutritional status and anthropometric parameters in patients with chronic hepatitis B. Journal of Health Sciences and Medicine 2021;4:809-15. [DOI: 10.32322/jhsm.964768] [Reference Citation Analysis]
|
| 827 |
Rajan C, Chiou FK, Merchant K, Phua KB. Hepatocellular Carcinoma in the Absence of Cirrhosis in a Child With Inactive Chronic Hepatitis B Infection. JPGN Reports 2021;2:e124. [DOI: 10.1097/pg9.0000000000000124] [Reference Citation Analysis]
|
| 828 |
Kakuda TN, Yogaratnam JZ, Westland C, Gane EJ, Schwabe C, Vuong J, Patel M, Snoeys J, Talloen W, Lenz O, Fry J, Chanda S, van Remoortere P. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers. Antiviral Therapy 2021;26:13-24. [DOI: 10.1177/13596535211044331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 829 |
Ramos TI, Villacis-Aguirre CA, Santiago Vispo N, Santiago Padilla L, Pedroso Santana S, Parra NC, Alonso JRT. Forms and Methods for Interferon's Encapsulation. Pharmaceutics 2021;13:1533. [PMID: 34683824 DOI: 10.3390/pharmaceutics13101533] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 830 |
Patel N, Post FA. Surveillance for hepatocellular carcinoma in people of African ancestry with HIV and Hepatitis B. Int J STD AIDS 2021;:9564624211042828. [PMID: 34546112 DOI: 10.1177/09564624211042828] [Reference Citation Analysis]
|
| 831 |
Jaquet A, Muula G, Ekouevi DK, Wandeler G. Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps. Curr Epidemiol Rep 2021;8:89-96. [PMID: 34532216 DOI: 10.1007/s40471-021-00273-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 832 |
Rydell GE, Prakash K, Larsson SB, Skoglund C, Ringlander J, Andersson M, Castedal M, Norder H, Lindh M. Quantification of viral RNA in multiple pieces of explant liver tissue shows distinct focal differences of hepatitis B infection. J Infect Dis 2021:jiab469. [PMID: 34534318 DOI: 10.1093/infdis/jiab469] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 833 |
Li C, Zhang W, Shi B, Chen G, Zheng Y, An Y, Sun M, Feng Y, Shang Q, Zhang X. Evaluation of the in situ assay for HBV DNA: An observational real-world study in chronic hepatitis B. Medicine (Baltimore) 2021;100:e27220. [PMID: 34664859 DOI: 10.1097/MD.0000000000027220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 834 |
Zhou J, Wang FD, Wang ML, Tao YC, Wu DB, Sheng YJ, Xiao GB, Chen XB, Chen X, Chen EQ. Antiviral Therapy for Chronic HBV Infection With Persistently Normal Alanine Aminotransferase: Controversy and Consensus. Front Med (Lausanne) 2021;8:717125. [PMID: 34527683 DOI: 10.3389/fmed.2021.717125] [Reference Citation Analysis]
|
| 835 |
de Almeida Pondé RA. Detection of the serological markers hepatitis B virus surface antigen (HBsAg) and hepatitis B core IgM antibody (anti-HBcIgM) in the diagnosis of acute hepatitis B virus infection after recent exposure. Microbiol Immunol 2021. [PMID: 34528725 DOI: 10.1111/1348-0421.12943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 836 |
Mak LY, Ko KL, To WP, Wong DK, Seto WK, Fung J, Yuen MF. Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. Gut Liver 2020;14:665-8. [PMID: 32457279 DOI: 10.5009/gnl19434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 837 |
Roggenbach I, Chi X, Lempp FA, Qu B, Walter L, Wu R, Gao X, Schnitzler P, Ding Y, Urban S, Niu J. HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection. Viruses 2021;13:1799. [PMID: 34578380 DOI: 10.3390/v13091799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 838 |
Yao K, Wang J, Wang L, Xia J, Yan X, Wu W, Liu J, Wang L, Yin S, Tong X, Ding W, Huang R, Wu C. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA. J Med Virol 2021. [PMID: 34499353 DOI: 10.1002/jmv.27327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 839 |
Zuccaro V, Asperges E, Colaneri M, Marvulli LN, Bruno R. HBV and HDV: New Treatments on the Horizon. J Clin Med 2021;10:4054. [PMID: 34575165 DOI: 10.3390/jcm10184054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 840 |
Shang J, Zhou J, Liu H, Ise RM, Tu Y, Ran J, Bai L, Tang H. Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients. BMC Infect Dis 2021;21:912. [PMID: 34488678 DOI: 10.1186/s12879-021-06554-1] [Reference Citation Analysis]
|
| 841 |
Huang M, Gao Y, Yin X, Zhang X, Hao Y, Hu J, Liu Z. Characterization of T cell immunity in chronic hepatitis B virus-infected mothers with postpartum alanine transaminase flare. BMC Infect Dis 2021;21:922. [PMID: 34488681 DOI: 10.1186/s12879-021-06634-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 842 |
Sandmann L, Cornberg M. Towards eradication of HBV: Treatment approaches and status of clinical trials. Curr Opin Pharmacol 2021;60:232-40. [PMID: 34474210 DOI: 10.1016/j.coph.2021.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 843 |
Wu Y, Wen J, Tang G, Zhang J, Xin J. On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B. J Infect 2021;83:594-600. [PMID: 34474058 DOI: 10.1016/j.jinf.2021.08.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 844 |
Abu-Freha N, Wainstock T, Poupko L, Sheiner E. Maternal Hepatitis B or Hepatitis C Virus Carrier Status is Not a Risk Factor for Long-Term Oncologic Morbidity of the Offspring: A Population-Based Cohort Study. Cancer Invest 2021;:1-6. [PMID: 33784229 DOI: 10.1080/07357907.2021.1910704] [Reference Citation Analysis]
|
| 845 |
Jaroenlapnopparat A, Chayanupatkul M, Tangkijvanich P. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review. J Gastroenterol Hepatol 2021;36:2349-62. [PMID: 33811375 DOI: 10.1111/jgh.15516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 846 |
Pataccini G, Pedrozo W, Mathet VL, Biglione MM, Delfino CM. Prevalence of hepatitis D virus in blood donors with different hepatitis B virus markers of infection. Eur J Gastroenterol Hepatol 2021;33:1229. [PMID: 34397641 DOI: 10.1097/MEG.0000000000001898] [Reference Citation Analysis]
|
| 847 |
Italian Association for the Study of the Liver (AISF). Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2021;53:1089-104. [PMID: 34321192 DOI: 10.1016/j.dld.2021.06.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 848 |
Nguyen YTH, Diep YN, Huynh YK, Pham TT, Nguyen T, Tran DTN, Tran LTN, Trinh CTH, Cao NM, Nguyen BT. Distribution of Hepatitis B Virus Genotypes, Subgenotypes, and Prevalence of Hepatitis B Virus Mutations in Untreated Patients With Chronic Hepatitis B From Mekong Delta. Infect Dis Clin Pract 2021;29:e301-e304. [DOI: 10.1097/ipc.0000000000000990] [Reference Citation Analysis]
|
| 849 |
Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut 2021;70:1782-94. [PMID: 34103404 DOI: 10.1136/gutjnl-2020-323888] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 33.5] [Reference Citation Analysis]
|
| 850 |
Choi HSJ, van Campenhout MJH, van Vuuren AJ, Krassenburg LAP, Sonneveld MJ, de Knegt RJ, Hansen BE, Janssen HLA. Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2021;19:1933-1940.e1. [PMID: 32890755 DOI: 10.1016/j.cgh.2020.09.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 851 |
Wu F, Lu R, Liu Y, Wang Y, Tian Y, Li Y, Li M, Wang W, Zhang X, Jia X, Dang S. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers. Liver Int 2021;41:2032-45. [PMID: 33896094 DOI: 10.1111/liv.14897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 852 |
Shan S, Jia J. Prevention of Mother-to-Child Transmission of Hepatitis B Virus in the Western Pacific Region. Clin Liver Dis (Hoboken) 2021;18:18-21. [PMID: 34484699 DOI: 10.1002/cld.1096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 853 |
De Pooter D, Van Gulck E, Chen A, Evans CF, Neefs JM, Horton H, Boden D. A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates. Vaccines (Basel) 2021;9:969. [PMID: 34579206 DOI: 10.3390/vaccines9090969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 854 |
Medas R, Liberal R, Macedo G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J Clin Cases 2021; 9(24): 6979-6986 [PMID: 34540953 DOI: 10.12998/wjcc.v9.i24.6979] [Reference Citation Analysis]
|
| 855 |
Ali Khan M, Haider MS, Nusrat B, Abbas Razvi SK, Shah ZZ, Shah AM, Khalid T, Haleem F. Demographics, Biochemical Characteristics, and Phases of Chronic Hepatitis B Virus Infection: Retrospective Analysis From a Secondary Care Setup. Cureus 2021;13:e16558. [PMID: 34430162 DOI: 10.7759/cureus.16558] [Reference Citation Analysis]
|
| 856 |
Ohsaki E, Suwanmanee Y, Ueda K. Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy. Viruses 2021;13:1691. [PMID: 34578273 DOI: 10.3390/v13091691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 857 |
Li Z, Li S, Tao H, Zhan Y, Ni K, Gong J, Li G. Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer. World J Surg Oncol 2021;19:251. [PMID: 34446030 DOI: 10.1186/s12957-021-02369-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 858 |
Zhang T, Zhang G, Deng X, Zeng J, Jin J, Zeping H, Wu M, Zheng R. APS (Age, Platelets, 2D Shear-Wave Elastography) Score Predicts Hepatocellular Carcinoma in Chronic Hepatitis B. Radiology 2021;301:350-9. [PMID: 34427463 DOI: 10.1148/radiol.2021204700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 859 |
Fukutomi K, Hikita H, Murai K, Nakabori T, Shimoda A, Fukuoka M, Yamai T, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T. Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus-Infected Hepatocytes During Interferon Administration. Hepatol Commun 2021. [PMID: 34558845 DOI: 10.1002/hep4.1804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 860 |
Delle Monache M, Petrelli A, Rossi A, Cecere R, Mirisola C, Costanzo G, Francia C, Cerini F, Cavani A, Nosotti L. Noninvasive Evaluation of Liver Fibrosis in a Sample of Putative Inactive HBV Carriers in Rome, Italy. Can J Infect Dis Med Microbiol 2021;2021:3068690. [PMID: 34426755 DOI: 10.1155/2021/3068690] [Reference Citation Analysis]
|
| 861 |
Chen MH, Wu CS, Chen MH, Tsai CY, Lee FY, Huang YH. High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus. Int J Mol Sci 2021;22:9116. [PMID: 34502025 DOI: 10.3390/ijms22179116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 862 |
Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 863 |
Wu D, Yan W, Han M, Ning Q. The potential immune regulation benefit of CpAMs beyond HBV suppression. Lancet Gastroenterol Hepatol 2021;6:680-2. [PMID: 34391513 DOI: 10.1016/S2468-1253(21)00256-9] [Reference Citation Analysis]
|
| 864 |
Sprinzl MF, Feist C, Koch S, Kremer WM, Lackner KJ, Weinmann A, Galle PR. Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B. BMC Health Serv Res 2021;21:846. [PMID: 34419018 DOI: 10.1186/s12913-021-06794-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 865 |
Song JE, Park JY. Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B. Expert Opin Pharmacother 2021;:1-7. [PMID: 34392744 DOI: 10.1080/14656566.2021.1967321] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 866 |
Wang L, Wu L, Li X, Zhang Y, Lai J, Zhu X, Xie C, Peng L. Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial. BMJ Open 2021;11:e048410. [PMID: 34408049 DOI: 10.1136/bmjopen-2020-048410] [Reference Citation Analysis]
|
| 867 |
Tarafdar S, Virata ML, Yan H, Zhong L, Deng L, Xu Y, He Y, Struble E, Zhang P. Multiple epitopes of hepatitis B virus surface antigen targeted by human plasma-derived immunoglobulins coincide with clinically observed escape mutations. J Med Virol 2021. [PMID: 34406663 DOI: 10.1002/jmv.27278] [Reference Citation Analysis]
|
| 868 |
Zhang H, Shi X, Wang L, Zeng Y, Kang X, Huang L. Performance of noninvasive tools for identification of minimal liver fibrosis in patients with hepatitis B virus infection. J Clin Lab Anal 2021;35:e23960. [PMID: 34403524 DOI: 10.1002/jcla.23960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 869 |
Song DS, Jang JW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B. Clin Infect Dis 2021;73:e892-903. [PMID: 33417679 DOI: 10.1093/cid/ciab007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 870 |
Riveiro-Barciela M, Marcos-Fosch C, Martinez-Valle F, Bronte F, Orozco O, Sanz-Pérez I, Torres D, Salcedo MT, Petta S, Esteban R, Craxi A, Buti M. Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. World J Gastroenterol 2021; 27(30): 5112-5125 [PMID: 34497439 DOI: 10.3748/wjg.v27.i30.5112] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 871 |
Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099 [PMID: 34497437 DOI: 10.3748/wjg.v27.i30.5088] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 872 |
Wang SJ, Chen ZM, Wei M, Liu JQ, Li ZL, Shi TS, Nian S, Fu R, Wu YT, Zhang YL, Wang YB, Zhang TY, Zhang J, Xiong JH, Tong SP, Ge SX, Yuan Q, Xia NS. Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection. Emerg Microbes Infect 2021;10:37-50. [PMID: 33296295 DOI: 10.1080/22221751.2020.1862631] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 873 |
Zhang M, Fu S, Ren D, Wu Y, Yao N, Ni T, Feng Y, Chen Y, Chen T, Zhao Y, Liu J. Maternal and Fetal Outcomes After Interferon Exposure During Pregnancy: A Systematic Review With Meta-Analysis. Front Reprod Health 2021;3:702929. [DOI: 10.3389/frph.2021.702929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 874 |
Li EM, Xiao LX, Xu Z, Mo ZS, Li JQ, Mei YY, Lin CS. Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy. BMC Pregnancy Childbirth 2021;21:551. [PMID: 34384374 DOI: 10.1186/s12884-021-04020-z] [Reference Citation Analysis]
|
| 875 |
Tournadre A, Sellam J, Morel J, Jullien D, Bouhnik Y, Cornec D, Devauchelle-Pensec V, Goupille P, Kluger N, Lazaro E, Goff BL, Lédinghen V, Lequerré T, Nocturne G, Seror R, Truchetet ME, Verhoeven F, Richez C, Pham T. Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine 2021;88:105210. [PMID: 34074455 DOI: 10.1016/j.jbspin.2021.105210] [Reference Citation Analysis]
|
| 876 |
Morel J, Tournadre A, Sellam J, Bouhnik Y, Cornec D, Devauchelle-Pensec V, Dieudé P, Goupille P, Kluger N, Lazaro E, Le Goff B, de Lédinghen V, Lequerré T, Nocturne G, Seror R, Truchetet ME, Verhoeven F, Pham T, Richez C. Practical Management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine 2021;88:105221. [PMID: 34183155 DOI: 10.1016/j.jbspin.2021.105221] [Reference Citation Analysis]
|
| 877 |
Takayama H, Komura T, Kagaya T, Sugimoto S, Orita N, Asahina Y, Nishikawa M, Ohta H, Kaneko S, Unoura M. Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B. Can J Gastroenterol Hepatol 2021;2021:3259833. [PMID: 34422709 DOI: 10.1155/2021/3259833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 878 |
Audsley J, Sasadeusz J. Challenges and opportunities for hepatitis B cure in the setting of HIV--hepatitis B virus co-infection. Curr Opin HIV AIDS 2020;15:193-9. [PMID: 32141889 DOI: 10.1097/COH.0000000000000624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 879 |
Lakoh S, Firima E, Jiba DF, Kamara MN, Gashau W, Deen GF, Adekanmbi O, Yendewa GA. Prevalence of sero-markers and non-invasive assessment of liver cirrhosis in patients with Hepatitis B virus infection in Freetown, Sierra Leone: a cross-sectional study. BMC Gastroenterol 2021;21:320. [PMID: 34372775 DOI: 10.1186/s12876-021-01892-5] [Reference Citation Analysis]
|
| 880 |
Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
|
| 881 |
Maepa MB, Jacobs R, van den Berg F, Arbuthnot P. Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus. Curr Opin HIV AIDS 2020;15:200-7. [PMID: 32141890 DOI: 10.1097/COH.0000000000000623] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 882 |
Cao D, Ge JY, Wang Y, Oda T, Zheng YW. Hepatitis B virus infection modeling using multi-cellular organoids derived from human induced pluripotent stem cells. World J Gastroenterol 2021; 27(29): 4784-4801 [PMID: 34447226 DOI: 10.3748/wjg.v27.i29.4784] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 883 |
Khoo T, Lam D, Olynyk JK. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. World J Gastroenterol 2021; 27(29): 4831-4845 [PMID: 34447229 DOI: 10.3748/wjg.v27.i29.4831] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 884 |
Zou W, Qian F, Jin F, Li D, Chen J. Characterization of mutations in the reverse transcriptase region of hepatitis B virus in treated and untreated chronic hepatitis B patients. Trans R Soc Trop Med Hyg 2021;115:870-7. [PMID: 33236067 DOI: 10.1093/trstmh/traa142] [Reference Citation Analysis]
|
| 885 |
Volinsky I. Stability Analysis of a Mathematical Model of Hepatitis B Virus with Unbounded Memory Control on the Immune System in the Neighborhood of the Equilibrium Free Point. Symmetry 2021;13:1437. [DOI: 10.3390/sym13081437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 886 |
Yang L, Wang Q, Cui T, Huang J, Jin H. Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis. Can J Gastroenterol Hepatol 2021;2021:9996358. [PMID: 34513751 DOI: 10.1155/2021/9996358] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 887 |
Chen H, Ding X, Liao G, Xia M, Ren Z, Fan R, Peng J. Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B. J Viral Hepat 2021;28:1121-9. [PMID: 33899998 DOI: 10.1111/jvh.13526] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 888 |
Heim K, Binder B, Sagar, Wieland D, Hensel N, Llewellyn-Lacey S, Gostick E, Price DA, Emmerich F< |
